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Background
Thyroid hormone is produced by the thyroid gland and its concentration is regulated by 
a negative feedback system known as the hypothalamic-pituitary-thyroid axis (depicted 
in Figure 1) 1. Thyroid hormone regulates metabolism and is essential for the develop-
ment and differentiation of practically all cells in the human body 1. For that reason, 
growth and differentiation of almost all tissues, especially those belonging to the central 
nervous system, are dependent on adequate thyroid function. 1-3. This is particularly im-
portant during the first half of pregnancy when placental development and fetal growth 
and differentiation completely depend on the maternal supply of thyroid hormone. 
Deficiency of thyroid hormone is associated with the impaired neural development 
and subsequent cognitive impairment 1-3. Thyroid dysfunction during pregnancy may 
have important consequences; first of all because low thyroid hormone availability is 
associated with the risk of premature delivery 4,5, and secondly because high thyroid 
hormone availability may have adverse effects on fetal development, increasing the risk 
of pre-eclampsia, low birth weight and suboptimal brain development 3,6-8. For that rea-
son, great effort has been put into investigation and explanation of pregnancy-specific 
changes, as well as into understanding of the pathophysiology of thyroid dysfunction in 
pregnancy, with the ultimate aim to improve both maternal and fetal care.
During pregnancy, an increased metabolic demand and hormonal alterations result 
in several adaptive changes in thyroid physiology 9 (depicted in Figure 2). First of all, the 
progression of pregnancy comes with an increase in concentration of thyroid hormone 
binding proteins (most notable thyroxine-binding globulin), which, together with the 
action of placental type 3 iodothyronine deiodinase, a thyroid hormone inactivating 
Figure 1. Hypothalamic-pituitary-thyroid axis
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enzyme, increases the need for thyroid hormone 9. Second, there is an increased need for 
maternal thyroid hormone availability for the fetus, as the fetal thyroid gland is not fully 
functional until the second half of pregnancy 10. Third, human chorionic gonadotropin 
concentration (hCG), due to its ability to stimulate the thyroid-stimulating hormone (TSH) 
receptor 11, induces an increase in free thyroxine (FT4) concentration and a decrease in 
TSH at the end of the first trimester 9. This complicated, multifaceted mechanism that en-
sures the supply of thyroid hormone to the fetus, emphasizes the importance of optimal 
thyroid hormone regulation for proper fetal growth and development.
Thyroid function and the placenta
A successful pregnancy requires optimal placental function, as the fetus completely 
depends on an optimally functioning placental barrier for its supply of nutrients, respira-
tory gas exchange and elimination of metabolic waste products 12,13. Furthermore, the 
placenta is a prime endocrine organ producing hormones that are crucial for maintaining 
the pregnancy, including hCG, estrogen, progesterone and prostaglandins 14. Placental 
dysfunction may result in pregnancy complications, such as pre-eclampsia, fetal growth 
restriction and premature delivery, which are the major causes of maternal and perinatal 
morbidity and mortality worldwide 15-18.
Trophoblast cells express thyroid hormone transporters and receptors 19-22 and a suc-
cessful placentation requires optimal thyroid hormone concentration 23. Placentation is 
a complex process that consists of interstitial invasion of trophoblast cells into maternal 
decidua and endovascular trophoblast (EVT) invasion into maternal spiral arteries 24. 
This is, in part, regulated by pro- and anti-angiogenic factors and cytokines 24. Thyroid 
hormone regulates the secretion of several growth factors and cytokines that are criti-
cal for EVT invasion and angiogenesis of maternal and fetal placental vessels, including 
Figure 2. Physiology of thyroid function during pregnancy
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angiogenin, angiopoietin 2 , vascular endothelial growth factor-A, interleukin 10 and 
tumor necrosis factor alpha 25. Furthermore, thyroid hormone may attenuate prolifera-
tion and invasion of trophoblast 20,26. 
Interestingly, placental dysfunction and thyroid dysfunction are associated with the 
same pregnancy complications, such as pre-eclampsia and fetal growth restriction 24,27. 
As these pregnancy complications may arise from impaired placentation 24 and given 
that placental tissue is responsive to thyroid hormone 19-22, part of this thesis focuses 
on how early-pregnancy thyroid function could regulate placental function and could 
potentially mediate the associations of thyroid function with pregnancy complications. 
Despite the existing experimental data suggesting a role of thyroid hormone in placen-
tation, there is a paucity of population-based studies investigating these effects. One of 
the aims of this thesis was to translate and quantify the experimental findings on the 
effects of thyroid hormone on placental function into a clinical context.
The role of hCG
hCG is a pregnancy-specific hormone, produced by the trophoblast cells from implanta-
tion of the embryo onwards, throughout the whole pregnancy 28. hCG plays a key role in 
promoting progesterone production by the corpus luteum during early pregnancy, as 
well as in the differentiation of trophoblast, placental development and angiogenesis 28,29. 
The latter is partly mediated via regulating effects of hCG on vascular endothelial growth 
factors 30-34. By co-regulating angiogenesis in a timely manner, hCG ensures a proper 
placental development which is crucial for the outcome of pregnancy 31,33. Because of 
the structural homology with TSH, hCG is able to stimulate the TSH receptor thereby 
stimulating the thyroid gland 9,28. The subsequent changes in thyroid physiology during 
pregnancy affect TSH and FT4 concentrations 9 (Figure 2), raising a question whether the 
effects of thyroid hormone on pregnancy-specific outcomes, such as pre-eclampsia or 
fetal growth restriction, might be initiated by hCG effects on the thyroid or if the effects 
of these two important hormones are linked at all.
Although clinical studies have shown that hCG is associated with adverse outcomes 
of pregnancy, these associations differ based on the gestational age at which hCG was 
measured or on the hCG isoform that was assessed. For example, while several studies 
suggest that in early and late pregnancy high hCG is associated with the risk of pre-
eclampsia 35-38, studies also report an association of low early-pregnancy β-hCG 39 and 
low early-pregnancy hyperglycosylated hCG 40 with the risk of pre-eclampsia. Similarly, 
there are reports of an association of high hCG concentrations 41,42 but also of low hCG 
concentrations 43,44 with fetal growth restriction. Little is known on the potential media-
tors in these associations, for instance angiogenic factors, as well as on the potential 
gestational-age dependent variation in the effects.
CHAPTER 1
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Thyroid function and metabolism
While thyroid hormone regulates metabolism of practically the whole body, thyroid 
hormone may specifically regulate the metabolism of homocysteine. This may occur via 
two potential mechanisms: first of all, proliferative processes that depend on folate and 
vitamin B12 concentrations are stimulated by thyroid hormone 45-47. A higher thyroid 
hormone concentration might therefore result in a higher homocysteine concentration, 
as this would lead to a lower availability of folate and vitamin B12 for re-methylation 
of homocysteine to methionine 47. Secondly, reports from animal studies suggest that 
the activity of enzymes required for re-methylation of homocysteine, methylenetet-
rahydrofolate reductase (MTHFR) and methionine synthase may be thyroid hormone 
dependent 47. Although human studies have shown that thyroid dysfunction is associ-
ated with higher homocysteine concentration 48-50, the direction and consistency of the 
association are not clear 48-52. This can be clinically relevant since high homocysteine 
concentrations are associated with adverse cerebrovascular, pregnancy-specific and 
neonatal outcomes 53-56. To date, population-based data investigating the association of 
thyroid function with homocysteine concentration are sparse and therefore it remains 
unknown to what extent these potential pathophysiological mechanisms altogether are 
of clinical relevance.
Thyroid function in childhood
Thyroid hormone is important for optimal childhood growth and development. This is 
for example reflected by the fact that even mild forms of thyroid dysfunction are associ-
ated with suboptimal developmental outcomes, such as weight gain, impaired growth, 
hyperlipidemia and impaired cognitive development 57. Interestingly, the effects of 
thyroid hormone on multiple organ systems have been extensively studied in adults, 
whereas population-based data on the effects in early childhood are sparse. For in-
stance, the effects of thyroid (dys)function on the cardiovascular system are well-known 
in the adult population, as is exhibited by the effects on vascular resistance, heart rate, 
cardiac contractility and mass 58, yet little is known about these effects during childhood 
when cardiac growth and development take place. Different types of evidence support 
the regulating role of thyroid hormone in cardiac development and function in early 
life 59. In line with this, cardiomyocytes express thyroid hormone receptors during fetal 
and postnatal life 60. Similarly, thyroid hormone has a critical role in the linear growth 
and bone maturation, and thyroid hormone receptors are expressed at the sites of bone 
formation 61. During childhood, hyperthyroidism is associated with premature accretion 
of growth plates and cranial sutures, resulting in short stature, whereas hypothyroid-
ism is associated with impaired bone ossification, also resulting in short stature 61,62. 
In adults, high thyroid function is associated with high bone resorption and low bone 
mineral density, leading to osteoporosis 61,62. Although the effects on the bone occur 
15
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via thyroid hormone, there are reports suggesting a direct role of TSH on osteoblasts 
and osteoclasts 63, however, this remains debated. Thus far, only few studies have inves-
tigated the effects of variation of thyroid function on the cardiovascular development, 
as well as on the potential association of body composition and/or its mediating role 
in the association of thyroid function with cardiovascular function during childhood. 
In addition, there is a paucity of data on the effects of variation of thyroid function on 
the bone development during childhood. Using an epidemiological approach and a 
population-based setting, part of these associations is investigated in this thesis. 
Proper TSH and FT4 reference ranges are essential for an adequate diagnosis of thy-
roid disease. Apart from the recommendation of the European Thyroid Association of 
using age-adjusted values 64, no further consensus has been reached on the definition 
of TSH and FT4 reference ranges during childhood, complicating the clinical diagnosis of 
thyroid dysfunction. The existing literature on childhood TSH and FT4 reference ranges 
is hampered by the heterogeneity in terms of age range, ethnicity and assay use. It is not 
known to what extent differences in the methodology and population-specific factors 
add to the overall heterogeneity. Furthermore, a proper understanding of the thyroid 
function determinants is crucial in order to identify and/or exclude a cause of an ab-
normal thyroid function test. This requires a thorough investigation, most importantly 
so that physicians may assess whether a reference range is generalizable to a specific 
patient population, but also that future studies, examining the association of thyroid 
function with various outcomes would take into account important confounding and 
mediating factors.
Aims
This thesis aims to examine the developmental and metabolic influence of endocrine 
factors, in particular related to thyroid function and hCG, on the outcomes of pregnancy 
and early childhood development. The studies described here investigate the associa-
tions of gestational thyroid function with placental hemodynamic function, homocyste-
ine concentration and its potential mediating role in pregnancy complications. In order 
to delineate to what extent there is a contributory role of hCG in the pathophysiology of 
pregnancy complications, the associations of hCG with pre-eclampsia and fetal growth 
are investigated. Furthermore, the determinants of childhood thyroid function and the 
associations of childhood thyroid function with the important target organs are investi-
gated along with the potential mediating role of body composition. The concept of the 
associations examined in this thesis is depicted in Figure 3.
Setting
The studies presented in this thesis are embedded in Generation R, a prospective 
population-based cohort from early fetal life onwards, in Rotterdam, the Netherlands 65. 
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This cohort was designed to study early environmental and genetic determinants of 
growth, development and health during fetal and postnatal life 65. Eligible participants 
for the study were 8879 pregnant women with an expected delivery date between April 
2002 and January 2006 that were enrolled in the cohort during pregnancy 65. Blood 
samples for TSH, FT4 and hCG measurements were obtained at inclusion in the study. 
Fetal weight and placental ultrasound measurements were performed during prenatal 
visits at mid- (18-25 week) and late (after 25th week) pregnancy 65. Pre-eclampsia diag-
nosis was confirmed by certified medical doctors by reviewing hospital charts. At birth, 
cord blood samples were drawn and TSH and FT4 concentrations were measured. At 
the median age of 6 years, children were invited to a dedicated research center where 
detailed body composition, bone mineral density and cardiovascular measurements 
were performed.
Outline of the thesis
Chapter 2 focuses on the associations of thyroid function in pregnancy with placental 
hemodynamics and homocysteine concentrations. In Chapter 2.1 the associations of 
gestational thyroid function with placental vascular resistance in mid- and late preg-
nancy were investigated, as well as the potential mediating role of placental function 
in the previously described associations of thyroid function with the outcomes of preg-
nancy. In Chapter 2.2 the associations of thyroid function with maternal and neonatal 
homocysteine concentrations were investigated. Chapter 3 focuses on the associations 
of hCG concentrations with the outcomes of pregnancy. Chapter 3.1 focuses on the 
association of hCG with the risk of pre-eclampsia and in Chapter 3.2 the association of 
hCG with fetal growth trajectory is presented. Chapter 4 focuses on the determinants of 
childhood thyroid function and the associations of childhood thyroid function with tar-
Figure 3. The associations examined in this thesis
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get organs. Chapter 4.1 provides a detailed overview of the existing literature on child-
hood reference ranges for TSH and FT4, and shows the determinants of these reference 
ranges in a population-based cohort. Chapter 4.2 focuses on the association of thyroid 
function with cardiovascular function and investigates the role of body composition in 
this association. Chapter 4.3 describes the association of childhood thyroid function 
with bone mineral density.
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ABSTRACT
Study question: What is the clinical association of maternal thyroid function with pla-
cental hemodynamic function?
Summary answer: Higher FT4 concentration in early pregnancy is associated with 
higher placental vascular resistance.
What is known already: Suboptimal placental function is associated with pre-eclampsia 
(which, in turn, further deteriorates placental hemodynamics and impairs fetal blood 
supply), fetal growth restriction and premature delivery. Studies have suggested that 
thyroid hormone has a role in placental development through the effects on trophoblast 
proliferation and invasion.
Study design, size, duration: This study was embedded in The Generation R cohort, 
a population-based prospective study from early fetal life onwards in Rotterdam, the 
Netherlands. In total, 7069 mothers with expected delivery date between April 2002 and 
January 2006 were enrolled during early pregnancy. 
Participants/materials, setting, methods: Thyroid stimulating hormone (TSH) and 
free thyroxine (FT4) concentrations were measured during early pregnancy (median 
13.4 weeks, 95% range 9.7-17.6 weeks). Placental function was assessed by Doppler ul-
trasound via measurement of arterial vascular resistance, i.e. umbilical artery pulsatility 
index (PI) and uterine artery resistance index (RI) (both measured twice, between 18-25th 
and after 25th gestational weeks) and the presence of uterine artery notching (once after 
the 25th gestational week) in 5184 pregnant women.
Main results and the role of chance: FT4 was positively linearly associated with um-
bilical artery PI in the second and third trimester as well as with uterine artery RI in the 
second trimester and the risk of uterine artery notching in the third trimester (P<0.05 for 
all). The association of thyroid function with preeclampsia and birth weight was partially 
mediated through changes in placental function, the percentages of mediated effects 
being 10.4% and 12.5%, respectively.
Limitations, reasons for caution: A potential limitation is the availability of a single TH 
measurement and differential missingness of placental ultrasound measurements for 
the adverse outcomes.
Wider implications of the findings: Higher FT4 concentration in early pregnancy is 
associated with higher vascular resistance in the second and third trimester in both the 
maternal and fetal placental compartment. These effects on placental function might 
explain the association of FT4 with adverse pregnancy outcomes, including preeclamp-
sia and fetal growth restriction.
Study funding/competing interest(s): This work was supported by a fellowship from 
ERAWEB, a project funded by the European Commission (to M.B.) and by clinical fel-
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lowship from The Netherlands Organization for Health Research and Development 
(ZonMw), Project 90700412 (to R.P.P.). Authors have no conflict of interest.
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INTRODuCTION
Adequate placental function is essential for an uncomplicated pregnancy and op-
timal fetal development as it enables fetal nutrient supply, respiratory gas exchange 
and elimination of metabolic waste products 1,2. Furthermore, the placenta produces 
hormones that are crucial for maintaining pregnancy including human chorionic go-
nadotropin (hCG), estrogen, progesterone and prostaglandins 3. A suboptimal placental 
function is associated with pregnancy complications, including pre-eclampsia (which, in 
turn, further deteriorates placental hemodynamics and impairs fetal blood supply ), fetal 
growth restriction and premature delivery, which are the major causes of maternal and 
perinatal morbidity and mortality worldwide 4-7.
Thyroid hormone (TH) transporters and receptors are expressed in the trophoblast 
cells 8-11 and optimal TH concentration is necessary to ensure appropriate placenta-
tion 12. Placentation is a complex process that requires proper interstitial invasion of fetal 
trophoblast cells into maternal decidua and endovascular trophoblast (EVT) invasion 
into maternal spiral arteries 13. This is, in part, regulated by pro- and anti-angiogenic 
factors and cytokines 13. TH regulates secretion of several growth factors and cytokines 
that are critical for EVT invasion and angiogenesis of maternal and fetal placental ves-
sels, including angiogenin, angiopoietin 2 (Ang-2), vascular endothelial growth factor-A 
(VEGF-A), interleukin 10 (IL-10) and tumor necrosis factor alpha (TNF-α) 14. Furthermore, 
TH attenuates epidermal growth factor (EGF)-initiated trophoblast proliferation 11, mo-
tility 15 and invasion 16. 
Low thyroid function has been associated with premature delivery 17,18 and high 
thyroid function has been associated with pre-eclampsia 19,20 and fetal growth restric-
tion 21,22, adverse pregnancy outcomes that could be arising from impaired placentation 
in early gestation 13. Given that placental tissue is responsive to TH 8-11, we hypothesized 
that early maternal thyroid function is a regulator of placentation. Despite the increas-
ing body of basic evidence suggesting that TH plays a role in regulation of placental 
development, there is a lack of data that translate these findings to clinical outcomes. 
Moreover, as thyroid dysfunction 17,19,21 and placental dysfunction 4 are associated with 
the same pregnancy complications, the clinical association of thyroid function with 
adverse pregnancy outcomes might be mediated via changes in placental function or 
vice versa.
Therefore, the aim of this study was to translate and quantify experimental findings 
on the link between thyroid hormone and placental function into a clinical context 
within a large prospective population-based cohort. In addition, we aimed to examine 
the mediating role of the placental function in the association of TH with birthweight, 
pre-eclampsia and premature delivery.
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MATERIALS AND METHODS
Study population 
This study was embedded in The Generation R cohort, a population-based prospective 
study from early fetal life onwards in Rotterdam, the Netherlands 23. The study was 
designed to identify early environmental and genetic causes leading to normal and 
abnormal growth, development and health during fetal life and childhood 23. In total, 
7069 mothers with expected delivery date between April 2002 and January 2006 were 
enrolled during early pregnancy. Thyroid-stimulating hormone (TSH) and free thyroxine 
(FT4) were determined in the first available serum sample during early pregnancy (<18 
weeks) and were available in 6065 women, from which 5289 had available placental func-
tion measurements. Women with thyroid disease, thyroid (interfering) medication, in 
vitro fertilization and/or twin pregnancies, were excluded from the analysis (N=76, N=4, 
N=25, respectively). The final population of women included in the analysis comprised 
5184 women (Figure 1). Written informed consent was obtained from all participants. 
The study has been approved by the local Medical Ethics Committee.
Figure 1. Flowchart showing selection procedure of the study population 
Mothers with TSH * and FT4 † measurement 
N=6065
N=105 excluded 
- Due to thyroid disesase (N=76) 
- Due to thyroid (interfering) medication 
(N=4) 
-    In vitro fertilisation/Twin pregnancies (N=25)
Mothers with available placental function 
measurements 
N=5289 
Mothers enrolled during early pregnancy  
N=7069 
 
Mothers with umbilical artery PI ‡ 
measurement 
 
In the 2nd trimester N=4531 
In the 3rd trimester N=4536 
 
Overlap N=3762 
Mothers with uterine artery RI §, 
measurement 
  
In the 2nd trimester N=3256 
In the 3rd trimester N=2592 
 
Overlap N=2062 
Mothers with uterine artery 
notching measurement 
available  
 
N=3278 
Final study population 
N=5184 
* TSH – thyroid stimulating hormone, † FT4 – free thyroxine, ‡ PI –pulsatility index, § RI – uterine artery 
resistance index
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Thyroid measurements
Maternal serum samples were obtained in early pregnancy (median 13.4 weeks, 95% 
range 9.7 -17.6 weeks). Plain tubes were centrifuged and serum was stored at -80°C. TSH 
and FT4 concentrations in maternal serum samples were determined using chemilu-
minescence assays (Vitros ECi; Ortho Clinical Diagnostics). Maternal thyroid peroxidase 
antibodies (TPOAbs) were measured using the Phadia 250 immunoassay (Phadia AB) 
and were regarded as positive when greater than 60 IU/ml 24. Euthyroidism was defined 
according to the 2.5th – 97.5th percentile reference range for the study population 24.
Placental function measurements
Measurements of placental vascular resistance were used as a reflection of placental 
function and a proxy measure of the placentation success 25. Placental vascular 
resistance was evaluated with recorded flow-velocity waveforms from the umbilical 
(representing the fetal vascular compartment) and uterine (representing the maternal 
vascular compartment) arteries in the second trimester (median 20.5 weeks, 95% range 
18.7-23.1 weeks) and third trimester (median 30.4 weeks, 95% range 28.6-32.8 weeks) 26, 
with the median time of 9.9 weeks between the two measurements. The median time 
intervals between blood sampling and placental hemodynamic measurements in the 
2nd trimester was 7.1 weeks and in the 3rd trimester was 17 weeks. A raised umbilical 
artery pulsatility index (PI) and uterine artery resistance index (RI) indicate increased 
placental vascular resistance which is a sign of (subsequent) placental insufficiency, that 
may occur as a result of impaired placentation 27,28. Umbilical artery PI was measured in 
a free-floating loop of the umbilical cord. Uterine artery RI was measured in the uterine 
arteries near the crossover with the external iliac artery. For each measurement, three 
consecutive uniform waveforms were recorded by pulsed Doppler ultrasound, during 
fetal apnea and without fetal movement. The mean of three measurements was used 
for further analysis. The presence of notching in the third trimester was assessed in the 
uterine arteries and reflects an abnormal waveform resulting from increased blood flow 
resistance, which is a sign of placental insufficiency 29. Ultrasound measurements and 
analyses were performed in a blinded fashion with regards to the previous measure-
ments and pregnancy outcome. 
Outcomes of pregnancy
Information on birth weight was obtained from hospital registries. Birth weight stan-
dard deviation scores adjusted for gestational age were constructed using the Niklas-
son percentile growth curves 30. Premature delivery was defined as a gestational age 
at birth <37 weeks. Gestational hypertension was defined as development of systolic 
blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥90mmHg after 20 weeks 
of gestation in previously normotensive women. These criteria plus the presence of 
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proteinuria (defined as 2 or more dipstick readings of 2+ or greater, 1 catheter sample 
reading of 1+ or greater, or a 24-hour urine collection containing at least 300 mg of 
protein) were used to identify women with pre-eclampsia 31.
Covariates
Information on maternal ethnicity and smoking status was obtained by questionnaires 
during pregnancy. Ethnicity was determined by the country of origin and was defined 
according to the classification of Statistics Netherlands 23. Maternal smoking was clas-
sified as no smoking, smoking until known pregnancy and continued smoking during 
pregnancy. Information on parity and sex of the child was obtained from hospital regis-
tries. Body mass index (BMI) was measured at inclusion in the study.
Statistical analysis
We investigated the associations of TSH and FT4 with umbilical artery PI and uterine 
artery RI by using multiple linear regression analyses with restricted cubic splines utiliz-
ing three knots, to account for possible non-linear associations 32. To study the associa-
tion of TSH and FT4 with the risk of notching in the uterine arteries, we used multiple 
logistic regression models with restricted cubic splines utilizing three knots. TSH and 
FT4 values were logarithmically transformed to allow for a better model fit. Multivari-
able associations were graphically depicted by plots (main manuscript) and β estimates/
odds ratios with 95% confidence intervals are shown in Supplemental Tables 2 and 3). 
In order to properly investigate placental function as a mediator in the associations of 
thyroid function with pregnancy outcomes, we investigated the prerequisite associa-
tions: the association of thyroid function and placental function was examined in this 
study, the associations of thyroid function and pregnancy outcomes were examined and 
described previously 17,19,21 as well as was the association of placental vascular resistance 
indices with pregnancy outcomes 33. To examine the mediating role of placental func-
tion in the associations of TH with pregnancy outcomes and vice versa, we analyzed 
the direct and indirect causal mediation effects by performing mediation analyses using 
Imai et al. approach 34.
All model covariates were selected based on biological plausibility based on the previ-
ous studies, change of the effect estimate of interest and/or residual variability of the 
model in this study. The analyses were adjusted for gestational age at blood sampling, 
smoking, maternal age, parity, ethnicity, BMI, fetal sex and gestational age at ultrasound 
measurement. We performed sensitivity analyses in order to examine whether additional 
adjustment to hCG, placental angiogenic factors (placental growth factor and soluble 
FMS-like tyrosine kinase, previously described as the determinants of thyroid function 
35), maternal blood pressure or presence of TPOAbs would affect the effect estimates. We 
also performed sensitivity analyses by selecting euthyroid women only.
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We accounted for the high number of statistical tests (38 in total) by controlling 
the false discovery rate (Benjamini and Hochberg) using the fdrtool package 36,37. This 
method allows for tailored identification of the expected proportion of false positive 
results among all rejected null hypotheses. We identified that a q-value of 0.045 (i.e. 
the cut-off for a 4.5% chance of having a type I error) was similar to a P-value of 0.05, 
therefore a P-value threshold of <0.05 was considered for statistical significance.
In the first part of the analysis, where we studied the association of TSH and FT4 with 
placental vascular resistance, we performed multiple imputation according to Markov 
Chain Monte Carlo method, for covariates with missing data 38. Before imputation of 
the missing values, we performed exploratory analyses by investigating the pattern of 
missingness for each variable. All variables showed random missingness patterns and 
the missingness was fully accounted for by complete variables rendering us to conclude 
the data was M(C)AR. The percentage of missing data was less than 1% for sex, parity, 
BMI and gestational age at birth variables. Furthermore, the percentage of missing data 
was 10.8% for smoking, 6.4% for education and 3.4% for ethnicity variables. Twenty 
imputed data sets were created and pooled for the analysis. Maternal smoking, educa-
tion, ethnicity, parity, BMI and fetal sex were then added to the model. Furthermore, we 
added umbilical artery PI, uterine artery RI, uterine artery notching, maternal TSH and 
FT4 concentrations as prediction variables only. No statistically significant differences 
in descriptive statistics were found between the original and imputed datasets. For me-
diation sub-analyses, differential missingness for data on placental hemodynamics on 
outcomes in datasets that were previously used to study adverse outcomes was coped 
with by performing multiple imputation for data on umbilical artery PI, uterine artery 
RI and uterine artery notching values 39 of placental function data. Twenty imputed 
data sets were created and pooled for the analysis. TSH and FT4 concentration, as well 
as pregnancy outcomes were used as predictor variables only and were not imputed. 
No statistically significant differences in descriptive statistics were found between the 
imputed datasets.
Statistical analyses were performed using Statistical Package of Social Sciences ver-
sion 21.0 for Windows (SPSS Inc. Armonk, NY) and R statistical software version 3.2.0 
(package rms, mediation and fdrtool).
RESuLTS
The final study population consisted of 5184 pregnant women (Figure 1) for which at 
least one placental function measurement was available. The concurrent measurements 
of second- and third-trimester umbilical artery PI and uterine artery RI were available for 
3762 and 2062 women, respectively (Figure 1). Descriptive statistics of the study popu-
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lation are shown in Table 1. As compared to women for which the placental function 
measurements were available, women without placental function measurements had 
blood samples drawn at slightly later gestational age, had higher BMI and were of lower 
educational level (Supplemental Table 1).
The association of thyroid function with placental vascular resistance indices
As is shown in Figure 2, TSH was negatively linearly associated with umbilical artery PI 
(P=0.011) but not with uterine artery RI (P=0.78) in the second trimester. Furthermore, 
FT4 was positively linearly associated with umbilical artery PI (P=0.027) and uterine 
artery RI (P=0.003) in the second trimester (Figure 2).
As Figure 3 shows, TSH was not associated with umbilical artery PI (P=0.18) and uter-
ine artery RI (P=0.75) in the third trimester. FT4 was positively linearly associated with 
umbilical artery PI (P=0.015) but not with uterine artery RI (P=0.91) in the third trimester 
(Figure 3).
Figure 2. The association of maternal thyroid function with the 2nd trimester placental function
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Plots show the linear regression models for TSH and FT4 and the resistance indices of the umbilical and 
uterine artery in the second trimester of pregnancy, as predicted mean with 95 percent confi dence interval. 
Analyses were adjusted for gestational age at blood sampling, gestational age at ultrasound, smoking, BMI 
and fetal sex. 
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Table 1. Descriptive Statistics of the Participants
Characteristic Value
TSH, median (95%range), mu/l, 1.34 (0.04-4.49)
FT4, median (95%range), pmol/l 14.7 (10.2-22.2)
Gestational age at blood sampling, median (95%range ) 13.4 (9.7-17.6)
umbilical artery PI, mean ±sd
Second trimester 1.20 ±0.18
Third trimester 0.98 ± 0.17
uterine artery RI, mean ±sd
Second trimester 0.54 ±0.09
Third trimester 0.48 ±0.08
uterine artery notching, n (%)
yes 326 (9.9)
no 2952 (90.1)
Age, mean ±sd , years 29.7 ±5.0
BMI, median, (95% range), kg/m2 23.5 (18.5-35.6)
Parity, n (%)
Nullipara 3057 (57.5)
Primipara 1589 (29.9)
Multipara 669 (12.6)
Smoking status, n (%)
Non smokers 3821 (71.9)
Stopped smokers 505 (9.5)
Smokers 989 (18.6)
Educational level, n (%)
No education or primary education 587 (11.0)
Secondary education 2429 (45.7)
Higher education 2299 (43.3)
Ethnicity, n (%)
Dutch 2726 (51.3)
Moroccan 350 (6.6)
Turkish 425 (8.0)
Surinam 477 (9.0)
Dutch Antilles 173 (3.3)
Asian 148 (2.8)
Other – Western 477 (9.0)
Other – Non-Western 539 (10.1)
Fetal sex, n (%)
male 2667 (50.2)
female 2648 (49.8)
TPO antibody positivity, n (%)
yes 274 (5.3)
no 4557 (87.9)
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Figure 4 shows thyroid function and the risk of uterine artery notching during the 
third trimester. Higher concentrations of FT4 were associated with a higher risk of notch-
ing (P=0.0001), whereas TSH was not associated with the risk of notching (P=0.075).
Sensitivity analyses showed no change in the results after adjusting for hCG, placental 
angiogenic factors, maternal blood pressure and TPOAbs. All reported associations 
remained similar when analyzed in euthyroid women only, except for the association of 
FT4 with umbilical artery PI measured in the second trimester that was not statistically 
signifi cant (Supplemental Figures 1-3).
Placental function as a potential mediator in the association of thyroid function 
with adverse pregnancy outcomes
In Supplemental Table 4, the results of mediation analysis for diff erent outcomes (pre-
eclampsia, birth weight and premature delivery) are shown. There was no mediation by 
placental function in the association of thyroid function with the risk of pre-eclampsia 
except for second-trimester uterine artery RI (P for mediation = 0.02, percentage of me-
Figure 3. The association of maternal thyroid function with the 3rd trimester placental function 
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Plots show the linear regression models for TSH and FT4 and the resistance indices of the umbilical and 
uterine artery in the third trimester of pregnancy, as predicted mean with 95 percent confi dence interval. 
Analyses were adjusted for gestational age at blood sampling, gestational age at ultrasound, smoking, BMI 
and fetal sex. 
CHAPTER 2.1
36
diated eff ect: 10.4%). Similarly, in the association of thyroid function with birth weight, 
there was no mediating role of placental function except for the second-trimester 
uterine artery RI (P for mediation <0.01, percentage of mediated eff ect: 12.5%). There 
was no mediating role of placental function in the association of thyroid function and 
the risk of premature delivery. 
DISCuSSION
Our data show an association of early gestational thyroid function with measures of 
placental vascular function in pregnancy. To our knowledge, this is the fi rst study that 
investigates the association of gestational thyroid function with the placental function 
in a clinical context. Higher maternal FT4 concentration during early pregnancy was as-
sociated with higher placental vascular resistance in the period of 18.7-23.1 weeks and 
28.6-32.8 weeks of gestation. Taken together, these results suggest that high thyroid 
function during early pregnancy may infl uence placental function during the second 
half of pregnancy, most likely through impaired placentation. Our results also suggest 
that 10.4% and 12.5% of the association of high thyroid function with pre-eclampsia 
and birth weight could be occurring through changes in placental hemodynamics, 
respectively.
In the current study, higher FT4 concentration was associated with higher vascular 
resistance in the second trimester, in both fetal and maternal compartment of the 
Figure 4. The association of maternal thyroid function with the risk of uterine artery notching in the 3rd 
trimester
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Plots show the logistic regression models for TSH and FT4 and the risk of 3rd trimester notching in the uter-
ine artery, as predicted mean with 95 percent confi dence interval. Analyses were adjusted for gestational 
age at blood sampling, smoking, BMI, gestational age at ultrasound, maternal age, ethnicity, parity and 
fetal sex. 
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placenta. This suggests that TH affects the formation of the placenta as a whole, i.e. 
both feto-placental and utero-placental circulation, and that high thyroid function in 
early pregnancy is a risk factor for impaired placentation and vascularization. This could 
be explained by a combination of TH-mediated effects; first of all, TH mediates down-
regulation of VEGF-A, a factor promoting maternal and fetal angiogenesis and increas-
ing trophoblast motility 40,41. Secondly, TH attenuates EGF-related actions on trophoblast 
motility and invasion 11. Furthermore, TH induces down-regulation of IL-10, necessary for 
vascular development, and up-regulates TNF-α, which is known to inhibit EVT invasion 
and trophoblast proliferation 14,42. 
Higher FT4 was associated with placental outcomes in the third trimester, namely a 
higher umbilical PI, as well as with a higher risk of uterine artery notching. This sug-
gests that the effects of TH on placental development during early pregnancy may have 
a persistent impact on the quality of placental vessels and function in both fetal and 
maternal compartment. On the other hand, FT4 was not associated with third-trimester 
uterine artery RI (a measure of placental function on the maternal side). This may sug-
gest that, although the placental development as a whole is affected by exposure to 
THs, the effects on the fetal side are more persistent, possibly due to the active placental 
transfer of maternal thyroxine to the fetus or due to gestational age-specific changes 
in the TH effects on the angiogenic factors and cytokines secretion 14. Alternatively, 
this might be explained by the second wave of EVT invasion which occurs during the 
second trimester 43. This process may remodel spiral arteries and thus improve placental 
angiogenesis and blood flow during later gestation, yet be differently affected by THs as 
compared to early trophoblast invasion.
The exact origin of impaired placentation has not been clarified completely. Placenta-
tion is a very precise process and impairment of any stage can result in pregnancy com-
plications 13. The fact that we observed similar associations also within the euthyroid 
subgroup of women, suggests that even “high-normal” FT4 values might be leading to a 
certain impairment in the placental function. 
TSH may have transient and limited effects on the placentation, compared to FT4 
effects. High TSH concentration was associated with lower vascular resistance in the 
umbilical artery during the second trimester, in line with the opposing effects of FT4 
at that time point. However, there was no association of TSH with umbilical artery 
resistance in the third trimester, nor with uterine artery vascular resistance in second 
or third gestational trimester. Similarly, other gestational outcomes determined by 
thyroid function, such as fetal brain development and pre-eclampsia, are shown to be 
associated with FT4 concentration and not with TSH concentration 19,44. Furthermore, TH 
production during pregnancy is considerably stimulated by hCG and the increase in FT4 
subsequently causes a transient decrease in TSH concentration 45. This might suggest 
that FT4 better reflects thyroid function during gestation and that the role of TSH as a 
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unique indicator of thyroid function is potentially less pertinent during pregnancy, com-
pared to a non-pregnant state. Together with the placental transfer of FT4 but not TSH, 
this could explain stronger associations of FT4 with placental hemodynamics compared 
to the associations with TSH observed in this study. 
Alternatively, we can speculate that the small effects of TSH we observed could be a 
physiological reflection of thyrotropin releasing hormone effects, which is shown to be 
present in substances released by placental tissue 46,47. Those effects might be timely 
regulated and pointed towards the control of the fetal hypothalamo-pituitary-thyroid 
axis formation occurring in early pregnancy. The potential transient nature of this phe-
nomenon could also explain the transient associations we observed between TSH and 
placental function measurements. 
It is known that pregnancies with overt hyperthyroidism, mostly caused by TSH recep-
tor stimulating antibodies in the context of Graves’ disease, are more likely to be com-
plicated with both maternal and fetal morbidity, including premature delivery, placenta 
abruptio and fetal growth restriction 48. Furthermore, even high-normal FT4 concentra-
tion is shown to be associated with higher risk of pre-eclampsia 19 and fetal growth 
restriction 21,22. Our results might suggest that the effects of TH on these outcomes are 
partially explained by the effects of high thyroid function on the placental function. 
Based on the performed mediation analysis, we observed that 10.4% and 12.5% of the 
association of TH with pre-eclampsia and birth weight could be mediated via changes 
in placental function, respectively. However, these effects are relatively small and were 
not consistent across pregnancy outcomes or ultrasound measurements. This suggests 
that the association of TH with pregnancy outcomes is largely explained by either (1) 
direct effects of TH, or (2) through effects on potential mediators other than placental 
function, such as effects on fetal growth and development or more generalized effects 
on overall metabolic state. On one hand, this could be expected since TH responsive 
tissues are widespread and the range of TH effects includes regulation of many maternal 
and fetal tissues. Nonetheless, the analyses in the current study should not yet overrule 
a potentially important role of the placenta as an influential mediator, as the methods 
used in this study might be insufficient to accurately examine and estimate potential 
effects. Further studies are needed to verify our results. Of particular interest would be 
to re-analyze clinical trials that have investigated the effects of levothyroxine treatment. 
Little is known about the effects of TH on the placentation in vivo and/or in humans. To 
our knowledge, no study has investigated the association of gestational thyroid func-
tion with a measure of placental function in a clinical setting. We were able to study the 
association of maternal thyroid function in early pregnancy with subsequent measures 
of placental function prospectively, in a large number of women and also at the two 
different time-points of gestation. 
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A potential limitation of this study is that only a single TH measurement was available 
and therefore we were not able to assess the association of TH changes during gestation 
with placental function. However, longitudinal studies in pregnant women have shown 
a relatively low intra-individual variation of TH during the course of gestation 49. Another 
potential limitation is differential missingness of placental ultrasound measurements, 
which may have introduced bias. This was particularly the case for the mediation analy-
ses on pre-eclampsia for which the missingness led to a large proportion of missing data 
of the outcome. However, we coped with this by imputing variables with missing data in 
the datasets used for mediation analyses. Finally, the observational nature of this study 
does not allow for inference of causality and does not preclude the existence of residual 
confounding.
In conclusion, our data demonstrate that high thyroid function in early pregnancy 
is associated with measures of placental vascular function in both maternal and fetal 
compartment during the second and third trimester. The underlying mechanism of 
these associations may involve TH effects on the key growth factors and cytokines in-
cluded in early placentation. Further research is necessary to investigate the biological 
mechanism by which maternal TH affects placental function and to further translate the 
findings from in vitro studies into clinically relevant associations.
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Supplemental Table 1. Descriptive Statistics of the Participants – Non response analysis
Characteristic
Value (response)
Value (non-
response)
P value
TSH, median (95%range), mu/l, 1.34 (0.04-4.49) 1.47 (0.06-4.52) 0.2
FT4, median (95%range), pmol/l 14.7 (10.2–22.2) 14.6 (9.4-22.6) 0.7
Gestational age at blood sampling, 
media median (95%range)
median (95% range), weeks
13.4 (9.7-17.6)
14.2 (10.5-17.8) <0.001
Age, mean ±sd, years 29.7±5.0 29.2 ±5.2 0.02
BMI, median, (95% range), kg/m2 23.5 (18.5-35.6) 24.2 (18.6-38.3) <0.001
Parity, n (%) 0.12
Nullipara 3057 (57.5) 270 (53.9)
Primipara 1589 (29.9) 147 (29.3)
Multipara 669 (12.6) 61 (12.2)
Smoking status, n (%) 0.4
Non smokers 3821 (71.9) 360 (71.9)
Stopped smokers 505 (9.5) 37 (7.4)
Smokers 989 (18.6) 104 (20.8)
Educational level, n (%) <0.01
No education or primary education 587 (11.0) 91 (18.2)
Secondary education 2429 (45.7) 227 (45.3)
Higher education 2299 (43.3) 153 (36.6)
Ethnicity, n (%) <0.01
Dutch 2726 (51.3) 238 (47.5)
Moroccan 350 (6.6) 37 (7.4)
Turkish 425 (8.0) 24 (4.8)
Surinam 477 (9.0) 53 (10.6)
Dutch Antilles 173 (3.3) 18 (3.6)
Asian 148 (2.8) 15 (3.0)
Other – Western 477 (9.0) 65 (13.0)
Other – Non-Western 539 (10.1) 51 (10.2)
Fetal sex, n (%) 0.7
Male 2667 (50.2) 250 (49.9)
Female 2648 (49.8) 251 (50.1)
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Supplemental Table 2. Association of maternal thyroid function with placental hemodynamic function
umbilical artery PI in 
the 2nd trimester 
uterine artery RI in 
the 2nd trimester 
umbilical artery PI in 
the 3rd trimester
uterine artery RI in 
the 3rd trimester
log TSH -0.017 (-0.030, -0.004) * 0.667 (-0.007, 0.008) 0.008 (-0.004, 0.021) -0.001 (-0.016, 0.014) )
log FT4 0.035 (0.005, 0.065) * 0.026 (0.009, 0.043) * 0.034 (0.006, 0.060)* 0.001 (-0.006, 0.008)
Values are regression coefficients (95% confidence intervals) from the multivariate linear regression analy-
ses. Models were adjusted for gestational age at blood sampling, gestational age at ultrasound, smoking, 
BMI and fetal sex
* P<0.05
† P<0.001
Supplemental Table 3. Association of maternal thyroid function with the risk of notching in the 3rd trimester
OR (95% CI)
log TSH 1.062 (0.978, 1.153) 
log FT4 1.050 (1.021, 1.080) †
Values are odds ratios (95% confidence intervals) from the multivariate logistic regression analyses. Models 
were adjusted for gestational age at blood sampling, gestational age at ultrasound, smoking, BMI, maternal 
age, ethnicity, parity and fetal sex
* P<0.05
† P<0.001
Supplemental Table 4. The mediation role of placental function in the association of thyroid function with 
gestational outcomes (imputed data)
Preeclampsia (FT4)
Total 
effect
P value Direct effect
Mediated 
effect
P value
Percentage of 
mediated effect
uMPI 3 † 0.0143 0.05 0.0141 0.0002 0.53 2.0
uTRI 2 ‡ 0.0149 0.03 0.0138 0.0020 0.02 10.4
Birth weight
(FT4) 
Total 
effect
P value Direct effect
Mediated 
effect
P value
Percentage of 
mediated effect
uMPI 2* -0.0143 0.00 -0.0140 -0.0003 0.51 2.0
uMPI 3 -0.0146 0.00 -0.0139 -0.0008 0.26 5.0
uTRI 2 -0.0143 0.00 -0.0125 -0.0018 0.00 12.5
Notching -0.0149 0.01 -0.0139 -0.0010 0.68 6.8
Premature delivery
(Hypothyroxinemia)
Total 
effect
P value Direct effect
Mediated 
effect
P value
Percentage of 
mediated effect
uTRI 2 0.0824 0.02 0.0811 0.0033 0.66 2.8
* UMPI 2 – umbilical artery pulsatility index in the 2nd trimester 
† UMPI 3 – umbilical artery pulsatility index in the 3rd trimester
‡ UTRI 2 – uterine artery resistance index in the 2nd trimester
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Supplemental Figure 1. The association of maternal thyroid function with the 2nd trimester placental 
function, among euthyroid mothers
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Plots show the linear regression models for FT4 and TSH and the resistance indices of the umbilical and 
uterine artery in the second trimester of pregnancy, as predicted mean with 95 percent confi dence interval. 
Analyses were adjusted for gestational age at blood sampling, gestational age at ultrasound, smoking, BMI 
and fetal sex. 
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Supplemental Figure 2. The association of maternal thyroid function with the 3rd trimester placental 
function, in euthyroid mothers
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Plots show the linear regression models for FT4/TSH and uterine artery RI, as predicted mean with 95 per-
cent confi dence interval. Analyses were adjusted for gestational age at blood sampling, gestational age at 
ultrasound, smoking, BMI and fetal sex. 
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Supplemental Figure 3. The association of maternal thyroid function with the risk of uterine artery notch-
ing, amongst euthyroid mothers
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Plots show the logistic regression models for TSH and FT4 and the risk of 3rd trimester notching in the uter-
ine artery, as predicted mean with 95 percent confi dence interval. Analyses were adjusted for gestational 
age at blood sampling, gestational age at ultrasound, smoking, BMI, ethnicity, parity and fetal sex. 
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ABSTRACT
Context: High homocysteine concentrations are associated with maternal pregnancy 
complications and low birth weight, jaundice and cerebrovascular accidents in neo-
nates. Thyroid hormone may interfere with homocysteine metabolism via stimulation 
of vitamin B12- and folate-dependent processes and via effects on enzymes of the re-
methylation pathway. 
Objective: Investigating the associations of maternal and neonatal thyroid function 
with homocysteine during pregnancy and after delivery, respectively.
Design, setting and participants: Within Generation R study, a population-based pro-
spective cohort, we studied the associations of maternal and neonatal TSH and FT4 with 
homocysteine, folate and vitamin B12 concentrations using multiple linear regression 
analyses.
Main outcome measures: Thyroid stimulating hormone (TSH), free thyroxine (FT4), ho-
mocysteine, folate and vitamin B12 concentrations were determined in early pregnancy 
(<18 weeks; N=1094 women without folic acid supplementation) and in cord blood of 
4475 neonates.
Results: In neonates, there was a positive association of FT4 with homocysteine and 
an inverse association of TSH with homocysteine. The associations attenuated after 
adjustment for folate and vitamin B12 concentration (β change for FT4: 0.00559 ±0.001, 
P<0.0001 to 0.00310 ±0.001, P=0.015; and for TSH: -0.00165 ±0.001, P=0.005 to -0.00086 
±0.001, P=0.11). In mothers, there was a positive association of FT4 with homocysteine 
(P=0.026) but no association of FT4 with folate or vitamin B12 (P≥0.08).
Conclusion: Higher thyroid function is associated with higher homocysteine concentra-
tions in pregnant women and in neonates. These data provide new insights into the 
effects of thyroid hormone on folate- and vitamin B12-dependent processes during 
early growth and development.
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INTRODuCTION
High concentrations of homocysteine, a non-protein amino acid, are associated with 
adverse coronary, cerebrovascular and maternal pregnancy-specific outcomes 1-6. In 
neonates, high homocysteine is associated with low birth weight, jaundice and cere-
brovascular accidents 7-9. In adults, high homocysteine may affect reproductive function 
and fertility 10 and is associated with neurological disorders 11. High homocysteine con-
centrations may have a role in early pregnancy loss, preeclampsia, premature delivery, 
placental abruption, delayed embryonic development and congenital birth defects 2-6,12. 
Homocysteine also serves as a marker of folate (vitamin B9) and vitamin B12 (cobala-
min) since conversion of homocysteine to methionine occurs through a re-methylation 
pathway which requires folate and vitamin B12 13. A deficiency of these vitamins nega-
tively affects re-methylation cycle resulting in higher homocysteine concentrations 13-16. 
Folate and vitamin B12 play a key role in important metabolic processes, including DNA 
and RNA synthesis, amino acid metabolism, cell proliferation and erythropoiesis 14,15,17. 
During fetal development and in the neonatal period, these metabolic and proliferative 
processes are particularly intense 18.
Thyroid hormone may affect homocysteine metabolism via two potential mechanisms. 
First of all, thyroid hormone stimulates folate- and vitamin B12-dependent biochemical 
processes, including DNA synthesis 19,20, amino acid metabolism 21, cell proliferation 22,23 
and erythroblast differentiation 24-26. A higher thyroid function and a consequent stimula-
tion of these folate- and vitamin B12-consuming metabolic processes may lead to higher 
homocysteine concentrations, as has been suggested previously 27,28. Secondly, animal 
studies indicate that thyroid hormone affects the activity of methylenetetrahydrofolate 
reductase (MTHFR) and methionine synthase, enzymes required for re-methylation 
of homocysteine 28. Although some studies in humans showed that thyroid dysfunc-
tion is associated with high homocysteine concentrations 29-31, others did not 32,33 and 
population-based studies are lacking.
There is a high demand for folate and vitamin B12 in the developing fetus 18. For that 
reason, folic acid/multivitamin supplementation is advised from the periconceptional 
period onwards to prevent neural tube defects 34. Still, high demands for folate and 
vitamin B12 continue in the neonatal period 18 and determinants of homocysteine 
metabolism in this period might indirectly have a role in the pathophysiology of clinical 
events associated with high homocysteine 8,9. We hypothesized that thyroid function 
may be a determinant of homocysteine concentration during gestation and in the 
neonatal period. 
The aim of this study was to investigate the association of thyroid function with ho-
mocysteine, folate and vitamin B12 concentrations in pregnant women and in neonates 
and to explore which of the two potential pathways may play a role. 
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METHODS
Study population
This study was embedded in Generation R, a population-based prospective cohort 
from early fetal life onwards, in Rotterdam, the Netherlands 35. The study was designed 
to identify early environmental and genetic causes leading to normal and abnormal 
growth, development, and health during fetal life and childhood 35. In total, 7069 moth-
ers with expected delivery date between April 2002 and January 2006 were enrolled 
during early pregnancy. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) 
were determined in the first available serum sample during early pregnancy (<18 weeks) 
in 5859 women, from which women with thyroid disease or thyroid (interfering) medica-
tion, twin pregnancies and /or IVF were excluded from the analysis (N=88, N=64, N=24, 
respectively; Figure 1). From these women, 5683 had homocysteine, folate or vitamin 
B12 concentration measurements available (Figure 1). Furthermore, a subgroup of 
women (N=1094; Figure 1) did not take folic acid supplementation during pregnancy. 
From the total population of women, 4968 neonates had available cord blood TSH and 
FT4 measurements available, from which 4475 had data on cord blood homocysteine, 
folate or vitamin B12 concentration available (Figure 1). Written informed consent was 
obtained from all participants. The general design, research aims and specific measure-
ments in The Generation R study have been approved by the Medical Ethical Committee 
of the Erasmus Medical Center, Rotterdam.
Thyroid function measurements
Maternal serum samples were obtained in early pregnancy (median 13.2 weeks, 95% 
range 9.7 – 17.6 weeks) and cord blood samples were obtained directly after birth (me-
dian gestation age at birth 40.1 week, 95% range 36.6 –42.3 weeks). Plain tubes were 
centrifuged and serum was stored at -80°C. TSH and FT4 concentrations in maternal and 
cord blood serum samples were determined using chemiluminiscence assays (Vitros ECI; 
Ortho Clinical Diagnostics). The intra- and interassay variation coefficients were < 4.1% 
for TSH at a range of 3.97–22.7 mU/ml and <5.4% for FT4 at range of 14.3 – 25.0 pmol/l. 
Homocysteine, folate and vitamin B12 measurements
Maternal and cord blood samples were obtained at the same time as for thyroid function 
measurements. Total homocysteine, folate and total vitamin B12 concentrations were 
measured using a chemiluminiscence immunoassay on the Architect System (Abbott 
Diagnostics B.V.) with a between-run variation coefficient ranging from 1.5 to 8.9%. The 
analytic ranges for homocysteine, folate, and vitamin B12 were 1–50 μmol/l, 1.8–45.3 
nmol/l and 44–1476 pmol/l, respectively.
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Folic acid supplement intake during pregnancy
Information on folic acid supplement use (0.4 – 0.5 mg) and the time of supplement 
initiation was obtained by questionnaires at study enrollment. We categorized women 
into 3 groups: (1) women with no use of supplements, (2) women that started the use 
during first 10 weeks of pregnancy and (3) women that started the use periconceptually. 
The percentage of available data for folic acid supplementation during pregnancy was 
75.1%.
MTHFR single nucleotide polymorphism (SNPs)
DNA was extracted from white blood cells obtained from early pregnancy blood samples 
in mothers and neonates at birth and C677T (rs1801133) and A1298C (rs1801131) were 
genotyped. In mothers, genotyping was performed using a Taqman allelic discrimina-
tion assay (Applied Biosystems) and Abgene QPCR Rox mix (Abgene, Hamburg, Ger-
many). The genotyping reaction was amplified by using the GeneAmp PCR system 9600 
Figure 1. Flowchart showing selection procedure of the study population
Population available for analyses 
N=5683 
Mothers enrolled during early pregnancy 
N=7069 
Mothers with TSH and/or FT4 measurement 
N=5859 
Excluded due to thyroid 
disorders/thyroid medication use  
N=88 
Excluded due to twin pregnancies 
N=64 
Excluded due to IVF treatment 
N=24 
Women that did not take folic acid 
supplementation during pregnancy 
N=1094 
Homocysteine  
N=1035 
Neonates with TSH and/or FT4 measurement 
N=4968 
Population available for analysis 
N=4475 
Homocysteine  
N=4229 
 
Folate 
N=4351 
 
 
Vitamin B12 
N=4438 
 
 
Folate 
N=1044 
 
 
Vitamin B12 
N=1003 
 
Neonates with cord blood samples 
N=5821 
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(95°C for 15 min), then 40 cycles of 94°C (15s) and 60°C (1 min). The fluorescence was 
detected on 7900 HT Fast Real-Time PCR System (Applied Biosystems) and individual 
genotypes were determined by using SDS software (version 2.3; Applied Biosystems)36. 
The genotype frequencies of MTHFR C677T were 31.8% (CC), 25.1% (TC) and 5.9% (TT) 
and A1298C were 30.3% (AA), 26.6% (CA) and 5.9% (CC). In neonates, genotype data were 
extracted from an imputed genomewide association scan (HapMap phase II release 22). 
The genotype frequencies of MTHFR C677T were 47.0% (CC), 38.2% (TC) and 8.3% (TT) 
and A1298C were 47.1% (AA), 37.5% (CA) and 9.7% (CC). The percentage of missing data 
for MTHFR SNPs was 47% in the maternal data (subgroup of women that did not take 
folic acid supplements) and 6.4% in the neonatal data.
Covariates
Information on ethnicity, educational level and smoking status was obtained by ques-
tionnaires at study enrollment. Ethnicity was determined by the country of origin and 
was defined according to the classification of Statistics Netherlands 35. Maternal smoking 
was defined as no smoking, smoking until known pregnancy and continued smoking 
during pregnancy. Information on parity and sex of the child was obtained from hospital 
registries. BMI was measured at study enrollment. 
Statistical analyses
The association of maternal and neonatal TSH and FT4 with homocysteine, folate and 
vitamin B12 concentrations was investigated using multiple linear regression analyses 
with restricted cubic splines utilizing three knots, to account for possible non-linear 
associations. Homocysteine, folate and vitamin B12 values were logarithmically trans-
formed in order to achieve normal distribution of the residuals of the regression models. 
Multivariable associations were graphically depicted by plots and β estimates with 95% 
confidence intervals are shown in Supplemental Tables 4 and 5. In order to identify as-
sociations that are more likely to reflect normal biology and to exclude the effect of folic 
acid supplements on the associations, main analysis with maternal data was performed 
in the subgroup of women that did not take any folic acid supplements during pregnan-
cy. In order to examine whether the association of thyroid function with homocysteine, 
folate or vitamin B12 differs based on MTHFR enzyme activity, we tested for interaction 
by adding product terms of TSH or FT4 and single nucleotide polymorphism (SNP) of 
MTHFR (rs1801133 and 1801131) to the models studying both mothers and neonates.
The mediator role of gestational homocysteine concentration in the association of 
thyroid function with birth weight (described previously 37) was investigated by per-
forming a mediation analysis using the approach of Imai et al. 38.
All model covariates were selected based on biological plausibility, change of the ef-
fect estimate of interest or residual variability of the model. The analyses were adjusted 
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for gestational age at blood sampling, ethnicity, maternal age, educational level, parity 
and smoking status in the maternal models and for birth weight standardized to gesta-
tional age, ethnicity, maternal age, educational level, parity and smoking in the neonatal 
models.
We performed multiple imputation according to Markov Chain Monte Carlo method for 
covariates with missing data 39. Before imputation of the missing values, we performed 
exploratory analyses by investigating the pattern of missingness for each variable. All 
variables showed random missingness pattern. In the maternal data, the percentage of 
missing data was less than 1% for BMI and parity, 4% for ethnicity, 7.1% for education 
level and 11.4% for smoking. In the neonatal data, the percentage of missing data was 
less than 1% for parity and maternal age, 3.6% for ethnicity, 6.7% for maternal educa-
tion, 2.0% for birthweight and 10.8% for smoking. Five imputed datasets were created 
and pooled for analysis. Maternal BMI, parity, educational level, ethnicity and smoking 
were then added to the maternal models and maternal age, parity, smoking, education 
level, neonatal birth weight and ethnicity were added to the neonatal models. Further-
more, we added TSH, FT4 concentrations as well as homocysteine, folate, and vitamin 
B12 concentrations as prediction variables only. There were no statistically significant 
differences in descriptive statistics between the original and imputed datasets. 
Statistical analyses were performed using Statistical Package of Social Sciences ver-
sion 21.0 for Windows (SPSS Inc. Armonk, NY) and R statistical software version 3.2.1 
(package ‘rms’ and ‘mediation’).
RESuLTS
After exclusions, the final study population consisted of 5683 women, of which 1094 
women did not use pre- or postconceptional folic acid supplements, and 4475 neonates 
(Figure 1). Descriptive statistics are shown in Table 1 (descriptives for the total group of 
women are shown in Supplemental Table 1).
Mothers (non-supplemented)
There was no statistically significant association of TSH with homocysteine (Figure 2A, 
P=0.06), whereas there was a positive association of FT4 with homocysteine (Figure 
2B, P=0.026). There was an inverse association of TSH with folate (Figure 2C, P=0.004), 
whereas there was no association of FT4 with folate (Figure 2D, P=0.30). There was a 
positive association of TSH with vitamin B12 (Figure 2E, P=0.033) whereas there was 
no statistically significant association of FT4 with vitamin B12 (Figure 2F, P=0.08). The 
association of thyroid function with homocysteine did not change after adjustment for 
folate and vitamin B12 concentrations (data not shown). The results remained similar 
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after adjustment for TPO antibodies or hCG concentrations and did not differ according 
to MTHFR SNPs (Supplemental Table 2).
Table 1. Descriptive Statistics of the Participants
Characteristic - mothers Value Characteristic - neonates Value
TSH, median (95%range), mu/l 1.3 (0.03-3.96) TSH, median (95% range), mu/l 9.12 (3.35-32.9)
FT4, median (95%range), pmol/l 14.5 (10.2-22.6) FT4, median (95% range), 
pmol/l
20.5 (15.4-28.5)
Homocysteine, median, 
(95%range), μmol/l
7.4 (4.6-15.0) Homocysteine, median (95% 
range) μmol/l
9.1 (5.2-16.5)
Folate, median, (95%range), 
nmol/l
8.6 (4.7-21.3) Folate, median (95% range), 
nmol/l
20.4 (10.4-38.4)
Vitamin B12, median, 
(95%range), pmol/l
157.0 (61.1-421.3) Vitamin B12, median (95% 
range), pmol/l
300.0 (120.0-900.0)
Gestational age at blood 
sampling, median (95%range), 
weeks
13.9 (9.6-17.8) Gestational age at birth, 
median (95% range), weeks
40.1 (36.6-42.3)
Age, mean ±sd , years 27.8 ±5.6 Birth weight, mean ± sd, g 3463.9 ±502.9
BMI, median, (95% range), kg/m2 23.5 (18.5-35.7) Gender, n (%)
Parity, n (%)  Males 2272 (50.8)
Nullipara 499 (45.6)  Females 2202 (49.2)
Primipara 334 (30.5) Ethnicity
Multipara 261 (23.9)  Dutch 2704 (55.0)
Smoking status, n (%)  Moroccan 354 (7.2)
Non smokers 756 (69.1)  Turkish 400 (8.1)
Stopped smokers 77 (7.0)  Surinamese 377 (7.7)
Smokers 261(23.9)  Asian 150 (3.1)
Educational level, n (%)  Other - European 355 (7.2)
No education or primary 
education
273 (25.0)  Other – Non-European 573 (11.7)
Secondary education 615 (56.2)
Higher education 206 (18.8)
Ethnicity, n (%)
Dutch 231 (21.1)
Moroccan 163 (14.9)
Turkish 188 (17.2)
Surinamese 156 (14.3)
Asian 51 (4.7)
Other – European 82 (7.5)
Other – Non-European 223 (20.4)
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The associations of TSH or FT4 with homocysteine, folate and vitamin B12 for the 
total group of women, irrespective of folic acid supplementation status, are shown in 
Supplemental Figure 1. 
Neonates
There was an inverse association of TSH with homocysteine (Figure 3A, P=0.005) and a 
positive association of FT4 with homocysteine (Figure 3B, P<0.0001). There was a posi-
tive association of TSH with folate (Figure 3C, P<0.0001) and an inverse association of 
FT4 with folate (Figure 3D, P=0.003). There was no association of TSH with vitamin B12 
(Figure 3E, P=0.43) and there was an inverse association of FT4 with vitamin B12 (Figure 
3F, P<0.0001). 
Figure 2. The association of maternal thyroid function with homocysteine, folate and vitamin B12 concen-
trations
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Plots show the linear regression models for the association of TSH and FT4 with folic acid, vitamin B12 and 
homocysteine concentrations, as predicted mean with 95 percent confi dence interval in the group of moth-
ers that did not take folic acid supplements anytime during pregnancy. Analyses were adjusted for gesta-
tional age at blood sampling, fetal sex, ethnicity, maternal age, educational level, parity and smoking status. 
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The association of TSH with homocysteine attenuated after adjustment for folate and 
vitamin B12 (beta estimate change: -0.00165 ±0.00058 (P=0.005) to -0.00086 ±0.00054 
(P=0.11)). Similarly, the association of FT4 with homocysteine attenuated after adjust-
ment for folate and vitamin B12 (beta estimate change: 0.00559 ±0.00138 (P<0.0001) 
to 0.00310 ±0.00127 (P=0.015)). Taken together, this indicates that in neonates, roughly 
48-55% of the association of thyroid function with homocysteine is mediated through 
changes in folate and vitamin B12. 
Although there was a positive association of maternal homocysteine concentrations 
with neonatal homocysteine concentrations (data not shown), the results remained 
similar after adjustment for maternal homocysteine, folate or vitamin B12 concentra-
tions, maternal folate supplementation status and did not diff er according to diff erences 
in neonate MTHFR SNPs (Supplemental Table 2).
Figure 3. The association of neonatal thyroid function with homocysteine, folate and vitamin B12 concen-
trations
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Plots show the linear regression models for the association of TSH and FT4 with folic acid, vitamin B12 
and homocysteine concentrations, as predicted mean with 95 percent confi dence interval in the neonates. 
Analyses were adjusted for birth weight standardized for gestational age, fetal sex, ethnicity, maternal age, 
educational level, parity and smoking status. 
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Of all covariates in the models, gestational age at blood measurement and ethnicity 
had the largest effect on the association studied (up to 36% and 27% change in the 
effect estimate, respectively).
The mediator role of homocysteine in the association of maternal thyroid 
function with birth weight
Mediation analysis showed that the effect of FT4 on birth weight was in part mediated 
through effects of FT4 on homocysteine concentrations (13.3% of mediated effect, 
P<0.001; Supplemental Table 3).
DISCuSSION
Our data show an association of thyroid function with homocysteine concentrations 
in pregnant women and in neonates. To our knowledge, this is the first study that 
investigates the associations of both maternal and neonatal thyroid function with 
homocysteine, folate and vitamin B12 concentrations in a population-based setting. In 
pregnant women, higher FT4 concentrations were associated with higher homocyste-
ine. In neonates, higher FT4 and lower TSH were associated with higher homocysteine 
concentrations and this was mediated by the effects of thyroid function on folate and 
vitamin B12 concentrations.
There is a paucity of population-based studies investigating the association of thyroid 
function with homocysteine. Some clinical studies suggest that hypothyroid patients 
have higher homocysteine concentration compared to euthyroid controls 29,30. Con-
versely, in patients with thyrotoxicosis, a positive association of FT4 with homocysteine 
is reported 31. However, due to differences in determinants of homocysteine as well as 
potential pathological influences in diseased and/or elderly populations, the previous 
findings are ungeneralizable to women in pregnancy or to children. 
We demonstrate that in neonates, higher FT4 and lower TSH concentrations are asso-
ciated with higher homocysteine concentrations. This suggests that a thyroid hormone-
mediated stimulation of metabolic effects may lead to lower availability and/or activity 
of factors necessary for homocysteine conversion or degradation. In neonates, higher 
thyroid function was also associated with a lower folate and vitamin B12 concentration, 
in line with the notion of depleting effects of higher thyroid function on folate and vita-
min B12 concentrations 27,28,31. This hypothesis is further supported by the attenuation 
of the association of thyroid function with homocysteine by 48-55% after adjustment 
for folate and vitamin B12 concentration. The growth of fetal tissues, especially in the 
last trimester, requires intense cell proliferation that is dependent on folate and vitamin 
B12 concentrations 18. The most important processes that depend on folate and vitamin 
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B12 consumption include DNA synthesis, amino acid metabolism and erythroblast 
differentiation 19-26. Animal data show that thyroid hormone is essential for adequate 
erythropoiesis especially at birth 40, in line with a progressive increase in erythrocyte 
content throughout gestation and the highest values at birth 41. This is in line with the 
timing of our thyroid function measurement and might in part explain the observed 
differences between maternal and neonatal analyses.
Animal studies show that hyperthyroidism leads to higher homocysteine concentra-
tions 42-44 and thyroid hormone dependent effects on methionine synthase activity have 
been suggested 28. In turn, this enzyme is vitamin B12 dependent 28. As such, higher 
thyroid hormone concentrations may affect the re-methylation cycle via lowering of 
vitamin B12 and or/folate availability, as well as via direct interference with the enzymes 
of the re-methylation cycle. However, our analyses regarding genetic variance in the 
MTHFR gene did not suggest that MTHFR enzyme is implicated in such mechanisms. Fu-
ture studies are required to further elucidate pathways through which thyroid hormone 
affects the metabolic cycle of homocysteine.
In mothers, higher FT4 concentrations were also associated with higher homocysteine 
concentrations. However, opposite to the results in neonates, this association could not 
be explained by the relation of FT4 with folate and vitamin B12. This difference between 
pregnant women and neonates could be explained by various factors. Firstly, diet and 
vitamin supplements during pregnancy may interfere with homocysteine metabolism 13. 
To minimize the latter effect, we focused only on women that were not taking folic acid 
supplements. However, no data were available on vitamin B12 supplementation or other 
vitamin supplementation. Furthermore, it is likely that some women would use combined 
(pre)conceptional multivitamin formulas and the availability of our data on supplement 
usage leaves the possibility of data misclassification. In contrast, the associations in 
neonates might potentially be less affected by such factors and might represent a better 
model for studying this association. Secondly, beside the re-methylation to methionine, 
a significant portion of homocysteine is actually converted to cystathionine via vitamin 
B6-dependent process 13. The positive association of FT4 with homocysteine in mothers 
could potentially be due to a greater effect of thyroid hormone on homocysteine con-
version to cystathionine than on re-methylation to methionine. In line with this, lower 
vitamin B6 concentrations were observed in hyperthyroidism compared to euthyroid 
state 45. Unfortunately, we do not have vitamin B6 concentrations available to further 
investigate this hypothesis. In addition, women with a higher general susceptibility to 
autoimmune disease may have both TPOAbs and gastric auto-antibodies, and the latter 
could affect vitamin B12 concentrations 46. Therefore, we adjusted all models for TPOAbs, 
which did not result in a change in the effect estimates. This suggests that the observed 
association is unlikely to be confounded by or mediated via higher susceptibility to 
autoimmunity in general. Finally, hemodilution and hormonal changes in pregnancy 
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might complicate the interpretation of the studied associations with homocysteine 47,48. 
Nonetheless, the positive association of maternal thyroid hormone with homocysteine 
concentration is worth of further investigation, especially considering its potential 
mediating role in the association of high thyroid hormone with lower birth weight we 
observed. Therefore, due to potential harmful effects of high homocysteine concen-
trations that may contribute to adverse pregnancy outcomes, clinical determinants 
of homocysteine concentrations may be helpful in predicting the risk of pregnancy 
complications. Future studies should confirm our findings regarding the association of 
high gestational thyroid hormone with high homocysteine concentrations and further 
investigate the extent of this effect and its potential role in pregnancy complications.
Our analyses showed that gestational age at blood sampling and ethnicity were the 
most important confounding variables, which indicates that future studies should take 
into account gestational age-related changes as well as potential genetic differences in 
thyroid function and homocysteine concentration.
A potential limitation of our study is the availability of a single TSH, FT4 and homo-
cysteine measurement only. This did not enable us to investigate whether the observed 
associations change in time, particularly in later stages of gestation. However, during 
pregnancy, both thyroid function 49 and homocysteine concentrations 48 are subject to a 
relatively low intra-individual change, indicating that no large changes in the current as-
sociations can be expected. Another potential limitation of the current study is the fact 
that a relatively large proportion of pregnant women (47%) had missing data on MTHFR 
SNPs. Therefore, analyses might have been underpowered to detect potential relevant 
MTHFR-dependent differences in the association of thyroid function with homocyste-
ine. However, MTHFR-dependent differences were not observed in neonates either, for 
which data on MTHFR SNPs were available in 93.6%. In addition, we cannot exclude the 
possibility that the difference in results between mothers and neonates is due to the 
lack of power to detect similar effects in our subset of women non-supplemented with 
folic acid. Finally, the observational nature of this study does not allow for inference of 
causality and does not exclude the existence of residual confounding.
In conclusion, our study demonstrates that higher thyroid function is associated with 
higher homocysteine concentration in pregnant women and in neonates. In neonates, 
the underlying mechanism of this association is likely to involve thyroid hormone medi-
ated stimulation of metabolic processes that require folate and vitamin B12. In pregnant 
women, different mechanisms seem to underlie the effects of thyroid function on homo-
cysteine metabolism. These data provide new insights into the effects of thyroid hormone 
on folate and vitamin B12-dependent biochemical processes during early growth and 
development. Further research is required to investigate the clinical significance of thyroid 
hormone dependent folate and/or vitamin B12 utilization, and to elucidate the potential 
role of thyroid function on vitamin B6 dependent pathway of homocysteine catabolism. 
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Supplemental Table 1. Descriptive Statistics of the Participants
Characteristic – mothers total group Value
TSH, median (95%range), mu/l 1.35 (0.05-4.51)
FT4, median (95%range), pmol/l 14.7 (10.3-22.1)
Homocysteine, median, (95%range), μmol/l 6.9 (4.6-12.1)
Folate, median, (95%range), nmol/l 15.7 (5.5-37.3)
Vitamin B12, median, (95%range), pmol/l 169.0 (72.0-417.7)
Gestational age at blood sampling, median (95%range), weeks 13.2 (9.7-17.6)
Age, mean ±sd , years 29.7 ±5.0
BMI, median, (95% range), kg/m2 23.5 (18.5-35.7)
Parity, n (%)
Nullipara 3096 (57.9)
Primipara 1574 (29.5)
Multipara 673 (12.6)
Smoking status, n (%)
Non smokers 3821 (71.9)
Stopped smokers 505 (9.5)
Smokers 989 (18.6)
Educational level, n (%)
No education or primary education 543 (10.2)
Secondary education 2254 (45.9)
Higher education 2346 (43.9)
Ethnicity, n (%)
Dutch 2791 (52.2)
Moroccan 319 (6.0)
Turkish 429 (8.0)
Surinamese 480 (9.0)
Asian 138 (2.6)
Other – European 449 (8.4)
Other – Non-European 737 (13.8)
Folic acid supplement use, n (%)
Not used 1094 (19.3)
Started during first 10 weeks 1386 (24.4)
Started periconceptionally 1844 (32.4)
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Supplemental Table 2. Interaction terms of TSH and FT4 with MTHFR SNPs
Interaction term
P value
Homocysteine Folate Vitamin B12
M
ot
he
rs
TSH*rs1801133 0.05 0.47 0.83
TSH*rs1801131 0.74 0.93 0.69
FT4*rs1801133 0.42 0.59 0.88
FT4*rs1801131 0.75 0.69 0.99
N
ew
bo
rn
s TSH*rs1801133 0.86 0.78 0.21
TSH*rs1801131 0.51 0.97 0.73
FT4*rs1801133 0.81 0.03 0.92
FT4*rs1801131 0.41 0.08 0.58
Supplemental Table 3. The role of homocysteine in the association of maternal thyroid function with birth 
weight.
Total effect P value Direct effect Mediated effect P value Percentage of mediated effect
-0.036 0.00 -0.031 0.005 0.00 13.3
Supplemental Table 4. The association of maternal thyroid function with homocysteine, folate and vita-
min B12 concentrations
Log (homocysteine) Log (folate) Log (vitamin B12)
TSH 0.016 (-0.001, 0.032) -0.034 (-0.057, -0.010)* 0.031 (0.003, 0.059)*
FT4 0.007 (0.001, 0.012)* 0.004 (-0.004, 0.012) 0.009 (-0.001, 0.019)
Values are beta coefficents (95% confidence intervals) from the multivariate linear regression analyses. 
Models were adjusted for gestational age at blood sampling, ethnicity, fetal sex, maternal age, educational 
level, parity and smoking status. Analyses show the associations 
* P<0.05
** P<0.001
The estimated coefficients should be interpreted as:
1. An increase in one unit of TSH would result in 3.4% decrease in folate and 3.1% increase in vitamin B12
2. An increase in one unit of FT4 would result in 0.7% increase in homocysteine
CHAPTER 2.2
64
Supplemental Table 5. The association of neonatal thyroid function with homocysteine, folates and vita-
min B12 concentrations
Log (homocysteine) Log (folate) Log (vitamin B12)
TSH -0.002 (-0.004, -0.001)** 0.003 (0.001, 0.004)** 0.001 (-0.002, 0.003)
FT4 0.007 (0.004, 0.010)** -0.011 (-0.003, -0.050)*
0.012 (0.000, 0.015)*
-0.041 (-0.063, -0.025)**
0.036 (-0.014, 0.004)
Values are beta coefficents (95% confidence intervals) from the multivariate linear regression analyses. 
Models were adjusted for for birth weight standardized for gestational age, fetal sex, ethnicity, maternal 
age, educational level, parity and smoking status. 
* P<0.05
** P<0.001
The estimated coefficients should be interpreted as:
1. An increase in one unit of TSH would result in 0.2% decrease in homocysteine and 0.3% increase in folate
2. An increase in one unit of FT4 would result in 0.7% increase in homocysteine and 1.1% decrease in folate 
and 4.1% decrease in vitamin B12
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Supplemental Figure 1. The association of maternal thyroid function with homocysteine, folate and vita-
min B12 concentrations in all mothers. 
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Plots show the linear regression models for the association of TSH and FT4 with folic acid, vitamin B12 and 
homocysteine concentrations, as predicted mean with 95 percent confi dence interval irrespective of folic 
acid intake during pregnancy. Analyses were adjusted for gestational age at blood sampling, ethnicity, fetal 
sex, maternal age, educational level, parity and smoking status. 
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ABSTRACT
Background: Abnormal placentation in early pregnancy and disturbance in the bal-
ance between pro- and anti-angiogenic factors play a role in the pathogenesis of pre-
eclampsia. Human chorionic gonadotropin (hCG) regulates placental development and 
angiogenesis and may affect the ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) and 
placental growth factor (PlGF) in the serum. We investigated the association of total hCG 
concentration with the risk of pre-eclampsia.
Methods: In a large, population-based prospective cohort (N=7754), we measured total 
hCG and sFlt-1 and PlGF concentrations at 14.4 weeks (95% range 10.1 – 26.1 weeks); in 
mid-pregnancy (median 20.4 weeks, 95% range 18.5 – 23.5 weeks) a second measure-
ment of sFlt-1 and PlGF was performed. Pre-eclampsia diagnosis was confirmed by a 
certified medical doctor reviewing hospital charts. We used multiple linear and logistic 
regression to study the association of hCG with sFlt-1/PlGF ratio and the risk of pre-
eclampsia, respectively.
Results: A high hCG concentration was associated with a 1.5-2.7-fold higher risk of 
pre-eclampsia (P=0.0001), and with a higher sFlt-1/PlGF ratio during early pregnancy 
(P<0.0001). The first association attenuated by 40% after adjustment for early pregnancy 
sFlt-1/PlGF ratio (β estimate change: from 0.19 ±0.10; P=0.052, to: 0.12 ±0.10; P=0.22). 
The association of high hCG with the risk of pre-eclampsia was more dominant in preg-
nancies with a male fetus compared to pregnancies with a female fetus (4.0-fold higher 
risk vs 2.2-fold higher risk, respectively) . 
Conclusion: High total hCG concentrations in early pregnancy are associated with a 
higher risk of pre-eclampsia. The effects of high hCG concentration on the balance 
between pro- and anti-angiogenic factors during pregnancy may have a role in the 
pathophysiology involved.
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INTRODuCTION
Pre-eclampsia is a multisystem disorder defined by new-onset hypertension and pro-
teinuria after the 20th week of pregnancy 1. Pre-eclampsia occurs in 2-8% of pregnancies 
and is a major cause of maternal morbidity and adverse perinatal outcomes, accounting 
for 10-15% cases of maternal deaths worldwide 2. In this life-threatening condition, 
maternal complications arise from excessive inflammation and endothelial damage 
to multiple organs, including the placenta 2. The known risk factors for pre-eclampsia 
include nulliparity, age over 40 years and pre-existing conditions such as hypertension, 
renal diseases or diabetes 2. 
Although the exact pathophysiological mechanism is unclear, it is postulated that an 
abnormal placentation in early pregnancy predisposes to pre-eclampsia 2 and that a 
disturbance in the balance between pro- and anti-angiogenic factors plays an important 
role 3,4. Placental growth factor (PlGF), a member of vascular endothelial growth fac-
tor (VEGF) family and a pro-angiogenic factor, is expressed in the placenta throughout 
pregnancy 5. Soluble fms-like tyrosine kinase 1 (sFlt-1) is a potent anti-angiogenic factor 
that binds VEGFs including PlGF, thereby inhibiting angiogenesis during pregnancy  6. 
An abnormal serum sFlt-1/PlGF ratio, with low concentrations of PlGF and elevated 
concentrations of sFlt-1, often occurs in pre-eclamptic women and may be a marker of 
impaired placentation 7,8.
Human chorionic gonadotropin (hCG), a pregnancy-specific hormone produced by 
trophoblast cells, regulates progesterone production, implantation, uterine growth 
and immune cell function 9. hCG also regulates placental development, angiogenesis 
and vasculogenesis, partially via effects on VEGFs 10-14. Several studies suggest that high 
and/or low hCG concentration is a marker of subsequent clinical manifestation of pre-
eclampsia 15-18. However, considerable between-study discrepancies exist, such as ges-
tational age of hCG measurement, specific hCG isoform that was assessed and specific 
pre-eclampsia phenotype analyzed 15-20. To our knowledge, no study has investigated the 
potential role of early placental function markers that may predispose to pre-eclampsia, 
such as the sFlt-1/PlGF ratio, in the association of hCG with the risk of pre-eclampsia. 
In the current study, we aimed to investigate the associations of total hCG concentra-
tions with sFlt-1 and PlGF ratio, and the risk of subsequent pre-eclampsia, in a large 
population-based prospective cohort. 
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MATERIALS AND METHODS
Study population
This study was embedded in Generation R, a population-based prospective cohort 
from early fetal life onwards, in Rotterdam, the Netherlands 21. This cohort was designed 
to study early environmental and genetic determinants of growth, development and 
health during fetal and postnatal life 21. Eligible participants for this study were 8879 
pregnant women with an expected delivery date between April 2002 and January 2006 
that were enrolled in the cohort during pregnancy 21. Women with in vitro fertilization 
treatment (N=38), twin pregnancies (N=91) or pre-existing hypertension (N=75) were 
excluded from the analysis. Total hCG was determined in all first available serum samples 
and these data were available in 7754 women 22. 
hCG measurements 
Total hCG (at 14.4 weeks, 95% range 10.1 – 26.1 weeks) was measured using a solid-phase 
two-site chemiluminescent immunometric assay, calibrated against WHO 3rd IS 75/537, 
on an Immulite 2000 XPi system (Siemens Healthcare Diagnostics, Deerfield, IL, USA). 
The assay detects serum intact hCG, hyperglycosylated hCG, serum nicked hCG, serum 
nicked hyperglycosylated hCG, serum asialo hCG, serum hCG free β-subunit and serum 
nicked hCG β. The inter assay variation coefficient was 8.0, 6.3 and 5.1% at the concentra-
tion of 9.7, 53.1 and 821.5 IU/L, respectively. hCG concentrations were standardized by 
calculating standard deviation scores adjusted to gestational age at blood sampling as 
described previously 22.
Pre-eclampsia
Pre-eclampsia diagnosis was confirmed by a certified medical doctor by reviewing hos-
pital charts 23 and was defined according to the criteria of the International Society for 
the Study of Hypertension in Pregnancy: the development of a systolic blood pressure 
(BP) of 140 mm Hg or greater and/or a diastolic BP of 90 mm Hg or greater (at least two 
BP readings) after 20 weeks of gestation in a previously normotensive woman plus the 
presence of proteinuria (defined as two or more dipstick readings of 2 or greater, one 
catheter sample reading of 1 or greater, or a 24h urine collection containing at least 300 
mg of protein) 1
Angiogenic factor measurements
sFlt-1 and PlGF concentrations were obtained from EDTA samples drawn in early preg-
nancy (median 13.2 weeks, 95% range 9.6 – 17.6 weeks) and in mid-pregnancy (median 
20.4 weeks, 95% range 18.5 – 23.5 weeks) and analyzed using a microparticle-enhanced 
immunoassay on the Architect System (Abbott Diagnostics BV, Hoofddorp). The 
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between-run coefficients of variation for sFlt-1 were 2.8% at 5.5ng/ml and 2.3% at 34.0 
ng/ml. The coefficients for PlGF were 4.7% at 24 pg/ml and 3.8% at 113 pg/ml. Measure-
ments were available for 70.8% and 87.5% women for the first and second time-point, 
respectively. For each measurement, we constructed a ratio of sFlt-1 and PlGF, defined 
as a clinical predictor factor of the risk of pre-eclampsia 7,8.
Covariates
Information on maternal age, educational level, ethnicity and smoking status was ob-
tained by questionnaires during pregnancy. Ethnicity was determined according to the 
country of origin and defined according to the classification of Statistics Netherlands 
and maternal smoking was classified as no smoking, smoking until known pregnancy 
and continued smoking during pregnancy 21. Information on in vitro fertilization treat-
ment, parity and sex of the child was obtained from community midwifery and hospital 
registries.
Statistical analysis
The association of hCG with sFlt-1/PlGF ratio was investigated using multiple linear 
regression models. The association of hCG with pre-eclampsia (and pregnancy-induced 
hypertension) was investigated using multiple logistic regression analyses. We used 
restricted cubic splines utilizing three or four knots to assess possible nonlinearity. 
Subsequently, to further quantify the risk of pre-eclampsia, we calculated odds ratios 
for the highest and the lowest 5th, 10th and 15th percentile cutoffs for hCG concentration. 
Multivariable associations were graphically depicted by plots and β estimates with 95% 
confidence intervals are shown in Supplemental Table 2. We tested for effect modifica-
tion by gestational age at blood sampling or fetal sex by introducing a product interac-
tion term of hCG * gestational age at blood sampling or hCG * fetal sex to the model and 
a P value of <0.15 was considered for stratification. 
All model covariates were selected based on biological plausibility, change in the ef-
fect estimate or residual variability of the model. All analyses were adjusted for maternal 
age, ethnicity, BMI, parity, educational level, smoking status and fetal sex. 
In order to cope with missing data on the covariates, we performed multiple imputa-
tion according to the Markov Chain Monte Carlo method 24. Before imputation, explor-
atory analyses were performed by investigating the pattern of missingness for each 
variable. All variables showed a random missingness pattern. The percentage of missing 
data was less than 1% for maternal age, BMI, parity and fetal sex, 5.3% for ethnicity, 
8.8% for education level and 12.6% for smoking. Five imputed datasets were created and 
pooled for analysis. hCG concentration adjusted for gestational age at the measurement 
and the risk of pre-eclampsia were used as predictor variables only. There were no differ-
ences in descriptive characteristics between the original and imputed datasets.
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Statistical analyses were performed using Statistical Package of Social Sciences ver-
sion 21.0 for Windows (SPSS Inc. Armonk, NY) and R statistical software version 3.2.1 
(package ‘rms’).
RESuLTS
After exclusions, the final population comprised 7754 women (Figure 1), descriptives 
of which are shown in Table 1. There were 165 (2.2%) women who developed pre-
eclampsia; 4075 (54.6%) women were nulliparous and the majority of the population 
was of Dutch origin (3574; 47.9%) (Table 1).
The association of hCG with angiogenic factors
There was a positive association of hCG with sFlt-1/PlGF ratio during early pregnancy 
(P<0.0001; Figure 2A). The positive association of hCG with sFlt-1/PlGF during mid-preg-
nancy (P=0.0002, Figure 2B) attenuated after adjustment for sFlt-1/PlGF measurement 
at inclusion (P=0.29; Figure 2C). There was no association of hCG with the delta (the 
difference between first and second measurement) sFlt-1/PlGF ratio after adjustment 
Figure 1. Flowchart showing selection procedure of study population
Mothers enrolled during pregnancy 
N=8879 
Unable to perform hCG 
measurement mainly due to (non) 
availability of serum, discontinuation 
of study participation, lab 
measurement errors. 
hCG measurement performed 
N=8194  
Exclusions  
-   In vitro fertilisation (N=38)  
- Twin pregnancies (N=91) 
- Preexisting hypertension (N=135) 
- Missing data on hypertensive 
disorders (N=176) 
 
Population with available data for 
analysis 
N=7754 
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for the sFlt-1/PlGF measurement at inclusion (P=0.29; Supplemental Figure 1). The as-
sociations of hCG with PlGF and sFlt-1, separately, are shown is Supplemental Figures 2 
and 3, respectively.
Table 1. Descriptive Statistics
Characteristic Value
hCG, median (95%range), IU/l 35522.0 (6074.9-99890.3)
Gestational age at blood sampling, median (95% range), weeks 14.4 (10.1 – 26.1)
Hypertensive disorders in pregnancy, n (%)
Pre-eclampsia 165 (2.2)
Pregnancy-induced hypertension 286 (3.7)
No disorder 7303 (94.2)
sFlt-1/PlGF ratio <18 weeks, median, (95% range) 117.0 (19.5 – 432.6)
sFlt-1/PlGF ratio 18-25 weeks, median, (95% range) 24.4 (5.3 – 106.8)
Age, mean (sd), years 29.6 (5.3)
BMI, mean (sd), kg/m2 24.7 (4.4)
Parity, n(%)
Nullipara 4075 (54.6)
Primipara 2260 (30.3)
Multipara 1133 (15.2)
Smoking status, n(%)
Non smokers 5466 (73.2)
Stopped smokers 632 (8.5)
Smokers 1370 (18.3)
Educational level, n(%)
No education or primary education 933 (12.5)
Secondary education 3510 (47.0)
Higher education 3025 (40.5)
Ethnicity, n(%)
Dutch 3574 (47.9)
Moroccan 556 (7.4)
Turkish 736 (9.9)
Surinam 686 (9.2)
Asian 437 (5.9)
Other – European 585 (7.8)
Other – Non-european 894 (12.0)
Fetal sex, n(%)
Male 3763 (50.4)
Female 3705 (49.6)
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The association of hCG with pre-eclampsia
Figure 3 shows the association of hCG with the risk of pre-eclampsia. A higher hCG con-
centration was associated with a 1.5-2.7-fold higher risk of pre-eclampsia, depending 
on the hCG cutoff  value (Figure 3). After addition of a product interaction term to the 
model (hCG*fetal sex, P=0.020), we stratifi ed the association of hCG with the risk of pre-
eclampsia for fetal sex, which showed a predominant association of high hCG with the 
risk of pre-eclampsia in pregnancies with male fetuses (4.0-fold higher risk in males vs 
2.2-fold higher risk in females, respectively; Supplemental Figure 4). We did not observe 
eff ect modifi cation by gestational age (hCG*gestational age, P=0.73; data not shown). 
Figure 2. The association of maternal hCG concentration with sFlt-1/PlGF ratio
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Plots show linear regression models for the association of hCG with the sFlt1/PlGF ratio, as predicted mean 
with 95 percent confi dence interval. Analyses were adjusted for ethnicity, BMI, maternal age, fetal sex, educa-
tional level, parity and smoking status. The latter association was associated for the measurement at baseline.
Figure 3. The association of maternal hCG concentration with the risk of pre-eclampsia
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Plot shows regression model for the association of hCG with the risk of preeclampsia, as predicted mean 
with 95 percent confi dence interval. Analyses were adjusted for ethnicity, BMI, maternal age, fetal sex, edu-
cational level, parity and smoking status. 
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Furthermore, when we adjusted the association of hCG with the risk of pre-eclampsia to 
sFlt-1/PlGF ratio (in the subgroup of women with available data on angiogenic factors), 
the association attenuated by 40% (β estimate change: from 0.19 ±0.10; P=0.052, to 0.12 
±0.10; P=0.22). The association of hCG with the risk of pregnancy-induced hypertension 
is shown in Supplemental Figure 5.
DISCuSSION
In this study, we show associations of high total hCG concentrations with high sFlt-1/
PlGF ratio and high risk of pre-eclampsia. Our results suggest that up to 40% of the 
association of hCG with pre-eclampsia might be mediated via effects of hCG on the 
angiogenic factors sFlt-1 and PlGF.
Pre-eclampsia is an important cause of maternal morbidity and mortality as well as 
premature deliveries worldwide 1,2,25,26. A great effort has been put into investigating 
the pathophysiological mechanisms leading to pre-eclampsia and the clinical markers 
of this condition 2. Although the exact mechanism remains to be elucidated, abnormal 
placentation and a subsequent hyperinflammatory response characterized by a distur-
bance in pro- and anti-angiogenic factors play a major role 2-4. Multiple studies have 
investigated the association of hCG with the risk of pre-eclampsia, comprising data 
on different hCG isoforms 15-20,27. Although in early and in late pregnancy high total 
hCG and high β-hCG concentrations are suggested as a marker of (subsequent) pre-
eclampsia 15-18, some studies report an association of low β-hCG in early pregnancy with 
pre-eclampsia 19,27 and one study suggests that a lower hyperglycosylated hCG in early 
pregnancy predisposes to pre-eclampsia 20. The interpretation and comparison of these 
studies are hampered by the differences in hCG measurement, given that different hCG 
isoforms predominate during distinct phases of gestation 28,29. Future studies that would 
meta-analyze individual participant data could particularly prove useful in elucidating 
the extent of these differences in the association with pre-eclampsia. 
In pre-eclamptic women, the sFlt-1/PlGF ratio is higher compared to healthy wom-
en 7,30,31. It is considered that high production of sFlt-1in the placenta largely counteracts 
the effects of PlGF and thereby contributes to the development of hypertension and 
proteinuria 6. In pathological states characterized by high hCG concentrations, such as 
molar pregnancy, which predisposes to pre-eclampsia, the expression of placental sFlt-1 
is higher compared to PlGF expression 32,33. As hCG may play a role in the regulation of 
placental angiogenesis via effects on the production of VEGFs 10-14, we hypothesized that 
abnormal hCG concentrations may be a contributing factor for the unfavorable balance 
in the expression of placental pro- and anti-angiogenic factors in pre-eclampsia. 
CHAPTER 3.1
82
There may be an additional underlying mechanism involved contributing to the as-
sociation of high hCG concentration with the higher risk of pre-eclampsia such as hCG-
modulating effects on immune cells, that may respond differently depending on the 
hCG concentration 34. In general, hCG has a protective effect on pregnancy and promotes 
fetal survival by promoting immune tolerance via interaction with macrophages, natural 
killer cells, B- and T-lymphocytes 34. However, in higher doses, hCG may exhibit harmful 
effects on the fetal development 35,36 and may induce an immune cell response with 
altered cytokine and reactive oxygen species production 37, triggering an exaggerated 
sFlt-1 production and thereby reinforcing the cumulative effect of factors predispos-
ing to pre-eclampsia 38. Alternatively, higher availability of sFlt-1 and anti-angiogenic 
effects characterizing pre-eclampsia might be due to higher hCG-stimulated binding of 
PlGF to membrane receptors and local circulating receptors, because of the modulating 
activity of hCG on VEGFs 4,10-14. Moreover, it has been proposed that dysregulation of not 
only concentrations of total hCG but also glycosylation patterns of hCG might underlie 
the pathophysiological events and impaired angiogenic and immune response in pre-
eclampsia 39. Despite its known pro-angiogenic effects in a normal pregnancy, the effects 
of altered hCG concentrations on the cross-talk between trophoblast, endothelial cells 
and immune system in pre-eclampsia are poorly understood 39. Therefore, future studies 
should further elucidate the multifactorial risk factor profile for the association of hCG 
with pre-eclampsia.
In an attempt to diminish the adverse effects of oxidative stress and hypertension 
occurring in pre-eclampsia, a series of maternal compensatory responses may occur 40,41. 
The association of a high hCG concentration with a higher risk of pre-eclampsia could 
therefore also represent a compensatory response of the trophoblast cells to feto-pla-
cental hypoxia, in which high hCG concentrations are supposed to stimulate angiogenic 
factors expression and improve placental function 5,6,10,14. Another relevant determinant 
of adaptive mechanisms in pregnancy is fetal sex, as hCG concentrations are dependent 
on fetal sex 42,43. The exact mechanism underlying the fetal sex-dependent variation 
in hCG concentration is not clear, although it is suggested that it originates from the 
hypothalamo-pityitary-gonadal axis and higher testosterone concentrations in the pres-
ence of Y chromosome 22,42,43. Although fetal sex-specific differences in placental func-
tion are shown between pre-eclamptic and healthy women 44, a recent meta-analysis 
did not detect a fetal sex-specific difference in the risk of overall pre-eclampsia 45. We 
demonstrate that women with high hCG concentrations and a male fetus have a higher 
risk of pre-eclampsia compared to women with a female fetus. Taken together, the sex-
specific differences observed in our study might be explained by a potentially greater 
susceptibility of male fetuses to the impact of hCG variation, or fetal-sex specific differ-
ences in the variation of hCG-isoforms could mediate these differences 22. In addition, 
the hypothesis of fetal sex-specific differences is further supported by our previous 
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study showing that the association of low hCG with lower fetal growth is stronger in 
male fetus pregnancies 46. 
We were able to perform analyses using prospectively collected data on total hCG 
measurements, rather than only a single isoform, and also had detailed data available on 
pre-eclampsia and relevant covariates available in a large population. We were limited 
by the fact that we only had a single hCG measurement available, rendering us unable to 
examine inter-individual differences in hCG variation during pregnancy. Future studies 
may want to assess whether hCG trajectories are associated with pre-eclampsia. An-
other potential limitation could be the availability of data on PlGF and sFlt-1 in 70.8% of 
the study population, which could potentially introduce bias. However, a non-response 
analysis showed no difference in mean hCG concentrations or in the frequency of pre-
eclampsia between participants with and without available data PlGF and sFlt-1. Finally, 
the current study is observational and thus does not allow for inference about causality 
and does not exclude residual confounding.
In conclusion, this study demonstrates that high hCG concentrations in early preg-
nancy are associated with a higher risk of pre-eclampsia. The effects of high hCG con-
centration on the balance between pro- and anti-angiogenic factors during pregnancy 
might partially explain this finding. 
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Supplemental Table 1. Descriptive Statistics – Non response for sFlt-1/PlGF
Characteristic Value (response) Value (non response) P value
hCG standardized for gestational age, mean (sd) 0.008 (1.000) -0.002 (0.989) 0.68
Hypertensive disorders in pregnancy, n (%) 0.051
Preeclampsia 96 (1.7) 41 (1.8)
Pregnancy induced hypertension 221 (4.0) 65 (2.9)
No disorder 5151 (93.8) 2152 (95.1)
Age, mean (sd), years 29.7 (5.0) 29.5 (5.8) 0.035
BMI, mean (sd), kg/m2 24.4 (4.4) 25.7 (4.7) <0.001
Parity, n(%) <0.001
Nulipara 3128 (57.0) 1159 (51.2)
Primipara 1653 (30.1) 672 (29.7)
multipara 711 (12.9) 431 (19.1)
Smoking status, n(%)
Non smokers 3974 (72.4) 1685 (74.5)
Stopped smokers 510 (9.3) 166 (7.3)
Smokers 1008 (18.4) 411 (18.2)
Educational level, n(%) <0.001
No education or primary education 577 (10.5) 375 (16.6)
Secondary education 2534 (46.1) 1117 (49.4)
Higher education 2381 (43.4) 770 (34.0)
Ethnicity, n(%) <0.001
Dutch 2879 (52.4) 883 (39.0)
Moroccan 330 (6.0) 227 (10.0)
Turkish 473 (8.6) 290 (12.8)
Surinam 463 (8.4) 242 (10.7)
Asian 299 (5.4) 142 (6.3)
Other – European 449 (8.2) 149 (6.6)
Other – Non-european 599 (10.9) 329 (14.5)
Fetal sex, n(%) 0.27
Male 2792 (50.8) 1119 (49.5)
Female 2700 (49.2) 1143 (50.5)
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Supplemental Table 2. The association of maternal hCG (sd) with sFlt-1/PlGF ratio
Beta (95% CI)
sFlt-1/PlGF <18 weeks 23.47 (20.46, 26.49)**
sFlt-1/PlGF 18-25 weeks 5.01 (2.34, 7.68)**
sFlt-1/PlGF 18-25 weeks
(adjusted for the measurement at baseline)
-1.88 (-5.41, 1.65)
Δ sFlt-1/PlGF 0.020 (0.018, 0.023) **
Δ sFlt-1/PlGF 
(adjusted for the measurement at baseline)
0.0002 (-0.0007, 0.0011)
Values are beta coeffi  cents (95% confi dence intervals) from the multivariate linear regression analyses. 
Models were adjusted for ethnicity, BMI, fetal sex, maternal age, educational level, parity and smoking 
status. hCG concentrations were transformed to standard deviation scores adjusted to gestational age at 
blood sampling.
* P<0.05
** P<0.001
Supplemental Figure 1. The association of maternal hCG concentration with ΔsFlt-1/PlGF ratio
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Plots show regression model for the association of hCG with Δ sFlt1/PlGF ratio, as predicted mean with 95 
percent confi dence interval. Analyses were adjusted for ethnicity, BMI, maternal age, fetal sex, educational 
level, parity and smoking status. 
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Supplemental Figure 2. The association of maternal hCG concentration with PLGF concentration
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Plots show regression model for the association of hCG with PLGF, as predicted mean with 95 percent confi -
dence interval. Analyses were adjusted for gestational age at blood sampling, ethnicity, BMI, maternal age, 
fetal sex, educational level, parity and smoking status. 
Supplemental Figure 3. The association of maternal hCG concentration with sFlt-1 concentration
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Plots show regression model for the association of hCG with sFlt1, as predicted mean with 95 percent confi -
dence interval. Analyses were adjusted for gestational age at blood sampling, ethnicity, BMI, maternal age, 
educational level, fetal sex, parity and smoking status. 
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Supplemental Figure 4. The association of maternal hCG concentration with the risk of preeclampsia 
stratifi ed for fetal sex
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Plots show regression model for the association of hCG with the risk of preeclampsia, as predicted mean 
with 95 percent confi dence interval. Analyses were adjusted for ethnicity, BMI, maternal age, educational 
level, parity and smoking status. 
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Supplemental Figure 5. The association of maternal hCG concentration with the risk of pregnancy-in-
duced hypertension
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Plots show regression model for the association of hCG with the risk of pregnancy induced hypertension, 
as predicted mean with 95 percent confi dence interval. Analyses were adjusted for, ethnicity, BMI, maternal 
age, fetal sex, educational level, parity and smoking status. 
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ABSTRACT
Background: Human chorionic gonadotropin (hCG) is a pregnancy-specific hormone 
that regulates placental development. hCG concentrations vary widely throughout 
gestation and differ based on fetal sex. Abnormal hCG concentrations are associated 
with adverse pregnancy outcomes including fetal growth restriction. We studied the 
association of hCG concentrations with fetal growth and birth weight. In addition, we 
investigated effect modification by gestational age of hCG measurement and fetal sex.
Methods: Total serum hCG (median 14.4 weeks, 95% range 10.1 – 26.2), estimated fetal 
weight (measured by ultrasound during 18-25th weeks and >25th weeks) and birth weight 
were measured in 7987 mother-child pairs from the Generation R cohort and used to 
establish fetal growth. Small for gestational age (SGA) was defined as a standardized 
birth weight lower than the 10th percentile of the study population.
Results: There was a non-linear association of hCG with birth weight (P=0.009). How-
ever, only low hCG concentrations measured during the late first trimester (11th and 12th 
week) were associated with birth weight and SGA. Low hCG concentrations measured in 
the late first trimester were also associated with decreased fetal growth (P=0.0002). This 
was the case for both male and female fetuses. In contrast, high hCG concentrations dur-
ing the late first trimester were associated with increased fetal growth amongst female, 
but not male fetuses.
Conclusion: Low hCG in the late first trimester is associated with lower birth weight 
due to a decrease in fetal growth. Fetal sex differences exist in the association of hCG 
concentrations with fetal growth.
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INTRODuCTION
Optimal intrauterine conditions are essential for proper fetal development and growth. 
Intrauterine conditions are highly dependent on the placental function since the pla-
centa is the main source of fetal nourishment and the main regulator of intrauterine 
environment 1,2. A suboptimal intrauterine environment leads to fetal adaptations that 
may affect fetal growth and thereby lead to lower birth weight 3,4. Low birth weight is 
an important determinant of child’s health and a major risk factor for several noncom-
municable diseases later in life including coronary heart disease, stroke, hypertension 
and type 2 diabetes 5,6. 
Human chorionic gonadotropin (hCG) is a pregnancy-specific hormone that is pro-
duced by trophoblast cells from the time of embryo implantation onwards 7. Besides 
promoting progesterone production by corpus luteal cells, hCG has been shown to 
regulate many processes that are related to fetal growth including trophoblast differen-
tiation, uterine growth, various aspects of placentation as well as uterine angiogenesis 
and vasculogenesis 7,8. More specifically, hCG has also been shown to stimulate the 
production of endocrine gland-derived vascular endothelial growth factor (EG-VEGF), 
which is involved in the physiology of placental development 9,10. By acting on cytotro-
phoblast cells, EG-VEGF is involved in the process of trophoblast shell and arterial plugs 
formation, necessary for preventing maternal blood flow into the intervillous space dur-
ing early pregnancy 9. hCG may also directly influence uterine and fetal growth by acting 
on gonadotropin receptors present in the uterine tissue and fetal membranes 8,11,12. 
Although clinical studies have shown that hCG is associated with adverse outcomes, 
this association seems to differ according to gestational age at which hCG is measured. 
Low hCG concentrations in the first trimester as well as high hCG concentrations in the 
second trimester have both been associated with pregnancy loss and pre-eclampsia 13-16. 
High hCG concentrations in the second trimester have also been associated with ges-
tational hypertension, fetal growth restriction, fetal death and preterm delivery 16,17. 
Given that hCG concentrations vary throughout gestation, it is remarkable that very 
little is known about potential gestational time-dependent effects of hCG on adverse 
pregnancy outcomes. 
Given the important role of hCG in many fetal growth-related processes, we examined 
the overall and gestational age-dependent associations of hCG with fetal growth, as 
well as possible fetal sex-specific differences, in a large population-based prospective 
cohort study. 
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MATERIALS AND METHODS
Study population
This study was embedded in The Generation R cohort, a population-based prospective 
study from early fetal life onwards in Rotterdam, the Netherlands 18. The study was 
designed to identify early environmental and genetic causes leading to normal and 
abnormal growth, development and health during fetal life and childhood 18. In total, 
8879 mothers with expected delivery date between April 2002 and January 2006 were 
enrolled during pregnancy. Total hCG was determined in all first available serum samples 
and this data, together with data on birth weight, was available in 7987 mother-child 
pairs. Women with twin pregnancies (N=90) or in vitro fertilization treatment (N=38) 
were excluded from the analysis.
hCG measurements 
Total hCG was measured in serum using a solid-phase two-site chemiluminiscent im-
munometric assay, calibrated against WHO 3rd IS 75/537, on an Immulite 2000 XPi system 
(Siemens Healthcare Diagnostics, Deerfield, IL, USA). The assay detects serum intact hCG, 
hyperglycosated hCG, serum nicked hCG, serum nicked hyperglycosated hCG, serum 
asialo hCG, serum hCG free β-subunit and serum nicked hCG β. hCG concentrations were 
transformed to standard deviation scores adjusted to gestational age at blood sampling 19.
Fetal growth and birth weight
Early fetal growth was estimated by ultrasound measurement of crown-rump length 
(CRL) in a subset of women (N=1526) which had a reliable and regular menstrual 
cycle 18,19. CRL values were transformed to standard deviation scores adjusted to gesta-
tional age of pregnancy determined according to the last menstrual period (LMP). CRL 
was measured by ultrasound in early pregnancy, in a true mid-sagittal plane with the 
genital tubercle and the fetal spine longitudinally in view 20. The maximum length from 
cranium to the caudal rump was measured as a straight line 20.
Fetal weight was estimated by ultrasound measurements in the period of 18-25th 
week of pregnancy (median=20.5 week, 95% range 18.5 -23.4 week; N=7471) and after 
the 25th week of pregnancy (median=30.3 week, 95% range 28.3 - 33.0 week; N=7641) 
and estimations for fetal weight were transformed to standard deviation scores adjusted 
to gestational age of pregnancy determined by crown-rump length and biparietal di-
ameter, as has been described previously 20. Information on birth weight was obtained 
from community midwives, obstetricians and hospital registries. Birth weight standard 
deviations scores, adjusted for gestational age, were constructed using the Niklasson 
percentile growth curves 21. Small for gestational age at birth (SGA) was defined as a 
standardized birth weight lower than the 10th percentile of the study population.
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Covariates
Information on maternal age, smoking status, educational level and ethnicity was ob-
tained by questionnaires during pregnancy. Ethnicity was determined by the country 
of origin and was defined according to the classification of Statistics Netherlands 18. 
Maternal smoking was classified as no smoking, smoking until known pregnancy 
and continued smoking during pregnancy. Information on fertility treatment, parity, 
placental weight at birth and sex of the child was obtained from community mid-
wives, obstetricians, and hospital registries. Gestational weight gain was defined as 
the difference between self-reported maternal weight before pregnancy and maternal 
weight measured in the third trimester (a sensitivity analysis using maternal weight 
measured in early pregnancy and in the third trimester did not reveal more confound-
ing potential or explained variability of the model). Free thyroxine (FT4) and thyroid 
stimulating hormone (TSH) were available in a subset of 5498 pregnant women during 
early pregnancy 22.
Statistical analysis
We investigated the association of hCG concentrations with CRL within a subset group 
of women (with regular cycles and known last menstrual period) and birth weight 
within the whole group by using multiple linear regression analysis with restricted 
cubic splines utilizing three knots. Multivariable associations were graphically depicted 
by plots (main manuscript) and the key β estimates with 95% confidence intervals are 
shown in Supplemental Table 3. We tested for effect modification with gestational age at 
blood measurement and fetal sex by introducing a product interaction term of hCG and 
gestational age at blood sampling or fetal sex to the model. Given the fetal growth dif-
ferences across gestational age and between male and female fetuses, a P-value of <0.15 
was considered for stratification. We subsequently stratified the analyses by quintiles of 
gestational age at blood sampling and in case of a difference between these time points, 
further stratification was performed per one or more gestational weeks. To study the 
association of hCG with the risk of SGA we used multiple logistic regression models with 
restricted cubic splines utilizing three knots. The association of hCG concentrations with 
fetal growth throughout gestation was analyzed using unbalanced repeated measure-
ment regression models for which the outcome consisted of standardized estimated 
fetal weight in the second and third trimester and standardized birth weight. These 
models take the correlation between repeated measurements of the same subject into 
account and allow for incomplete outcome data 23. We used an unstructured covariance 
matrix with fixed effects, and added the interaction term of hCG with the time compo-
nent (gestational age) in the models, and adjusted for covariates. Based on the size of 
effect estimate differences and biological plausibility extracted from the literature, we 
stratified these analyses in a similar manner as previously described analyses on birth 
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weight. Lower statistical power in subsequent subset analyses and the need for test-
ing three-way interactions were deemed statistically not viable. The hCG cutoff in the 
repeated measurement analyses was chosen based on the optimal power necessary for 
the biologically plausible reference group.
All model covariates were selected based on biological plausibility, change in effect 
estimate of interest or residual variability of the model. All analyses were adjusted for 
maternal age, smoking status, BMI, parity, educational level, ethnicity, fetal sex, placen-
tal weight at birth, gestational age at blood sampling and gestational weight gain of the 
mother. Placental weight, as a marker for trophoblast cell mass, may be an important 
determinant of both hCG concentrations 19 and fetal growth and from that reason was 
adjusted for in the models. Maternal weight gain was taken as a proxy for the potential 
confounding effects of hyperemesis gravidarum (HG). Gestational weight change is an 
important clinical marker of the HG effects 24 and the same goes for other symptoms of 
HG such as reflux/belching, nausea and vomiting – but addition of these factors did not 
change our models.
For covariates with missing data, multiple imputation according to the Markov Chain 
Monte Carlo method was used 25. Five imputed data sets were created and pooled for 
the analysis. Maternal smoking, education, ethnicity, BMI, parity, placental weight, ges-
tational weight gain and fetal sex were added to the model. Furthermore, we added ges-
tational age at blood sampling, hCG level and maternal FT4 level as prediction variables 
only. No statistically significant differences in descriptive statistics were found between 
the original and imputed datasets.
Statistical analyses were performed using Statistical Package of Social Sciences ver-
sion 21.0 for Windows (SPSS Inc. Armonk, NY), R statistical software with RMS package 
version 3.2.0 and SAS software for Windows version 9.3.
Figure 1. Flowchart showing selection procedure of study population
Mothers with hCG measurement 
N=8193 
N=168 excluded 
- Missing birth weight (N=78) 
- In vitro fertilisation (N=38)  
- Twin pregnancies (N=90) 
Final study population 
N=7987 
Mothers enrolled during pregnancy 
N=8879 Unable to perform measurement 
mainly due to (non) availability of 
serum, discontinuation of study 
participation, lab measurement 
errors. 
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RESuLTS
The final study population consisted of 7987 pregnant women (Figure 1), descriptive 
statistics of which are shown in Table 1. Maternal hCG concentrations were measured at 
the moment of inclusion in the study (median 14.4 weeks, 95% range 10.1 – 26.2 weeks). 
In the study population,  mean (±SD) birth weight was 3412.0 (±559.7) grams, mean 
gestational age at birth was 39.8 (±1.9) weeks,  mean maternal age was 29.6 (±5.3) years, 
women were predominantly nulliparous (55.3%), non-smokers (72.7%) and of Dutch 
origin (46.6%). 
Table 1. Descriptive Statistics of Mother and Child Pairs
Characteristic Value
hCG, median (95%range), Iu/l, 35559.0 (6106.8-101808.5)
Birth weight, mean (sd), g 3412.0 (559.7)
Gestational age at blood sampling, median (95% range), weeks 14.4 (10.1-26.2) 
Gestational age at birth, mean (sd), weeks 39.8 (1.9)
Age, mean (sd), years 29.6 (5.3)
BMI, median (95% range), kg/m2 23.9 (18.7-36.5)
Parity, n(%)
Nullipara 4531 (55.3)
Primipara 2475(30.2)
Multipara 1187 (14.5)
Smoking status, n(%)
Non smokers 5953 (72.7)
Stopped smokers 691 (8.4)
Smokers 1549 (18.9)
Educational level, n(%)
No education or primary education 1046 (12.8)
Secondary education 3844 (46.9)
Higher education 3303 (40.3)
Ethnicity, n(%)
Dutch 3742 (46.6)
Moroccan 530 (6.6)
Turkish 710 (8.8)
Surinam 686 (8.5)
Other – European 598 (7.5)
Other – Non-european 1758 (21.9)
Fetal sex, n(%)
Male 4124 (50.3)
Female 4069 (49.7)
Gestational weight gain, mean (sd), kg 10.0 (5.1)
Placental weight at birth (g), median, (95% range) 620.0 (390.0-950.0)
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The association of maternal hCG with birth weight
In the whole population, there was a non-linear association of maternal hCG concentra-
tions with birth weight (Supplemental Figure 1, P=0.009) and the risk of SGA (Supplemen-
tal Figure 1, Supplemental Table 1, P=0.028). Considering that hCG concentrations vary 
throughout gestation, we investigated whether gestational age at blood sampling modi-
fies the association of hCG concentrations with birth weight. After addition of a product 
interaction term to the model (hCG*gestational age at blood sampling; P=0.10), we strati-
fied the association of hCG concentration with birth weight by gestational age at blood 
sampling (Figure 2 and Supplemental Figure 2). The association of hCG with birth weight 
was present in the 11th week (Figure 2, P=0.03; beta estimates shown in Supplemental 
Table 3) and 12th week of pregnancy (Figure 2, P=0.002; Supplemental Figure 3), but not 
from the 13th week onwards (Figure 2; Supplemental Figure 3). The association of hCG with 
the risk of SGA showed a consistent trend with the results from linear regression analysis 
with birth weight, with a tendency of higher odds of SGA in low hCG concentrations in the 
11th and 12th week (Figure 2 and Supplemental Figure 3). The odds of SGA in women with 
low hCG concentration measured in the 11th and 12th week (<5th to <15th percentile) were 
1.80 - 2.21 fold higher than the reference group (Supplemental Table 2).
Subsequently, we set out to investigate if the association of hCG with birth weight oc-
curs due to changes during early pregnancy (crown rump length) or also due to changes 
in the second half of pregnancy (fetal growth).
The association of maternal hCG with crown rump length
In the subset of women with regular cycles and known last menstrual period, in which 
CRL measurement was available, hCG concentrations during early pregnancy were 
negatively associated with CRL, but this analysis did not reach statistical significance 
(Supplemental Figure 4; N=1526).
The association of maternal hCG with fetal growth
Maternal hCG concentrations were associated with estimated fetal weight in the whole 
population, but this association was most prominent in pregnancies in which hCG 
was measured in the 12th week of gestation (Table 2). The association between hCG 
concentrations measured in the 12th week of pregnancy and estimated fetal weight 
is illustrated in Figure 3. The estimated fetal weight in women with a relatively high 
hCG concentration (Figure 3, 3rd tertile, depicted by the dotted line) was lower in mid 
pregnancy but accelerated throughout gestation, finally reaching a birth weight similar 
to the reference group (2nd tertile). In contrast, estimated fetal weight in women with 
low hCG concentration (Figure 3, 1st tertile, depicted by the solid line) was similar in 
mid-pregnancy, but was associated with lower birth weight than the reference group 
after a decrease of fetal growth in the second half of pregnancy.
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Table 2. The association of maternal hCG with fetal growth throughout gestation.
Beta ±SE P-value 95% Confi dence Interval
hCG in all 0.002 ±0.001 0.0017 (0.001, 0.003)
hCG stratifi ed per week of measurement Number of participants per week
11th week -0.001 ±0.003 0.81 (-0.007, 0.005) 254
12th week 0.007 ±0.002 0.0002 (0.003, 0.010) 783
13th week 0.000 ±0.001 0.94 (-0.003, 0.003) 1412
14th week 0.000 ±0.002 0.78 (-0.003, 0.004) 1060
Table shows the eff ects estimates of repeated measurement model for the association of total hCG (stan-
dardized according to gestational age at measurement; SD) with fetal growth (standardized estimated fetal 
weight measured using ultrasound in mid pregnancy (18-25 weeks), late pregnancy (>25 weeks) and birth 
weight), as beta estimate with standard error. Analyses were performed after exclusion of women with IVF 
treatment (N=38), twin pregnancy (N=90) and were adjusted for maternal age, smoking, BMI, parity, educa-
tion level, ethnicity, gestational weight gain, placental weight at birth and fetal sex. 
Figure 2. The association of maternal hCG with birth weight and small for gestational age (SGA) stratifi ed 
per week of hCG measurement
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Plots show the linear regression models for total hCG (standardized according to gestational age at mea-
surement; SD) and birthweight (standardized according to gestational age at birth; SD), as well as the lo-
gistic regression model for hCG and birthweight small for gestational age (defi ned as birthweight below 
10th percentile for gestational age) as predicted mean with 95 percent confi dence interval. Analyses were 
adjusted for maternal age, smoking, BMI, parity, placental weight at birth, education level, ethnicity, gesta-
tional weight gain and fetal sex. 
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Sex-specific differences in the association of hCG with birth weight and fetal 
growth
Considering the biological differences in fetal growth and in hCG physiology between 
male and female fetuses, we tested for effect modification by fetal sex. After addition of 
a product interaction term to the model (hCG*fetal sex; P=0.10), we stratified analyses 
according to fetal sex. The association of hCG concentrations (measured in week 11-12) 
and birth weight did not differ for fetal sex (Supplemental Figure 5 and 6). However, 
in women with low hCG concentrations (<10th or <15th percentile), the risk of SGA was 
higher in male than in female fetal-sex (Supplemental Table 4).
The association of hCG concentrations with estimated fetal weight differed according 
to fetal sex (Supplemental Table 5). In women with relatively low hCG during the late first 
trimester (Figure 4, 1st tertile, depicted by the solid lines), estimated fetal weight in mid-
pregnancy was overall lower in male than in female fetuses. However, in female fetuses, 
low maternal hCG was associated with a greater deceleration of fetal growth than in 
male fetuses (-0.17 SD decrease in male fetus pregnancies versus -0.26 SD decrease in 
female fetus pregnancies; Figure 4). 
In women with high hCG concentrations during the late first trimester (Figure 4, 3rd 
tertile, depicted by the dotted lines), estimated fetal weight during mid-pregnancy was 
Figure 3. The association of maternal hCG measured in the 12th week of pregnancy with fetal growth 
throughout gestation
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Graph depicts the beta estimates from a repeated measurement model of the association of total hCG 
(standardized according to gestational age at measurement; SD) with fetal growth (standardized estimated 
fetal weight measured using ultrasound in mid pregnancy (18-25 weeks), late pregnancy (>25 weeks) and 
birth weight). Analyses were adjusted for maternal age, smoking, BMI, parity, education level, ethnicity, 
gestational weight gain, placental weight at birth and fetal sex.
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overall lower in female than in male fetuses. However, in female fetuses, high maternal 
hCG concentrations were associated with an acceleration of fetal growth as compared to 
a slight deceleration in male fetus pregnancies (-0.07 SD decrease in males versus +0.26 
SD increase in females; Figure 4).
There was no effect modification by, or change in the results after adjustment for 
maternal FT4 and TSH concentrations (data not shown).
DISCuSSION
Our study shows that low hCG concentrations in the late first trimester are associated 
with lower birth weight and an increased risk of SGA. We demonstrate that the associa-
tion of low hCG concentrations in the late first trimester with lower birth weight arises 
due to a decrease in fetal growth during the second half of pregnancy. In contrast, high 
concentrations of hCG in the late first trimester were associated with growth accelera-
tion which resulted in a normal birth weight. A low hCG concentration was associated 
with a decrease in fetal growth, independent of fetal sex. However, high hCG concentra-
tions were associated with an accelerated fetal growth in female, but not in male fetuses.
Figure 4. The association of maternal hCG in 11th or 12th week with fetal growth stratified by fetal sex
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Fetal growth and birth weight reflect intrauterine conditions during pregnancy. Major 
healthcare problems such as cardiovascular diseases and type 2 diabetes are preor-
dained in utero and low birth weight is one of the main determinants of those disor-
ders 5,6. Previous studies that investigated hCG as a potential determinant of fetal growth 
restriction mostly focused on either the first or second trimester. Furthermore, most of 
those studies examined only the association of the β-hCG isoform and fetal growth, 
meaning that non-measured differences in other important active hCG-isoforms could 
have influenced the results 26. A large Danish study of 9450 women in the 8th -13th week 
of pregnancy reported that a low free β-hCG concentration is associated with SGA 27. A 
study of 8012 pregnant women by Krantz et al. reported that a low free β-hCG concen-
tration in the 10th-13th week of pregnancy is associated with an increased risk of fetal 
growth restriction (FGR) 28. Amongst 100 women, Abdel Moety et al. also reported that 
low concentrations of free β-hCG measured in 11th to 14th week of gestation are associ-
ated with FGR 29. In contrast, other studies showed that a high hCG concentration in the 
second trimester is associated with a decrease in fetal growth and/or FGR 16,17. To date, 
no study had investigated the association of total hCG with fetal growth or investigated 
the role of gestational age of hCG measurement and/or fetal sex in this association. 
In the current study, low hCG concentrations were only associated with low birth 
weight when hCG was measured in the 11th or 12th week of gestation, suggesting that 
hCG has a specific role in fetal growth during the transitional period from the first to the 
second trimester. This period marks the start of maternal blood supply in the intervillous 
space and the end of the hypoxic fetal environment 30. Oxidative stress in early gestation 
is a risk factor for adverse pregnancy outcomes including fetal growth restriction, which 
might be due to a lack of antioxidant enzymes in fetal tissues at that time 31. hCG is 
indirectly involved in the maintenance of early pregnancy hypoxia via regulating endo-
crine gland-derived vascular endothelial growth factor (EG-VEGF), a factor that at least 
partially ensures physiologically low oxygen concentrations during early pregnancy 
through stimulation of the arterial plugs formation 9. The specific association in the cur-
rent study of low hCG in the late first trimester with decreased fetal growth might be due 
to a suboptimal development of the trophoblast shell and arterial plugs, or an earlier 
release of the arterial plugs via lower levels of EG-VEGF. This could potentially expose the 
fetus to the harmful effects of O2 free radicals. Further studies are needed to replicate 
our findings and investigate the association of repeatedly measured hCG concentrations 
with fetal growth.
Studies have shown that fetal growth and maternal hCG concentrations differ de-
pending on fetal sex. hCG concentrations in pregnancies with a female fetal sex are 
higher from as early as the third post-fertilization week 32-35. In this study, the continuous 
association of hCG concentrations measured at the end of the first trimester with birth 
weight did not differ between pregnancies with a male or female fetus. Nevertheless, 
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low hCG concentrations were associated with a higher risk of SGA in male fetal sex. This 
discrepancy already suggests that there is a fetal sex-specific association of hCG with 
fetal growth patterns. Moreover, further analyses revealed that the association of low 
hCG during the late first trimester with fetal growth deceleration was stronger in female 
fetal sex. Furthermore, high hCG concentrations during the late first trimester were as-
sociated with growth acceleration in the female, but not male fetuses.
Male fetuses may be more susceptible to the impact of relatively low hCG concen-
trations during the late first trimester than female fetuses, considering the fact that 
mean hCG concentrations are lower in pregnancies with a male fetus 32,33. On the other 
hand, our findings show that the association of low hCG concentrations with decreased 
fetal growth is present in both female and male fetal sex. This suggests that low hCG 
concentrations during the first trimester have an impact on the fetal growth trajectory 
independent of fetal sex. Interestingly, the main difference between males and females 
in the current study was the association of high late first trimester hCG with growth ac-
celeration during mid-pregnancy, which was only present in female fetuses. This might 
be due to the higher concentrations of hCG in female fetal sex, or due to fetal sex-specific 
differences in hCG isoforms 19. Future studies are needed to investigate the mechanisms 
that underlie the differential effects of female fetal sex in the association of hCG and 
fetal growth in more depth. In addition, replication of fetal sex-specific differences in the 
association of hCG with fetal growth will be required, preferably in samples that have 
adequate power to test for higher order interactions.
The strengths of the current study include the availability of hCG concentrations as well 
as detailed fetal growth data with serial fetal weight measurements in a large popula-
tion. The fact that hCG measurements were also available across a wide gestational time 
span, enabled us to observe a change in the association of hCG with fetal growth across 
gestational age. We were, however, limited by the fact that a single hCG measurement 
was available. As a consequence, we were not able to assess interindividual differences 
in the change of hCG concentrations during pregnancy. Also, the observational nature of 
this study does not allow for inference of causality and does not preclude the existence 
of residual confounding. As such, it is possible that it is the fetal size that affects maternal 
hCG concentration and/or that placental growth plays a confounding or mediating role. 
However, the latter seems less likely since the addition of placental weight to the model 
did not cause any meaningful changes in effect estimates. 
In conclusion, we demonstrate that late first trimester hCG concentrations are associ-
ated with fetal growth and birth weight. In women with low hCG concentrations during 
the late first trimester, fetal growth is lower resulting in a lower birth weight. In female 
fetal-sex pregnancies, a high maternal hCG concentration at the end of the first trimester 
is associated with fetal growth acceleration. The underlying mechanism of these effects 
might involve a flawed protection from oxidative stress due to the effects of hCG on 
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arterial plug formation. Further research is necessary to investigate the causality of 
this association and the biological mechanism by which maternal hCG in the late first 
trimester affects fetal growth. 
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Supplemental Table 1. The association of maternal hCG cutoffs with SGA.
hCG cut-off OR (95%CI) P-value
<5 1.24 (0.88-1.75) 0.22
<10 1.07 (0.82-1.39) 0.61
<15 1.18 (0.95-1.47) 0.14
>85 1.08 (0.86-1.35) 0.52
>90 1.06 (0.81-1.37) 0.69
>95 1.18 (0.84-1.66) 0.34
Table shows the association between different cut-off levels for total hCG (standardized to gestational 
age; SD) and small for gestational age (defined as birthweight below 10th percentile for gestational age) as 
odds ratio with 95 percent confidence interval. Analyses were performed after exclusion of women with 
IVF treatment (N=38), twin pregnancy (N=90) and were adjusted for maternal age, smoking, BMI, parity, 
placental weight at birth, education level, ethnicity, gestational age at birth, gestational weight gain and 
fetal sex. 
Supplemental Table 2. The association of maternal hCG measured in the 11th or 12th week cutoffs with 
small for gestational age.
hCG cut-off OR (95%CI) P-value
<5 2.21 (1.04-4.70) 0.04
<10 2.00 (1.09-3.67) 0.03
<15 1.80 (1.05-3.10) 0.03
>85 0.81 (0.39-1.66) 0.57
>90 1.02 (0.45-2.32) 0.96
>95 1.52 (0.58-4.01) 0.40
Table shows the association between different cut-off levels for total hCG (standardized to gestational 
age; SD) and small for gestational age (defined as birthweight below 10th percentile for gestational age) as 
odds ratio with 95 percent confidence interval. Analyses were performed after exclusion of women with 
IVF treatment (N=38), twin pregnancy (N=90) and were adjusted for maternal age, smoking, BMI, parity, 
placental weight at birth, education level, ethnicity, gestational age at birth, gestational weight gain and 
fetal sex. 
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Supplemental Table 3. Association of hCG (sd) with birth weight (sd)
11th week of 
gestation
12th week of 
gestation
13th week of 
gestation
hCG (sd) < 0 0.191 (-0.026, 0.408) hCG (sd) < 0 0.194 (0.063, 0.326)** hCG (sd) 0.006 (-0.043, 0.056) 
hCG (sd) ≥ 0 -0.115 (-0.398, 0.167) hCG (sd) ≥ 0 -0.053 (-0.211, 0.105) 
Values are regression coefficients (95% confidence intervals) from the linear regression models for total 
hCG (standardized according to gestational age at measurement; SD) and birthweight (standardized ac-
cording to gestational age at birth; SD). Analyses were performed after exclusion of women with IVF treat-
ment (N=38), twin pregnancy (N=90) and were adjusted for maternal age, smoking, BMI, parity, placental 
weight at birth, education level, ethnicity, gestational weight gain and fetal sex. Non-linear associations are 
presented with the two estimates for hCG (sd) and the cut-off was based on the shape of the association.
* P<0.05
** P<0.001
Supplemental Table 4. The association of maternal hCG measured in the 11th or 12th week and SGA strati-
fied by fetal sex.
Amongst male fetuses Amongst female fetuses
hCG cutoff OR (95%CI) P-value hCG cutoff OR (95%CI) P-value
<5 2.08 (0.73-5.92) 0.17 <5 2.39 (0.70-8.07) 0.16
<10 2.77 (1.27-6.02) 0.01 <10 1.22 (0.39-3.80) 0.73
<15 2.58 (1.26-5.28) 0.009 <15 1.16 (0.47-2.86) 0.76
>85 1.09 (0.99-1.20) 0.07 >85 0.85 (0.35-2.04) 0.71
>90 0.33 (0.04-2.96) 0.32 >90 1.14 (0.45-2.93) 0.78
>95 0.53 (0.05-5.24) 0.58 >95 1.88 (0.59-5.93) 0.28
Table shows the association between different cutoff levels for total hCG (standardized to gestational age; 
SD) and small for gestational age (defined as birthweight below 10th percentile for gestational age) as odds 
ratio with 95 percent confidence interval. Analyses were performed after exclusion of women with IVF treat-
ment (N=38), twin pregnancy (N=90) and were adjusted for maternal age, smoking, BMI, parity, placental 
weight at birth, education level, ethnicity, gestational age at birth, gestational weight gain and fetal sex. 
Supplemental Table 5. The association of maternal hCG with fetal growth throughout gestation stratified 
by fetal sex.
Week of hCG measurement Fetal sex Beta ±SE P-value
95% Confidence 
interval
All weeks male 0.012 ±0.009 0.06 (-0.000, 0.003)
11th and 12th week only male 0.003 ±0.002 0.19 (-0.002, 0.007)
All weeks female 0.002 ±0.001 0.0075 (0.001, 0.004)
11th and 12th week only female 0.006 ±0.002 0.005 (0.002, 0.010)
Table shows the repeated measurement model for the association of total hCG (SD), fetal weight (measured 
twice during pregnancy) and birthweight, as predicted mean with 95 percent confidence interval. Analyses 
were performed after exclusion of women with IVF treatment (N=38), twin pregnancy (N=90) and were 
adjusted for maternal age, smoking, BMI, parity, education level, ethnicity, gestational weight gain and 
placental weight at birth.
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Supplemental Figure 1. The association of maternal hCG with birth weight and SGA in the whole study 
population
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Plots show the linear and logistic regression models for total hCG (standardized to gestational age; SD) and 
birthweight (standardized to gestational age at birth; SD) as predicted mean with 95 percent confi dence 
interval. Analyses were adjusted for maternal age, smoking, BMI, parity, placental weight at birth, education 
level, ethnicity, gestational age at birth, gestational weight gain and fetal sex. 
Supplemental Figure 2. The association of maternal hCG with birth weight stratifi ed by gestational age 
at hCG measurement
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Plots show the linear regression model for the association between total maternal hCG (standardized to 
gestational age at measurement; SD) and birthweight (standardized to gestational age at birth; SD) as pre-
dicted mean with 95 percent confi dence interval. Analyses were adjusted for maternal age, smoking, BMI, 
parity, placental weight at birth, education level, ethnicity, gestational age at birth, gestational weight gain 
and fetal sex. 
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Supplemental Figure 3. The association of hCG measured in the 11th or 12th week with birth weight and 
SGA
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Plots show the linear and logistic regression models for total hCG (standardized to gestational age at 
measurement; SD) and birthweight (standardized to gestational age at birth; SD) as predicted mean with 
95 percent confi dence interval. Analyses were adjusted for maternal age, smoking, BMI, parity, placental 
weight at birth, education level, ethnicity, gestational age at birth, gestational weight gain and fetal sex. 
Supplemental Figure 4. The association of maternal hCG with crown-rump length within the subgroup of 
women with a reliable cycle and known last menstrual period (N=1526)
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Plot shows the linear regression model for total hCG (SD) and crown-rump length (adjusted according to 
week of gestation; available in n=1526;SD) as predicted mean with 95 percent confi dence interval. Analyses 
were adjusted for maternal age, smoking, BMI, parity, education level, ethnicity, gestational weight gain 
and fetal sex. 
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Supplemental Figure 5. The association of maternal hCG per week of measurement with birth weight 
stratifi ed by fetal sex
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Plots show the logistic and linear regression models for total hCG (standardized according to gestational 
age at measurement; SD) and birthweight (standardized according to gestational age at birth; SD) or small 
for gestational age (defi ned as birthweight below 10th percentile for gestational age) as predicted mean 
with 95 percent confi dence interval. Analyses were adjusted for maternal age, smoking, BMI, parity, placen-
tal weight at birth, education level, ethnicity and gestational weight gain.
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Supplemental Figure 6. The association of maternal hCG measured in the 11th or 12th week with birth 
weight stratifi ed by fetal sex
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Plots show the linear and logistic regression models for total hCG (standardized to gestational age; SD) and 
birthweight (standardized to gestational age at birth; SD) or small for gestational age (defi ned as <10th 
percentile of gestational age specifi c birth weight) as predicted mean with 95 percent confi dence interval. 
Analyses were adjusted for maternal age, smoking, BMI, parity, placental weight at birth, education level, 
ethnicity, gestational age at birth and gestational weight gain.
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ABSTRACT
Background: Reported cutoffs for childhood TSH and FT4 reference ranges vary widely 
and the knowledge on the determinants of childhood thyroid function is sparse. We 
aimed to summarize the existing studies on thyroid function reference ranges in chil-
dren. Furthermore, our objective was to investigate the determinants of childhood TSH 
and FT4 concentration in a population based-prospective cohort.
Methods: First, to identify studies on childhood thyroid reference ranges, we systemati-
cally searched The National Library of Medicine’s PubMed, Embase, Ovid Medline, Web 
of Science and Google Scholar databases. Second, in a non-selected sample of 4273 
children (median age 6.0 years, range 4.9 – 9.1 years) from our cohort, we studied the 
associations of age, sex, anthropometric characteristics, ethnicity, maternal education, 
time and season at venipuncture with TSH and FT4 concentrations. We also investigated 
to what extent between-individual variations in the determinants of TSH and FT4 could 
influence the calculation of reference ranges.
Results: Published reference ranges for TSH and FT4 differ per age range and within 
age ranges (cutoffs low TSH: 0.13 to >1 mU/L; high TSH: 2.36 to >10 mU/L; low FT4: 7.0 
to >10 pmol/L; high FT4: 15.5 to >30 pmol/L). In our cohort, weight, sex and ethnicity 
were determinants of TSH (P≤0.03) and FT4 concentrations (P≤0.01), height and time at 
venipuncture were determinants of TSH only (P<0.0001). The between-individual varia-
tion depending on clinical determinants for TSH ranged between 0.64 and 0.96 mU/L 
(total population 0.87 mU/L) for the lower limit and 4.30 and 5.62 mU/L (total population 
5.20 mU/L) for the upper limit, whereas for FT4, the lower limit ranged between 13.6 and 
14.2 pmol/L (total population 13.8 pmol/L) and the upper limit ranged between 20.2 
and 23.0 pmol/L (total population 20.8 pmol/L).
Conclusions: Considerable differences exist in the reported reference ranges for child-
hood TSH and FT4 across and within age ranges and assays. In our cohort, we show 
only a minimal association between TSH and FT4 suggesting that the hypothalamus-
pituitary-thyroid axis remains unaffected by thyroid interfering factors. We identified 
various determinants of TSH and FT4 in children which accounted for a considerable 
variation of reference range cutoffs. 
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INTRODuCTION
Adequate thyroid function is important for proper growth and development in child-
hood 1,2. Hypothyroidism in childhood is associated with cognitive deficits, decelerated 
growth, delayed skeletal maturation and delayed puberty, whereas overt hyperthyroid-
ism is associated with growth acceleration, advanced bone age, tachycardia and mood 
disorders 2,3. Furthermore, even mild forms of thyroid dysfunction in childhood are 
associated with suboptimal outcomes including weight gain, impaired growth velocity, 
poor school performance, impaired psychomotor skills, disturbed cognitive develop-
ment and increased cholesterol levels 4-6.
In order to diagnose thyroid disease, adequate reference ranges for TSH and FT4 are 
essential. The guidelines of the European Thyroid Association for the management of 
subclinical hypothyroidism in children recommend the use of age-related normative 
values 7. However, there is no further consensus on the definition of TSH and FT4 refer-
ence ranges during childhood. This complicates the interpretation of thyroid function 
tests and clinical diagnosis of thyroid dysfunction, as is for example illustrated by the 
wide range of TSH cutoffs (between 5.0 to 10 mU/L) currently used to define subclinical 
hypothyroidism during childhood 7.
Multiple studies have been performed to define thyroid function reference ranges in 
pediatric populations 8-43. Although some studies adhere to the recommendations by 
the International Federation of Clinical Chemistry, there is considerable between-study 
heterogeneity as studies have been conducted across various age ranges, using differ-
ent assays and in populations comprising different ethnicities and from different geo-
graphical conditions. It is currently unknown to what extent between-study variations 
in methodology and between-population differences in thyroid function determinants 
add to this heterogeneity.
Although some studies have indicated that TSH and FT4 reference ranges are influ-
enced by child age, Tanner stage, ethnicity, anthropometric characteristics and/or io-
dine intake, data on determinants of thyroid function during childhood are sparse 22,43,44. 
Further knowledge on determinants of TSH and FT4 concentrations during childhood 
may help to identify specific causes that underlie an abnormal test result. In addition, 
such knowledge enables physicians to assess the generalizability of described reference 
ranges to a specific patient population. With regards to the research setting, knowledge 
on determinants is important to define mediating and/or confounding factors that can 
influence studies on the effects of thyroid function on clinical outcomes. 
The aim of the current study was to systematically assess and summarize the current 
literature on thyroid function reference ranges during childhood in order to create a 
general overview of TSH an FT4 reference ranges during childhood. Subsequently, in 
a large, iodine sufficient pediatric population, we aimed to investigate which clinical 
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characteristics are determinants of thyroid function and quantify to what extent these 
determinants affect reference ranges for TSH and FT4. 
METHODS
Literature overview
A systematic literature search of The National Library of Medicine’s PubMed, Embase, 
Ovid Medline, Web of Science and Google Scholar databases was performed to identify 
studies published from inception until November 18th, 2016 (search terms are outlined 
in the supplemental appendix). Two reviewers (IO, MB) independently screened the ob-
tained titles and abstracts and, subsequently reviewed the full manuscripts for their eli-
gibility for the literature overview. These individual results were cross-checked and upon 
disagreement a third reviewer (TK) assessed the manuscript to reach consensus. Studies 
with less than 400 participants, non-representable sample selection for the underlying 
population and the use of parametric methods (other than those corresponding to a 
95% range) used to calculate reference ranges for thyroid function were not included for 
summary results. 11,15,18,20,21,23-26,28,31-33,38,42
Original study
Design and participants
This study was embedded in The Generation R Study, a population-based prospective 
cohort from early fetal life onwards in Rotterdam, the Netherlands. This study has been 
described in detail elsewhere 45. In total, all children with consent for follow-up during 
childhood (N=8305) were invited to visit the research center of which 6674 children 
visited. After consent by the mother and child, serum samples were obtained for 4593 
children and TSH and/or FT4 concentrations were determined in 4286 samples with ad-
equate serum volumes. Children with known thyroid disease, chronic illness (endocrine, 
inflammatory, autoimmune, cancer or kidney disease) or thyroid (interfering) medica-
tion usage (levothyroxine or growth hormone) were excluded (N=13), resulting in a final 
population of 4273 children (median age 6.0 years, range 4.9 – 9.1 years).
Determinants and covariates
We selected potential determinants based on the literature, biological plausibility and 
data availability 13,22,46. These included age, sex, ethnicity, height, weight, maternal edu-
cation level (as a marker of social economic status), time and season of venipuncture. 
Information on these determinants was obtained by questionnaires and measurements 
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during the visit to the research center (on the same day as blood sampling). Medical 
history was assessed by questionnaires and answers were verified by certified medical 
doctors. Information on maternal education level was obtained through postal ques-
tionnaires. Child ethnicity was determined by the country of origin of the child and/
or parents and was defined according to the classification of Statistics Netherlands and 
categorized according to the major ethnic groups in Rotterdam.45 These were: Dutch, 
Turkish, Moroccan, Surinamese, Dutch Antilles, African/Cape Verdian, other Western 
(European, Oceanian and Caucasian descent Americans /Asians) and other non-Western. 
Procedures
Plain tubes were centrifuged and serum was stored at -80°C. Child TSH and FT4 con-
centrations were determined using an electrochemiluminescence immunoassay on the 
Cobas e601immunoanalyzer (Roche Diagnostics, Germany). The intra- and interassay 
coefficients of variation were 1.1 – 3.0 % for TSH at a range of 0.4 – 0.04 mU/l and 1.6 – 5.0 
% for FT4 at a range of 1.6 - 24.1 pmol/l. 
Statistical analyses
Reference ranges for TSH and FT4 in the Generation R were defined by the 2.5th and 
97.5th percentiles. For analyses aimed to identify thyroid function determinants, TSH con-
centrations were log transformed to adhere to model assumptions (back-transformed 
values are displayed in graphs to allow for better interpretation). We used multiple linear 
regression models to investigate the association between the determinants and child-
hood TSH or FT4. Non-linearity of the association between continuous variables and 
childhood TSH or FT4 concentrations was investigated by ordinary least squares linear 
regression models with restricted cubic splines utilizing 3-5 knots. As a sensitivity analy-
sis, we repeated the analyses after exclusion of children with TSH or FT4 concentrations 
outside of the 95% range to investigate the effect of potential data outliers. To study the 
effects of highest and lowest values of TSH and FT4 determinants on the TSH and FT4 
reference ranges, we calculated the 95% range for both TSH and FT4 at the highest 10% 
and lowest 10% of each determinant. We used multiple imputation to cope with missing 
data for determinants/covariates. The multiple imputation model included maternal 
education level, ethnicity of the child, height, weight, age, sex, time of venipuncture and 
season (missing data in 15.4%, 2.5%, 0.2%, 0.2% and for the rest, 0%, respectively) and 
TSH and FT4 concentrations were used as prediction variables only. Five imputed data 
sets were created and pooled for further analyses. There were no statistically significant 
differences between the original and imputed datasets. All analyses were performed 
using Statistical Package of Social Sciences version 20.0 for Windows (SPSS Inc. Chicago, 
IL, USA) and R statistical software version 3.03 (‘rms’ package). 
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RESuLTS
Literature overview 
The systematic search yielded 4704 studies of potential interest of which 4620 studies 
were excluded after assessment of the title and the abstract. After further examination, 
35 studies were finally included for extraction of the data on TSH and/or FT4 reference 
ranges (Supplemental Figure 1). An overview of all included studies and reference 
ranges for various age categories is shown in Supplemental Tables 1-8. In general, the 
variability of reported upper and lower limits reference ranges for TSH and FT4 was the 
highest in the first week of life and became lower as the age of the study population 
becomes older. Similar effects were observed in studies with longitudinal data on TSH 
and FT4 reference ranges 22-28. There were considerable differences in the reported lower 
and upper limits of TSH and FT4, as is shown in Table 1. Taken together, in children aged 
≥1 years the lower limit for TSH ranged between 0.32 and 1.30 mU/L while the upper 
limit for TSH ranged from 2.36 to 6.57 mU/L (Table 1). Furthermore, in children aged ≥1 
years, the lower limit for FT4 in these age groups ranged between 7.0 and 18.0 pmol/L, 
and the upper limit for FT4 ranged between 15.5 and 34.7 pmol/L (Table 1).
Original study
We studied which child characteristics are determinants of thyroid function. Subse-
quently, we aimed to identify to what extent differences in such determinants between 
populations underlie the large between-study differences in reference range limits for 
TSH and FT4. Descriptive characteristics of the study population are shown in Supple-
mental Table 9. After exclusions, the final study population comprised N=4273 children 
(Figure 1). There were no considerable differences in characteristics between children 
with or without data available on TSH or FT4 concentrations (Supplemental Table 10). 
Child serum samples were obtained at a median age of 6.0 years (95% range 5.7 – 8.0 
Table 1. The ranges for lower and upper limits of TSH and FT4 reference ranges
1 to 7 days 7 days to 3 
months
3 months to 
1 year
1 year to 5 
years
5 years to 10 
years
11 years to 20 
years
TSH cut-offs (mU/l)
Lower limit 0.13 – 1.79 0.16 – 1.80 0.30 – 1.80 0.53 – 0.97 0.48 – 1.30 0.32 – 0.88
Upper limit 9.23 – 57.2 4.38 – 12.56 4.23 – 8.14 2.94 – 6.57 3.36 – 5.66 2.36 – 6.45
FT4 cut-offs (pmol/l)
Lower limit 8.9 – 20.3 8.9 – 19.3 9.2 – 12.3 9.0 – 18.0 8.3 – 14.4 7.0 – 14.2
Upper limit 26.8 – 46.6 21.3 – 33.1 19.5 – 25.3 19.0 – 34.7 16.4 – 24.6 15.5 – 31.5
Reference ranges derived from 2.5th and 97.5th percentiles. Reference ranges that were calculated in popula-
tions with overlapping age ranges were counted for the category with most overlap.
Derived from the data extracted from the reviewed studies
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years) and the majority of subjects were of Dutch origin (57.8%; Supplemental Table 9). 
The number of drawn samples was equally distributed throughout the year and samples 
were on average taken in the afternoon (median time 14:02h, 95% range: 11.17-5.17h, 
Supplemental Table 9). The median and reference range (2.5th - 97.5th percentile) for 
TSH concentrations were 2.30 and 0.87 – 5.20 mU/L, respectively (Table 2). The median 
and reference range (2.5th - 97.5th percentile) for FT4 were 16.8 and 13.8 – 20.8 pmol/L, 
respectively (Table 2). There was a negative, non-linear association of FT4 with TSH, ex-
hibiting a stable TSH concentration across FT4 concentrations ranging between roughly 
12 and 18 pmol/L (Figure 2).
Assessment of thyroid function determinants
Boys had a higher TSH concentration than girls (Figure 3; P<0.0001). TSH differed according 
to ethnicity, with the lowest concentration in children of Dutch Antilles origin and the high-
est concentration in Dutch children (Figure 3; P=0.0003). Height was negatively associated 
with TSH (P<0.0001) and there was a positive linear association of weight with TSH (Figure 
3; P=0.03). There was a U-shaped association of time at venipuncture with TSH, with higher 
TSH concentrations during the morning and late afternoon (Figure 3; P<0.0001). Age, ma-
ternal education and season at venipuncture were not associated with TSH concentrations 
(Figure 3, P=0.90; Supplemental Figure 2, P=0.20 and P=0.15, respectively).
Figure 1. Flowchart showing selection procedure of the study population
Children invited to visit  
the research center 
(n=8305) 
Successful venipuncture after  
maternal and child consent 
(n=4286) 
Children that visited the research 
center 
(n=6674) 
Data of children used for the study 
(n=4273) 
Exclusion of children with thyroid 
disease, chronic illness or thyroid 
interfering medication usage (n=13) 
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Boys had a lower FT4 concentration than girls (Figure 4; P<0.0001). FT4 diff ered ac-
cording to ethnicity, with the lowest concentration in Dutch children and the highest 
concentration in children of non-Western or Surinamese origin (Figure 4; P<0.0001). 
There was a negative linear association of weight with FT4 concentrations (Figure 4; 
P=0.002). There was a non-linear association of age with FT4 concentrations in which 
FT4 was higher at the lower age range (Figure 4; P=0.01). Season at venipuncture was 
associated with FT4, with the highest FT4 concentration during autumn and higher 
maternal education was associated with lower FT4 (Supplemental Figure 2; P=0.006 
and P<0.0001, respectively). Height and time at venipuncture were not associated 
with FT4 (Figure 4, P=0.10 and P=0.23, respectively). All results remained similar after 
exclusion of children outside of the 95% reference range for TSH and/or FT4 or when 
age-standardized values for height or weight were studied. 
Subsequently, reference ranges were stratifi ed according to the studied thyroid func-
tion determinants and their highest and lowest values (10% and 90% cut-off s; Table 2). 
The lower limit of TSH in our study ranged between 0.64 and 0.96 mU/L (total population 
0.87 mU/L) according to between-individual variation in clinical determinants (Table 2). 
The upper limit ranged between 4.30 and 5.62 mU/L (total population 5.20 mU/L; Table 
2). For FT4, the lower limit ranged between 13.6 and 14.2 pmol/L (total population 13.8 
pmol/L) and the upper limit ranged between 20.2 and 23.0 pmol/L (total population 20.8 
pmol/L) according to between-individual variation in clinical determinants (Table 2).
Figure 2. The association of FT4 with TSH concentrations
12              14              16              18              20              22
1.8
2.0
2.2
2.5
P < 0.0001
TS
H
 (m
U
/L
) 
FT4 (pmol/L) 
2.7
Plot shows the association of FT4 with TSH in children (median age 6 years, 95% range 5.7-8.0) with cor-
responding 95% confi dence interval, adjusted for age, sex, ethnicity, height, weight, time at venipuncture, 
season and maternal education.
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We performed sensitivity analyses to examine whether the association of the various 
determinants with TSH and FT4 concentrations diff ers based on ethnicity but we did not 
identify any relevant eff ect modifi cation (data not shown). 
DISCuSSION
In the current study, we provide a literature overview of published reference ranges for 
thyroid function in children, demonstrating large diff erences in the reported reference 
ranges for TSH and FT4 during childhood. Diff erences were present across diff erent age-
categories, between studies using diff erent assays but also between studies utilizing a 
similar assay. Subsequently, in our population-based cohort, from an iodine suffi  cient 
area, we identifi ed child age, sex, ethnicity and various anthropometric characteristics 
as thyroid function determinants. Already within this population, between-individual 
variation in a single clinical determinant accounted for variation in the lower and upper 
cut-off s of 0.64 to 0.96 mU/L and 4.30 to 5.62 mU/L for TSH, and 13.6 to 14.2 pmol/L and 
20.2-23.0 pmol/L for FT4.
Figure 3. The association of potential determinants with TSH
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P = 0.0003
Diff erent biological determinants and their association with TSH with corresponding 95% confi dence inter-
val. Every association has been adjusted for the remaining determinants and further adjusted for season of 
the year and maternal education status (supplement). 
OnW: Other non western ethnicities. Afr/Ca: African and Cape Verdian. Moro: Moroccan. DuAnt: Dutch An-
tilles. Surinam: Surinamese. Turk: Turkish. OthWes: other western ethnicities.
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In both the clinical as well as the research setting, there is very little consensus on how 
to defi ne an abnormal thyroid function in children and reference ranges 7. For example, 
some studies from our literature overview defi ned pediatric reference ranges for thyroid 
function using a non-parametric approach utilizing the 2.5th-97.5th range or the 5th-95th 
range to defi ne a normal TSH or FT4, while others used a (semi-) parametric approach 
defi ning normality based on +/- 1.96 or 2 standard deviations from the mean 25. Such 
methodological diff erences are the most likely cause of the large diff erences in pediatric 
reference ranges for TSH and FT4 in the literature, as shown in our literature overview. 
These diff erences hamper translation of research fi ndings to the clinical setting and also 
aff ect the accuracy of the literature summary. Our fi ndings demonstrate the need for 
standardization of reference range methodology in this fi eld and suggest that further 
studies are required to optimize clinical diagnosis of thyroid disease in children. 
Apart from diff erences in the methodology of calculating reference ranges, also the 
study size, study population selection and exclusion of individuals with major disease 
known to aff ect thyroid function may play an important role 47. Many studies identifi ed 
through our literature overview lack a suffi  ciently sized population to generate appro-
Figure 4. The association of potential determinants with FT4
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priate reference ranges for different age intervals. Although a minimum of 120 subjects 
is often proposed to define reference ranges, this is only recommended as an absolute 
minimum for the calculation of non-parametric 90% coverage intervals (e.g. 5th and 95th 
percentile reference ranges) 48-51. However, because of the high inter-individual vari-
ability and skewness of TSH and to some extent also FT4, a minimum of approximately 
400 individual measurements per partition is required for these measurements 48-51. As 
shown in our literature overview, 14 studies presented data derived from less than 100 
measurements 11,15,18,20,21,23,24,26,28,31-33,38,42.
Another important determinant of the large differences in reference ranges for TSH 
and FT4 concentrations is the assay that is used. While most studies used an immunoas-
say, some studies used equilibrium dialysis and/or LCMS 8,20. However, even when similar 
assays were used, large between-study differences were present. For comparison, for the 
5 to 8-year-old children from our cohort study, the reference range was 0.87 – 5.20 mU/L 
for TSH. Studies that used a similar assay report a TSH reference range that lies anywhere 
between 0.48 and 5.66 mU/L 8,12,22. This variation may suggest that also differences in 
population characteristics can account for some of the between-study differences in 
thyroid function reference ranges. Although characteristics such as child age and 
anthropometry have previously been identified as determinants of thyroid function, it 
is unknown to what extent these may affect reference ranges 22,43,44. In our population-
based cohort study, we show that already within a population representing children 
from a small geographical area, lower and upper cut-offs for TSH may vary up to 0.21 
mU/l and 0.93 mU/L (up to 21% and 31%), respectively, according to a single thyroid 
function determinant. For lower or upper FT4 cut-offs, this variation was much lower 
(0-2.5 pmol/L, or up to 4.3% and 12.0%, respectively). This larger variation according to 
determinants in TSH than in FT4 may reflect only mild alterations in the hypothalamic-
pituitary-thyroid axis (HPTa). In the vast majority of young children, it is likely that the 
HPTa is not yet subjected to pathophysiological processes such as development of toxic 
nodules or thyroid autoimmunity. This is supported by the results from our cohort study, 
showing a stable association of FT4 with TSH. Therefore, we speculate that the majority 
of the between-individual differences in TSH and FT4 presented in this study are more 
likely caused by differences in the HPTa set point, for example based on genetic varia-
tion 52. In order to further clarify the explained variability in thyroid function, genetic 
studies in children could thus prove to be valuable. Higher TSH values in boys compared 
to girls that we identified differ from study results in adults in which women tend to have 
higher TSH values compared to men 53. These differences could perhaps be explained 
by genetic differences which cause more prominent TSH differences at the age where 
less pathophysiology is present, or alternatively, slight sex differences could be present 
in the maturation of the HPTa. Another relevant difference in determinants of TSH and 
FT4 as identified in the current paper is that height was associated with TSH but not 
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FT4 while weight was associated with both TSH and FT4. This may indicate that the as-
sociation of height with TSH is perhaps caused by genetic pleiotropy, implicating the 
existence of genes affecting both the HPTa set-point as well as height, while weight is 
more likely to interfere with the HPTa 54. Although the fat component of weight could 
potentially increase TSH and decrease FT4 via higher leptin concentrations and higher 
TBG concentrations 54, respectively, we demonstrated that the lean body mass but not 
fat mass is associated with FT4 concentrations in a previous study 55. Since it is likely that 
the association of body composition with thyroid function is at least partly subject to 
reverse causation 56, further studies are needed to clarify the underlying mechanisms of 
our results.
In the current literature overview, we provide a detailed summary of the existing stud-
ies on the thyroid function reference ranges during childhood. Furthermore, we were 
able to study clinical determinants of thyroid function in a large prospective population-
based cohort of children living in an iodine sufficient area. A limitation of this study is 
the fact that our population comprised a relatively narrow age range. It is therefore not 
possible to extrapolate our results to other age categories. These data should be col-
lected in the future. In addition, venipuncture in our study was mostly done in the after-
noon (median time 14:02 h, 95% range 11:20 – 17:20 h) in a non-fasting state. In clinical 
practice, determining thyroid function usually occurs in the morning, in a fasting state. 
Current literature about childhood reference ranges does not often consider the time of 
venipuncture or the fasting state 9,14,19,22-28,31,36,41,42, which makes the comparison between 
studies challenging. Furthermore, several studies have determined reference ranges 
in different fasting and non-fasting states 13,21,29,33, which could potentially complicate 
the interpretation of reference ranges even further. The lower concentrations of TSH in 
our study when the time of venipuncture was in the early afternoon could be partially 
mediated by food intake, as FT3 concentrations rise and TSH concentrations decrease 
postprandially 57. However, the design of this study was not adequate for investigating 
postprandial thyroid function changes as breakfast or lunch were not consumed at set 
times and snacks were provided to the children during the visit. In addition, opposite to 
some studies 13,21,29,33, the majority of studies on childhood thyroid function reference 
ranges do not consider the time of venipuncture or the fasting state 9,14,19,22-28,31,36,41,42. 
Based on our results regarding the time of venipuncture, this makes the comparison 
of thyroid function tests between studies and between individuals in a clinical setting 
more challenging. Another potential limitation of our cohort study is that we did not 
have available data on TPO antibodies (Ab). However, it is unlikely that the relatively 
short exposure to thyroid autoimmunity in children with a median age of 6 years already 
affects thyroid function. This is illustrated by the fact that lower FT4 concentrations were 
not associated with higher TSH concentrations in our cohort study. Moreover, it has been 
shown that thyroid function in children with positive serum TPO Abs is not lower than in 
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TPOAbs negative children 58. Finally, the observational nature of the population-based 
cohort study leaves the possibility of residual confounding and the uncertainty about 
causality within studied associations. 
In conclusion, in the current literature overview we demonstrate a large heterogeneity 
in pediatric thyroid function reference ranges in the existing literature. In our population-
based cohort study, we demonstrate a minimal association of TSH and FT4, suggesting 
that the HPTa in children is still unaffected by thyroidal pathological processes and we 
show that child age, sex, ethnicity, anthropometry and time of venipuncture are de-
terminants of TSH and/or FT4 concentrations and that between-individual variations in 
these determinants can influence the calculation of reference ranges. The identification 
of these determinants and quantification of their effects can help with the interpreta-
tion of thyroid function tests. Future efforts should focus on generating evidence based 
recommendations to define abnormal thyroid function in children, in order to tackle the 
large heterogeneity in the current literature. 
CHAPTER 4.1
134
Supplemental Figure 1. Flowchart of the literature search strategy 
Articles identified through extensive 
search in databases (n=4704) 
Articles added 
- after examining reference lists  
- after free text search 
(n=4)  
Eligible articles for further detailed 
examination  
(n=31) 
Studies included  
(n=35) 
Articles eligible for further 
examination 
 (n=84)  
Articles excluded after reading 
title/abstract  
(n=4620)  
Articles excluded due to 
- duplicate papers 
- no third/fourth generation assay  
- inappropriate age categories 
- different study questions 
(genetics/animals) 
(n=53) 
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Supplemental Figure 2. Association of the season of blood sampling and maternal education with thyroid 
function with 95 percent confi dence interval
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Supplemental Table 9. Descriptive statistics of the study population. *European, Oceania, American west-
ern, Asian western, **Indonesian, American non - western, Asian non - western
Median or N per group (95% range or %)
Age (years) 6.0 (5.7 – 8.0)
Child sex (boys %) 2202 (51.5)
Length (cm) 119 (109.1 – 132.9)
Weight (kg) 22.6 (17.6 – 34.7)
Ethnicity child (N%)
Dutch 2402 (57.8)
Moroccan 253 (6.1)
Dutch Antilles 132 (3.2)
Surinamese 296 (7.1)
Turkish 296 (7.1)
Cape Verdian/African 218 (5.2)
Other Western * 351 (8.4)
Education of mother (N%)
No education finished/primary school/secondary phase 1 457 (12.6)
Secondary phase 2 1110 (30.5)
Higher phase 1 1002 (27.5)
Higher phase 2 1072 (29.4)
Season (N%)
Spring 1159 (27.1)
Summer 1074 (25.1)
Autumn 1111 (26.0)
Winter 929 (21.7)
Average time of venipuncture (h) 14:02 (11.17 – 5.17)
Supplemental Table  10. Statistically significant differences found in non-response analysis. Estimates 
shown are derived from linear regression analyses with the clinical characteristics as the dependent vari-
able and missing TSH/FT4 (binary yes/no) as the independent variable. Other tested variables such as ma-
ternal education level, season, BMI and ethnicity did not differ.
Dependent determinants
Age (years) Height (cm) Weight (kg)
β P β P β P
Independent
Missing TSH -0.057 P<0.001 -0.864 P<0.001 -0.369 P=0.001
Missing FT4 -0.056 P<0.001 -0.838 P<0.001 -0.351 P=0.001
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Supplemental appendix. Search queries for all databases
Database Predetermined search terms
PubMed
((“Thyroid Hormones”[Mesh]) AND (“Reference Values”[Mesh] OR “Reference Standards”[Mesh] 
)) AND “Child”[Mesh]
Embase
(‘thyroid hormone’/de OR ‘thyroxine’/de OR ‘thyrotropin’/de OR ‘thyroid hormone blood 
level’/exp OR ‘thyrotropin blood level’/de OR ‘thyroid function’/exp OR ‘thyroid disease’/
de OR hypothyroidism/exp OR ‘hyperthyroidism’/exp OR ‘thyroid function test’/de OR 
‘hypophysis hormone’/de OR (((thyroid* OR hypophysis OR pituitar*) NEAR/6 (hormone* OR 
function* OR dysfunction*)) OR thyroxin* OR thyrotropin* OR tsh OR free-T4 OR euthyroid* 
OR hypothyroid* OR hyperthyroid*):ab,ti) AND (‘reference value’/de OR ‘normal value’/de OR 
(((reference* OR standard* OR normal) NEAR/6 (value* OR interval* OR range* OR limit* OR 
data OR level* OR mean OR median OR concentrat*)) OR (reference* NEAR/3 standard*)):ab,ti) 
AND (child/exp OR adolescent/exp OR adolescence/exp OR ‘child behavior’/de OR ‘child 
parent relation’/de OR pediatrics/exp OR childhood/exp OR ‘child nutrition’/de OR ‘infant 
nutrition’/exp OR ‘child welfare’/de OR ‘child abuse’/de OR ‘child advocacy’/de OR ‘child 
development’/de OR ‘child growth’/de OR ‘child health’/de OR ‘child health care’/exp OR ‘child 
care’/exp OR ‘childhood disease’/exp OR ‘child death’/de OR ‘child psychiatry’/de OR ‘child 
psychology’/de OR ‘pediatric ward’/de OR ‘pediatric hospital’/de OR ‘pediatric anesthesia’/de 
OR (adolescen* OR preadolescen* OR infan* OR newborn* OR (new NEXT/1 born*) OR baby 
OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR 
minors OR underag* OR (under NEXT/1 (age* OR aging)) OR juvenil* OR youth* OR kindergar* 
OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* 
OR school* OR preschool* OR highschool*):ab,ti) AND (‘observational study’/exp OR ‘cohort 
analysis’/exp OR ‘longitudinal study’/exp OR ‘retrospective study’/exp OR ‘prospective study’/
exp OR ‘health survey’/de OR ‘health care survey’/de OR ‘epidemiological data’/de OR ‘case 
control study’/de OR ‘cross-sectional study’/de OR ‘population research’/de OR ‘family study’/
de OR ‘major clinical study’/de OR ‘multicenter study’/de OR ‘comparative study’/de OR 
‘follow up’/de OR ‘clinical study’/de OR ‘clinical article’/de OR ‘community trial’/de OR ‘review’/
exp OR ‘systematic review’/exp OR ‘meta analysis’/de OR (((observation* OR epidemiolog* 
OR communit*) NEAR/6 (stud* OR data OR research)) OR cohort* OR longitudinal* OR 
retrospectiv* OR prospectiv* OR population* OR (national* NEAR/3 (stud* OR survey)) OR 
(health* NEAR/3 survey*) OR ((case OR cases OR match*) NEAR/3 control*) OR (cross NEXT/1 
section*) OR multicenter* OR multi-center* OR follow-up* OR followup* OR clinical* OR 
review* OR meta-analy*):ab,ti) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim 
OR [Editorial]/lim) NOT ([animals]/lim NOT [humans]/lim)
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Supplemental appendix. (continued)
Database Predetermined search terms
Ovid Medline
(“Thyroid Hormones”/ OR “thyroxine”/ OR “thyrotropin”/ OR “Thyroid Function Tests”/ OR 
“Thyroid Diseases”/ OR exp Hypothyroidism/ OR exp “Hyperthyroidism”/ OR “Pituitary 
Hormones”/ OR (((thyroid* OR hypophysis OR pituitar*) ADJ6 (hormone* OR function* OR 
dysfunction*)) OR thyroxin* OR thyrotropin* OR tsh OR free-T4 OR euthyroid* OR hypothyroid* 
OR hyperthyroid*).ab,ti.) AND (“Reference Values”/ OR (((reference* OR standard* OR normal*) 
ADJ6 (value* OR interval* OR range* OR limit* OR data OR level* OR mean OR median OR 
concentrat*)) OR (reference* ADJ3 standard*)).ab,ti.) AND (exp Child/ OR exp Infant/ OR exp 
Adolescent/ OR exp “Child Behavior”/ OR exp “Parent Child Relations”/ OR exp “Pediatrics”/ OR 
“Child Nutrition Sciences”/ OR “Infant nutritional physiological phenomena”/ OR exp “Child 
Welfare”/ OR “Child Development”/ OR exp “Child Health Services”/ OR exp “Child Care”/ OR 
“Child Rearing”/ OR exp “Child development Disorders, Pervasive”/ OR “Child Psychiatry”/ OR 
“Child Psychology”/ OR “Hospitals, Pediatric”/ OR (adolescen* OR infan* OR newborn* OR 
(new ADJ born*) OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR 
teen* OR boy* OR girl* OR minors OR underag* OR (under ADJ age*) OR juvenil* OR youth* 
OR kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR 
paediatric* OR school* OR preschool* OR highschool*).ab,ti.) AND (“Observational Study”/ OR 
exp “Cohort Studies”/ OR “Health Surveys”/ OR exp “Epidemiologic Studies”/ OR “Case-Control 
Studies”/ OR “Cross-Sectional Studies”/ OR “Multicenter Study”/ OR “Comparative Study”/ OR 
“Clinical Study”/ OR “Review”/ OR “Meta-Analysis”/ OR (((observation* OR epidemiolog* OR 
famil* OR comparativ* OR communit*) ADJ6 (stud* OR data OR research)) OR cohort* OR 
longitudinal* OR retrospectiv* OR prospectiv* OR population* OR (national* ADJ3 (stud* OR 
survey)) OR (health* ADJ3 survey*) OR ((case OR cases OR match*) ADJ3 control*) OR (cross 
ADJ section*) OR correlation* OR multicenter* OR multi-center* OR follow-up* OR followup* 
OR clinical* OR review* OR meta-analy*).ab,ti.) NOT (letter OR news OR comment OR editorial 
OR congresses OR abstracts).pt. NOT (exp animals/ NOT humans/)
Web of 
Science
TS=(((((thyroid* OR hypophysis OR pituitar*) NEAR/5 (hormone* OR function* OR 
dysfunction*)) OR thyroxin* OR thyrotropin* OR tsh OR free-T4 OR euthyroid* OR 
hypothyroid* OR hyperthyroid*)) AND ((((reference* OR standard* OR normal) NEAR/5 (value* 
OR interval* OR range* OR limit* OR data OR level* OR mean OR median OR concentrat*)) OR 
(reference* NEAR/2 standard*))) AND ((adolescen* OR preadolescen* OR infan* OR newborn* 
OR (new NEAR/1 born*) OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* 
OR teen* OR boy* OR girl* OR minors OR underag* OR (under NEAR/1 (age* OR aging)) OR 
juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* 
OR pediatric* OR paediatric* OR school* OR preschool* OR highschool*)) AND ((((observation* 
OR epidemiolog* OR communit*) NEAR/5 (stud* OR data OR research)) OR cohort* OR 
longitudinal* OR retrospectiv* OR prospectiv* OR population* OR (national* NEAR/2 (stud* 
OR survey)) OR (health* NEAR/2 survey*) OR ((case OR cases OR match*) NEAR/2 control*) OR 
(cross NEAR/1 section*) OR multicenter* OR multi-center* OR follow-up* OR followup* OR 
clinical* OR review* OR meta-analy*)) )
Google 
Scholar
“thyroid|hypophysis|pituitary hormones|function”|thyroxin|thyrotropin 
“reference|standard|normal values|intervals|ranges|limits|data|levels”|”reference standard” ad
olescents|children|infants|newborns|child
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ABSTRACT
Objective: The cardiovascular system is a known target for thyroid hormone. Early-life 
cardiovascular alterations may lead to a higher risk of cardiovascular disease in adult-
hood. Little is known about the effects of thyroid hormone on cardiovascular function 
during childhood, including the role of body composition in this association.
Design: Population-based prospective cohort of children (N=4251, median age 6 years, 
95% range 5.7-8.0 years).
Methods: Thyroid stimulating hormone (TSH) and free thyroxine (FT4) concentrations 
were measured to assess thyroid function. Left ventricular (LV) mass was assessed with 
echocardiography. Arterial stiffness was assessed with carotid-femoral pulse wave veloc-
ity (CFPWV). Systolic and diastolic blood pressure (BP) was measured. Body composition 
was assessed by dual-energy X-ray absorptiometry scan. 
Results: FT4 was inversely associated with LV mass (P=0.002), and with lean body mass 
(P<0.0001). The association of FT4 with LV mass was partially mediated through vari-
ability in lean body mass (55% mediated effect). TSH was inversely associated with LV 
mass (P=0.010), predominantly in boys. TSH was positively associated with systolic and 
diastolic BP (both P<0.001). FT4 was positively associated with CFPWV and diastolic BP 
(P<0.0001, P=0.008, respectively), and the latter association attenuated after adjustment 
for CFPWV. 
Conclusions: At the age of 6, higher FT4 is associated with lower LV mass (partially 
through effects on lean body mass) and with higher arterial stiffness which may lead 
to higher BP. Our data also suggest different mechanisms via which TSH and FT4 are 
associated with cardiovascular function during early childhood. 
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INTRODuCTION
Cardiovascular disease is the leading cause of morbidity and mortality worldwide 1. Struc-
tural and functional cardiac parameters, as well as blood pressure, track from childhood to 
adulthood 2-6, suggesting that early-life metabolic and physiological alterations may lead 
to an adaptive response of the cardiovascular system. Consequently, the risk of developing 
cardiovascular disease in adult life may increase 7 and the determinants of childhood cardiac 
structure and function could have predictive value for clinical events in adulthood. Child-
hood cardiovascular structure and function are mainly determined by changes in the body 
size that occur due to somatic growth 8, however, little is known about other determinants.
The cardiovascular system is a well-known target for thyroid hormone (TH), as is 
exhibited by profound effects of TH on systemic vascular resistance, contractility, heart 
rate, blood volume and cardiac mass 9. Different types of evidence also support a role for 
TH in the regulation of early cardiac function and growth 10,11. During fetal and postnatal 
life, cardiomyocytes express TH receptors (TRα and TRβ) 12 and the transcription of genes 
encoding contractile proteins of myosin heavy chains is TH-dependent 13. 
Although the role of thyroid function in the regulation of cardiovascular system has 
been extensively studied in adults, data about the effects of variation in thyroid function 
on cardiovascular development and function during childhood are scarce. Furthermore, 
there is a lack of data on the effects of thyroid function on body composition and its 
potential role in the association of TH with cardiovascular system in the pediatric popu-
lation. Therefore, we aimed to study the association of childhood thyroid function with 
cardiovascular structure and function and body composition measurements.
SuBJECTS AND METHODS
Study population 
This study was embedded in Generation R, a population-based prospective cohort 
from early fetal life onwards in Rotterdam, the Netherlands 14. The study was designed 
to identify early environmental and genetic causes leading to normal and abnormal 
growth, development and health during fetal life and childhood 14. All children were born 
between 2002 and 2006 14. In total, 6690 children (median age 6 years, 95% range 5.7-8.0 
years) attended the research center for the follow-up measurements. Successful serum 
sampling was performed in 4593 children and thyroid-stimulating hormone (TSH) and 
free thyroxine (FT4) concentrations were determined in 4306 serum samples. Children 
with thyroid/chronic disease and thyroid (interfering) medication, cardiac abnormali-
ties or with missing data on cardiac ultrasound (N=23, N=32, N=182, respectively) were 
excluded from the analysis (Supplemental figure 1). 
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Thyroid measurements
Serum samples were obtained at the time of the visit to the research center. Plain tubes 
were centrifuged and serum was stored at -80°C. TSH and FT4 concentrations were 
determined using an electrochemiluminescence immunoassay on the Cobas e601 im-
munoanalyzer (Roche Diagnostics). The intra- and interassay coefficients of variation 
were 1.1-3.0% for TSH at a range 0.04-0.4 mU/L and 1.6-5.0% for FT4 at a range of 1.6-
24.1 pmol/L.
Cardiovascular measurements
M-mode echocardiographic measurements were performed using the ATL-Philips 
Model HDI 5000 (Seattle, WA, USA) or the Logiq E9 (GE Medical Systems, Wauwatosa, 
WI, USA) device 15,16. Experienced sonographers performed the measurements and were 
supervised by a pediatric cardiologist. To minimize the inter-observer differences, 
quality checks were frequently carried out and feedback was provided regularly. To 
assess reproducibility of echocardiographic measurements, the intraobserver intraclass 
correlation coefficient were calculated for LAD, AOD, interventricular end-diastolic 
septum thickness (IVSD), left ventricular diastolic diameter (LVDD) and left ventricular 
posterior wall thickness (LVPWD) in 28 subjects (median age 7.5 years, interquartile 
range 3.0 – 11.0) and varied between 0.91 to 0.99 and 0.78 and 0.96, respectively 17. 
Missing echocardiograms were random, and mainly due to participant circumstances or 
unavailability of equipment or sonographer. Aortic root diameter (AOD), LVDD, LVPWD 
and IVSD were measured and fractional shortening (FS) and left ventricular (LV) mass 
were calculated; LV mass was computed using the formula by Devereux et al: LV mass = 
0.80 × 1.04((IVSTD + LVEDD + LVPWTD)3 − (LVEDD)3)+ 0.6 18. 
Carotid-femoral pulse wave velocity (CFPWV), the reference method to assess arterial 
stiffness 19, was measured in a supine position using the automatic Complior SP device 
(Complior; Artech Medical, Pantin, France). CFPWV was calculated as a ratio of the dis-
tance traveled by the pulse wave and the time delay between the upstroke of carotid 
and femoral waveforms. The mean of at least 10 consecutive pressure waveforms was 
used in order to cover a complete respiratory cycle. CFPWV can be measured reliably, 
with good reproducibility, in large pediatric population-based cohorts 20.
Systolic blood pressure (BP) and diastolic BP was measured at the right brachial 
artery in a supine position, four times with one-minute intervals. The automatic sphyg-
momanometer Datascope Accutorr Plus (Paramus, New Jersey, USA) was used 21. The 
mean value was calculated by using the last three blood pressure measurements. Pulse 
pressure was calculated as the difference between mean systolic and mean diastolic 
pressure. In this study high BP was defined as the highest 5 percentiles of the study 
population 22.
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Anthropometric measurements 
Height and weight were measured without shoes and heavy clothing and were used to 
determine body surface area (BSA), calculated according to the Haycock formula 23,24. 
Dual-energy X-ray absorptiometry scan (iDXA, General Electrics – Lunar, 2008, Madison, 
WI, USA) was performed to assess lean and fat mass of the body composition; subse-
quently, lean mass and fat mass indices were determined according to formula: lean 
mass index = lean mass / height 2 and fat mass index = fat mass / height 2 25. 
Covariates
Information on ethnicity was obtained through questionnaires and was classified by 
the countries of birth of the parents, according to the classification of Statistics Neth-
erlands 14. Information on the educational level of the mother was used as a proxy for 
socioeconomic status and was obtained through questionnaires, as well as information 
about maternal smoking during pregnancy 14. 
Statistical analysis
We investigated the associations of TSH and FT4 with mean LV mass, AOD, FS, lean mass, 
fat mass, CFPWV, systolic and diastolic BP by using multiple linear regression analyses, 
utilizing restricted cubic splines with three knots to account for possible non-linear as-
sociations. Multiple logistic regression models were used to assess the association of 
TSH with the risk of high BP. All model covariates were selected based on biological 
plausibility, change of the effect estimate of interest or residual variability of the model. 
The analyses were adjusted for sex, age, ethnicity and maternal educational level. Ma-
ternal smoking during pregnancy did not affect the estimates and was not included 
in the model. For the models of cardiac ultrasound measurements, sensitivity analyses 
were performed to examine potential effect modification by BP level. For the BP models, 
analyses were performed to examine the potential mediation effect of arterial stiffness, 
as well as to test effect modification by BMI. Multivariable associations were graphically 
depicted by plots (main manuscript) and β estimates with 95% confidence intervals are 
shown in Supplemental Table 1. We tested for effect modification with sex by introduc-
ing a product interaction term of TSH or FT4 with sex to the model. A P-value cut-off of 
<0.15 was considered for quantification of the effect difference by subsequent stratifica-
tion of the association.
We accounted for the high number of statistical tests (39 in total) by controlling the 
false discovery rate using the fdrtool package 26. This method allows for tailored iden-
tification of the expected proportion of false positive results among all rejected null 
hypothesis. We identified that a q-value of 0.055 (i.e. the cut-off for a 5.5% chance of a 
type I error) was similar to a P-value of 0.05. Therefore, a P-value threshold of <0.05 was 
considered for statistical significance.
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As body surface area (BSA) explains a large percentage of the variability in cardiac 
size 8, BSA-adjusted SDS for AOD and LV mass were constructed for analyses. Height-
adjusted SDS for BP and CFPWV were constructed for analyses. All SDS were constructed 
using Generalized Additive Models for Location, Size and Shape (GAMLSS). 
Since TH regulates body composition, which is also an important determinant of LV 
mass, the association of thyroid function with cardiac ultrasound measurements could 
be mediated via changes in body composition 27 28. To examine the mediating role of BSA 
in the association of FT4 with LV mass, we analyzed the direct and indirect mediation ef-
fects of BSA by performing mediation analysis, using the approach described previously 
by Imai et al. 29. To further examine the mediating effects of specific body composition 
components in the association of FT4 with LV mass, we performed similar analyses with 
lean mass index as a potential mediator.
For covariates with missing data, multiple imputation according to Markov Chain 
Monte Carlo method was used 30. The percentage of missing data was 2.7% for ethnicity 
and 14.8% for maternal educational level variables. Five imputed data sets were created 
and pooled for analysis. Child ethnicity and maternal educational level were then added 
to the model. We added age, mean systolic and diastolic BP, TSH and FT4 concentra-
tions and cardiac ultrasound measurements as prediction variables only. No statistically 
significant differences in descriptive statistics were found between the original and im-
puted datasets. Statistical analyses were performed using Statistical Package of Social 
Sciences version 21.0 for Windows (SPSS Inc. Armonk, NY) and R statistical software 
version 3.2.0 (package rms, mediation, GAMLSS and fdrtool).
RESuLTS
After exclusions, the final study population consisted of 4251 children (Supplemental 
figure 1), descriptives of which are shown in Table 1. There were no differences between 
the participants with or without (N=182) available cardiac ultrasound data (Supplemen-
tal Table 2) with the exception of FT4 concentrations (median 16.8 vs 16.4, P=0.033). 
There was no difference between participants with or without available data on CFPVW 
(Supplemental Table 3) or BP (data not shown).
The association of thyroid function with cardiac structure and function
There was an inverse linear association of both TSH and FT4 concentrations with LV mass 
(P=0.010 and P=0.002, respectively; Figure 1A,B) which remained same after additional 
adjustment for blood pressure. TSH and FT4 concentrations were not associated with 
AOD or FS (Figure 1C-F). After addition of a product interaction term to the model 
(TSH*sex, P=0.09), we stratified the association of TSH with LV mass by sex (Supplemen-
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tal Figure 2). The association of TSH with LV mass was present in boys and not in girls 
(P=0.004 and P=0.46, respectively; Supplemental figure 2). There were no sex-specific 
differences in the association of FT4 concentration with LV mass or in the associations of 
TSH and FT4 with AOD or FS.
Table 1. Descriptives of the Study Population
Characteristic Value
TSH, median (95%range), mu/l, 2.29 (0.87-5.20)
FT4, median (95%range), pmol/l 16.8 (13.8-20.7)
Age, median (95%range), years 6.0 (5.7-8.0)
BMI, mean, (sd), kg/m2 16.2 (1.7)
BSA (sd), m2 0.9 (0.1)
Lean mass index, median (95%range), kg/m2 1.14 (0.98-1.33)
Fat mass index, median (95%range), kg/m2 0.37 (0.24-0.79)
Blood pressure, median (95%range), mmHg
Systolic 102 (88-120)
Diastolic 60 (48-74)
Pulse pressure 42 (30-56)
Carotid-femoral pulse wave velocity, median, (95%range), m/s 5.39 (4.08-7.53)
Aortic root diameter, mean, (sd), mm 19.3 (1.8)
Left ventricular mass, mean, (sd), g 53.8 (11.7)
Fractional shortening, mean (sd), % 35.3 (4.5)
Ethnicity, n(%)
Dutch 2439 (57.6)
Moroccan 266 (6.3)
Turkish 305 (7.2)
Surinamese 308 (7.3)
Other-Western 339 (8.0)
Other-Non-Western 581 (13.7)
Child sex, n(%)
Male 2199 (51.5)
Female 2071 (48.5)
Maternal education, n(%)
No education/primary 196 (4.6)
Secondary 1692 (39.9)
Higher 2350 (55.5)
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The role of body composition in the association of thyroid function with left 
ventricular mass
We observed an inverse linear association of FT4 with BSA (beta coeffi  cient = -0.002, 
95% confi dence interval: (-0.004, -0.001), P value < 0.001, data not shown), and we sub-
sequently investigated if the association of FT4 with LV mass could be mediated by BSA. 
The mediation analysis showed that 26% of the eff ect of FT4 on LV mass was mediated 
via changes in BSA (Table 2). As BSA roughly refl ects the variability in lean mass and fat 
mass, and TH may diff erentially aff ect these body composition segments 31, we further 
investigated the association of thyroid function with lean mass and fat mass. There was 
an inverse linear association of FT4 with lean mass (Figure 2B, P<0.0001), whereas FT4 
Figure 1. The association of thyroid function with cardiac ultrasound measurements
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Plots show the linear regression models for TSH, FT4 and cardiac ultrasound measurements, as predicted 
mean with 95 percent confi dence interval. Analyses were adjusted for ethnicity, age, sex and maternal 
educational level. 
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was not associated with fat mass (Figure 2D, P=0.92). TSH was not associated with lean 
mass or fat mass (Figure 2A,C, P=0.76, P=0.09, respectively). 
To specifi cally study the mediating role of the particular body composition compo-
nents in the association of FT4 with LV mass, we performed a mediation analysis with the 
lean mass index as a potential mediator. This analysis showed that 55% of the associa-
tion was mediated through changes in lean mass (Table 3).
Table 2. BSA as a mediator in the association of FT4 with LV mass
Mediator: BSA estimate 95% confi dence interval P value
Mediated eff ect -0.164 -0.275, -0.064 <0.001
Direct eff ect -0.465 -0.611, -0.306 <0.001
Total eff ect -0.629 -0.830, -0.453 <0.001
Percentage of mediated eff ect 26%
Figure 2. The association of thyroid function with body composition components
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The association of thyroid function with CFPWV and blood pressure
TSH was not associated with CFPWV (P=0.59, Figure 3A) whereas there was a positive 
linear association of FT4 with CFPWV (P<0.0001, Figure 3B). 
There was a positive linear association of TSH with systolic and diastolic BP (P<0.0001 
and P=0.0001 respectively; Figure 4A,C). The association of TSH with systolic BP was 
more prominent in girls, and girls with higher TSH concentration had a higher risk of 
high BP (OR 1.92 – 2.12 depending on the TSH cutoff ; Supplemental Figure 3). FT4 was 
not associated with systolic BP whereas there was a positive linear association of FT4 
with diastolic BP (P=0.21 and P=0.008, respectively; Figure 4B,D). There was a positive 
linear association of CFPWV with BP (beta coeffi  cient 0.15±0.02, P<0.001 and 0.18±0.02, 
P<0.001 for systolic and diastolic BP, respectively, data not shown). After adding CFPWV 
to the model, the association of FT4 with diastolic BP attenuated (beta coeffi  cient de-
creased 30% (from 0.022 ±0.009 to 0.016 ±0.009, P=0.07, data not shown.) There was no 
association of TSH or FT4 with pulse pressure (data not shown). 
Table 3. Lean body mass as a mediator in the association of of FT4 with LV mass
Mediator: lean
body mass index
estimate 95% confi dence interval P value
Mediated eff ect -0.339 -0.423, -0.249 <0.001
Direct eff ect -0.282 -0.465, -0.098 <0.001
Total eff ect -0.620 -0.810, -0.421 <0.001
Percentage of mediated eff ect 55%
Figure 3. The association of thyroid function with carotid-femoral pulse wave velocity
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Plots show the linear regression models for TSH/FT4 and carotid femoral pulse wave velocity, as predicted 
mean with 95 percent confi dence interval. Analyses were adjusted for ethnicity, age, child sex and BMI. 
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DISCuSSION
Early-life determinants may shape the development of the cardiovascular system and 
infl uence subsequent predisposition for cardiovascular disease in adult life. In the cur-
rent study, we show that thyroid function is a determinant of LV mass and this eff ect 
is partially mediated by the eff ects of FT4 on lean body mass. We also demonstrate a 
positive association of TSH with BP and a positive association of FT4 with diastolic BP 
that was dependent on the diff erences in arterial stiff ness, suggesting that TSH and FT4 
are associated with BP via diff erent mechanisms. 
Little is known about the eff ects of thyroid hormones on cardiac structure and func-
tion at a young age, and to our knowledge, no study has investigated the association of 
thyroid function with LV mass in children. In adults, population-based studies do not ob-
serve an association of TSH concentrations with LV mass 32-34, whereas a higher LV mass 
Figure 4. The association of thyroid function with mean arterial blood pressure. 
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Plots show the linear regression models for TSH, FT4 and systolic/diastolic blood pressure, as predicted 
mean with 95 percent confi dence interval. Analyses were adjusted for ethnicity, age, sex, maternal educa-
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has been described in individuals with subclinical and/or overt hyperthyroidism  35-37, 
although a longitudinal study showed no effect of subclinical hyperthyroidism on the 
progression of cardiac hypertrophy in adults 38. One study in hypertensive individuals 
reports an inverse linear association of TSH concentration with LV mass 39. 
In the current study, there was an inverse linear association of TSH concentration with 
LV mass in children. Importantly, various differences between adult and childhood fac-
tors need to be taken into account when interpreting these associations. In children, 
the changes in LV mass are predominantly determined by changes in body size 8, and 
the influence of pathological conditions on the cardiovascular system is much lower 
than in adults. Factors contributing to a chronically high cardiac load likely underlie the 
association of thyroid function with LV mass in hyperthyroid and hypertensive state 
during adulthood 35,36,39, whereas during childhood, LV mass is essentially determined 
by growth 8. This is in line with our results showing no effect of additional adjustment for 
blood pressure. An alternative explanation for the effects of TSH could potentially be the 
underling effects of thyrotropin-releasing hormone (TRH) on the cardiovascular system, 
as studies in animals demonstrate a positive association of TRH concentration on LV 
mass 40,41. Furthermore, in our study, higher TSH was associated with lower LV mass only 
in boys. Interestingly, studies in adults report no sex-specific differences in the associa-
tion of thyroid function with LV mass 32-34,39. Hence, these differences are more likely to 
reflect a sex-specific diversity in the rate of both somatic growth as well as heart growth, 
as LV mass is higher in boys than in girls already in prepubertal period 42. This is in line 
with the higher TSH concentrations in boys in The Generation R cohort (unpublished 
data), suggesting a potential for stronger effects of TSH in boys. 
Surprisingly, not only higher TSH, but also higher FT4 was associated with lower LV 
mass. Most of the previous studies on thyroid function and cardiac structure did not 
examine the association of FT4 with LV mass 32-35 and only focused on TSH as a measure-
ment of thyroid function. A positive association of FT4 with LV mass has been reported in 
euthyroid hypertensive adults 39, most likely due to cardiovascular adaptations induced 
by chronic hypertension and relatively high BMI of the study participants. In our study, 
the association of FT4 with LV mass was partially mediated via effects of FT4 on the 
lean body mass but not fat mass. Similar to a previous study, higher FT4 was associated 
with lower lean mass 31, and we subsequently identified that this effect may mediate 
approximately 55% of the association of FT4 with LV mass. This is in line with the notion 
that lean mass is a much stronger determinant of LV mass than fat mass in children 
27,43. Taken all together, our results suggest that the association of thyroid function with 
LV mass is a reflection of different biological mechanisms through which TSH and FT4 
are associated with LV mass, which could explain a similar direction of these associa-
tions. The inverse association of FT4 with LV mass in our study suggests that children 
with lower FT4 are more likely to have higher LV mass at this age, and it remains to be 
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determined if these individuals have a higher tendency towards LV hypertrophy later in 
life 2. The underlying mechanism of this association remains unclear, but it is likely that 
in the healthy population of a young age, we examined the developmental influence of 
TH on cardiac structure and function. 
We did not observe an association of thyroid function with fractional shortening or 
aortic root diameter, which is in line with previous reports in adults 33,34. This lack of as-
sociation suggests that, at the age of 6 years, the effects of thyroid function are predomi-
nant on the cardiac structure and/or growth, as represented by changes in the LV mass. 
Large differences in thyroid function that could be caused by underlying thyroid disease 
are practically absent in this young population. As a consequence, any association of 
thyroid function with cardiac functional parameters will probably be less pronounced. 
As LV mass tracks from childhood to adulthood 2,3, the observed associations might have 
implications for cardiac function in the future. However, future studies are needed to 
further study such long-term effects.
In line with previous reports 44,45, we show that higher TSH is associated with higher 
BP. A positive association of TSH and BP was reported earlier in obese children as well, 
but here the association of TSH with BP may have been amplified because obesity has 
been shown to affect both TSH and BP levels 46,47. However, we did not find any effect 
modification by BMI. It has been speculated that this association might be occurring 
through common genetic factors that are associated with both thyroid function and 
BP 48.
A novel finding of this study is that FT4 is associated with diastolic BP via differences in 
arterial stiffness. The mechanism underlying this association is likely to be different from 
the association of TSH with BP, as in our study, CFPWV (a measure of arterial stiffness), 
was strongly associated with FT4 but not with TSH. Previous studies have also reported 
a positive association of FT4 with arterial stiffness 49,50 and speculated that FT4 modifies 
arterial elasticity 50. Thyroid hormone can initiate endothelial dysfunction 51,52, which is 
an early sign of atherosclerosis 53 that underlies arterial stiffness. Taken together, this 
suggests that direct effects of thyroid hormone on arterial tissue may create structural 
changes that could have consequences for BP levels already during childhood.
To our knowledge, this is the first population-based study that examined the associa-
tion of thyroid function with cardiovascular structural and functional parameters during 
childhood. We had detailed data available on thyroid function, cardiac ultrasound mea-
surements, serial BP measurements, arterial stiffness, body composition assessment and 
potential confounding variables. The main limitation of this study is the cross-sectional 
study design, which does not allow for studying casual inference and does not impede 
residual confounding. Another limitation is the narrow age range of children (5.7 - 8.0 
years), which limits the generalization of the results to older ages in childhood. Further-
more, in this study, we identified lean mass, and not fat mass, as a potential mediator of 
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the effects of thyroid function on LV mass. The association of thyroid hormone with fat 
mass is complex, potentially bidirectional and/or confounded by food intake/fasting 54. 
In adults, a positive association of FT4 with fat body mass has been described 31. In our 
study, however, FT4 concentration was not associated with fat mass, rendering the pos-
sibility of mediation pathway through fat mass implausible.
In the current study, we translate the findings of the effects of thyroid function on 
cardiovascular growth and function from experimental studies to humans in the young 
age. We observed that thyroid function is associated with the measurement of cardiac 
growth (LV mass), in part via effects on lean body mass. We also observed that TSH and 
FT4 might have different underlying mechanisms in the association with BP, with a role of 
arterial stiffness in the latter case. Although these findings have relatively limited clinical 
implications, the observed associations designate the importance of thyroid function 
as an important cardiovascular determinant, as it might affect cardiovascular health 
during the lifespan. These results need further research to confirm the observations and 
investigate the association of thyroid function with longitudinal cardiac structure and 
function measurements during childhood, as well as the extent of arterial stiffness effect 
in the association of FT4 with BP.
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Supplemental Figure 1. Flowchart showing selection procedure of the study population. 
Children with enough serum available 
for TSH and/or FT4 measurement 
N=4306 
Children with succesfull blood draw 
N=4593 
Children with blood pressure 
measurement available  
N=4137 
 
N=23 excluded 
• due to thyroid/chronic diseases 
or thyroid (interfering) 
medication 
N=32 excluded 
• due to cardiac abnormalities  
 
 
Children attended the research center 
N=6690 
Children with cardiac 
ultrasound 
data available  
N=4069 
AOD 
N=4056 
 
LV mass 
N=3977 
 
FS 
N=4037 
 
Children with CFPWV available 
N=3394 
Study population 
N=4251 
• AOD – aortic root diameter
• LV mass – left ventricular mass
• FS – fractional shortening
• CFPWV – carotid femoral pulse wave velocity
Supplemental Figure 2. The association of TSH with left ventricular mass stratifi ed for sex
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Plots show the linear regression models for TSH and left ventricular mass, as predicted mean with 95 per-
cent confi dence interval. Analyses were adjusted for ethnicity, age and maternal educational level. 
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Supplemental Figure 3. The association of thyroid function with the risk of high arterial blood pressure 
stratifi ed for sex
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Plots show the logistic regression models for TSH, FT4 and systolic/diastolic blood pressure, as predicted 
mean with 95 percent confi dence interval. Analyses were adjusted for ethnicity, age, child sex, maternal 
education level and BMI. 
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Supplemental Table 1. Regression coefficients (95% confidence intervals) from the multivariate linear re-
gression analysis
Association of thyroid function with cardiac ultrasound measurements
Left ventricular mass (SD) Aortic root diameter (SD) Fractional shortening
TSH -0.035 (-0.063, -0.008)* -0.005 (-0.032, 0.022) -0.012 (-0.027, 0.002)
FT4 -0.027 (-0.044, -0.010) * -0.001, (-0.017, 0.015) -0.071 (-0.147, 0.003)
Sex-specific differences in the association of thyroid function with left ventricular mass
boys girls
TSH -0.055 (-0.093, -0.017) * -0.013 (-0.053, 0.026)
FT4 -0.024 (-0.049, 0.002) -0.028 (-0.052, -0.004)*
Association of thyroid function with blood pressure and CFPWV
Systolic blood 
pressure (SD)
Diastolic blood pressure 
(SD)
Pulse pressure 
(SD)
CFPWV
TSH 0.079 (0.052, 0.106) ** 0.060 (0.034, 0.088) **
0.018 (-0.005, 
0.042)
0.009 (-0.022, 
0.034)
FT4 0.01 (-0.006, 0.0026) 0.022 (0.006, 0.039) **
-0.012 (-0.027, 
0.002)
0.040 (0.022, 
0.057) **
Sex-specific differences in the association of TSH with systolic blood pressure
Systolic blood pressure (SD) Systolic blood pressure (SD)
boys girls
TSH 0.047 (0.011, 0.083)* 0.117 (0.078, 0.156) **
Values are regression coefficients (95% confidence intervals) from the multivariate linear regression analy-
ses. Models were adjusted for ethnicity, age, sex, maternal educational level.
* P<0.05
** P<0.001
CHAPTER 4.2
180
Supplemental Table 2. Descriptives of the Study Population– Non response analysis
Characteristic Value 
(response) 
Value (non 
response) 
P value
TSH, median (95%range), mu/l, 2.29 (0.87-5.18) 2.25 (0.89-5.55) 0.36
FT4, median (95%range), pmol/l 16.8 (13.8-20.8) 16.4 (13.6-20.4) 0.033
Age, median (95%range), years 6.0 (5.7-8.0) 6.0 (5.7-7.0) 0.38
BSA (sd), m2 0.9 (0.1) 0.88 (0.08) 0.62
Lean body mass index, mean (95%range), kg/m2 1.14 (0.98-1.33) 1.14 (0.98-1.33) 0.76
Fat body mass index, median (95%range), kg/m2 0.37 (0.24-0.79) 0.36 (0.22-0.81) 0.12
Ethnicity, n(%) 0.81
Dutch 2236 (57.6) 103 (56.6)
Moroccan 254 (6.3) 12 (6.6)
Turkish 289 (7.1) 16 (8.8)
Surinamese 298 (7.3) 10 (5.5)
Other-Western 321 (7.9) 18 (9.9)
Other-Non-Western 558 (13.8) 23 (12.6)
Child sex, n(%) 0.65
Male 2085 (51.4) 97 (53.3)
Female 1971 (48.6) 85 (46.7)
Maternal education, n(%) 0.84
No education/primary 189 (4.7) 7 (3.8)
Secondary 1617 (39.9) 75 (41.2)
Higher 2250 (55.5) 100 (54.9)
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Supplemental Table 3. Descriptives of the Study Population – Non Response for CFPWV
Characteristic Value
P value – difference between 
the participants with and 
without available data
TSH, median (95%range), mu/l, 2.30 (0.78-5.50) 0.17
FT4, median (95%range), pmol/l 16.6 (13.6-20.7) 0.05
Age, median (95%range), years 6.0 (5.6-7.6) 0.40
BMI, mean, (sd), kg/m2 16.3 (1.96) 0.32
Blood pressure, median (95%range), mmHg
Systolic 102 (87-120) 0.44
Diastolic 60 (48-76) 0.19
Pulse pressure 42 (30-56) 0.69
Ethnicity, n(%) 0.02
Dutch 477 (58.4)
Moroccan 36 (4.4)
Turkish 51 (6.2)
Surinamese 72 (8.8)
Other-Western 55 (6.7)
Other-Non-Western 126 (15.4)
Child sex, n(%) 0.92
Male 422 (51.7)
Female 395 (48.3)
Maternal education, n(%) 0.89
No education/primary 37 (4.5)
Secondary 321 (39.3)
Higher 459 (56.2)
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Supplemental Table 4. Difference in participants’ characteristics based on availability of thyroid function 
measurement
Characteristic Value (available 
thyroid function) 
Value (unavailable 
thyroid function) 
P value
Age, mean (sd), years 6.2 (0.5) 6.2 (0.5) 0.83
Ethnicity, n(%) 0.03
Dutch 2098 (58.5) 1709 (55.0)
Moroccan 216 (6.0) 253 (8.1)
Turkish 278 (7.8) 221 (7.1)
Surinamese 260 (7.3) 211 (6.8)
Dutch Antillean 181 (5.0) 279 (9.0)
Other-Western 281 (7.8) 269 (8.7)
Other-Non-Western 271 (7.5) 250 (8.1)
Child sex, n(%) 0.65
Male 1819 (50.7 1533 (49.4)
Female 1766 (49.3) 1572 (50.6)
Maternal education, n(%) 0.001
No education/primary 140 (3.9) 177 (5.7)
Secondary 1452 (40.5) 1300 (41.9
Higher 1993 (55.6) 1628 (52.4)
Lean body mass, mean (sd), kg 16.4 (2.3) 16.3 (2.4) 0.05
Fat body mass, mean (sd), kg 5.9 (2.4) 5.9 (2.4) 0.82
Blood pressure, mean (sd)
Systolic 102 (8) 102 (8) 0.71
Diastolic 60 (7) 60 (7) 0.59
Carotid-femoral pulse wave velocity, mean, (sd), (m/s) 5.5 (0.9) 5.5 (0.9) 0.17
Aortic root diameter, mean, (sd), mm 19.3 (1.9) 19.1 (1.8) 0.01
Left ventricular mass, mean, (sd), g 53.8 (11.8) 52.9 (11.7) 0.01
Fractional shortening, mean, (sd), % 35.3 (4.5) 35.2 (4.7) 0.14
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ABSTRACT
Background: The skeleton is a well-known target organ for thyroid hormone. Little 
data are available on the association of thyroid function and bone development during 
childhood. The aim of this study was to prospectively examine and quantify the effects 
of thyroid function on bone density in a population-based cohort of children. 
Methods: Serum TSH and FT4 were measured in samples collected at median age of 
6 years (95% range 5.6-7.9 years). For 4204 participants of The Generation R Study, 
information on thyroid function and bone density at the age of 6 was available; for 3404 
participants information was available for thyroid function and bone density at the 
age of 10. A total body dual-energy x-ray absorptiometry (DXA) (used for none mineral 
density (BMD) and bone mineral content (BMC)) scan was performed at median age of 6 
and 10 years (95% range 5.6-7.9 years and 9.0-10.9 years, respectively). 
Results: At the age of 6, TSH and FT4 were inversely associated with both BMD and 
BMC (TSH: P=0.003 and P=0.038, respectively, and FT4: P=0.047 and P=0.003, respec-
tively). TSH was not associated with BMD and BMC at the age of 10 (P=0.15 and P=0.52, 
respectively), whereas FT4 was inversely associated with BMD and BMC at the age of 10 
(P=0.048 and P=0.018, respectively). In the European subgroup TSH was not associated 
with BMD and BMC at the age of 6 (P=0.11 and P=0.21, respectively) or at the age of 
10 (P=0.79 and P=0.79, respectively) and FT4 was not associated with BMD (P=0.10), 
whereas FT4 was inversely associated with BMC at 6 (P=0.014) and BMC and BMD at 10 
years (P=0.031 and P=0.037, respectively). 
Conclusion: In this large population-based cohort, we observed an inverse association 
of FT4 with bone density at the age of 6 and at the age of 10 years. We did not detect 
consistent associations of TSH with bone density measurements.
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INTRODuCTION
Thyroid hormone regulates metabolism in practically all tissues of the human body 1 
and plays an important role during childhood growth and development 2, in neurode-
velopment and neuropsychological function 3,4 and in the cardiovascular system 5. Bone 
is a well-known target organ for thyroid hormone, which is especially important for 
proper linear growth and development during childhood 2. In line with this, congenital 
hypothyroidism is associated with delayed skeletal development and impaired bone 
maturation, leading to short stature 2 and thyroid hormone replacement can induce 
‘catch-up’ growth and acceleration of skeletal maturation 6, leading to achievement of 
normal height and normal bone mass 7,8. On the other hand, juvenile hyperthyroidism 
is associated with accelerated skeletal development and rapid growth 9,10. In adults, 
hyperthyroidism increases the risk of osteoporosis, which is reflected by low bone 
mineral density (BMD) and the risk of fracture 11. Studies in healthy adults suggest that 
even high-normal thyroid hormone and low-normal thyroid stimulating hormone (TSH) 
concentrations are associated with high bone turnover state, leading to a net increased 
bone resorption and thereby a decreased BMD and consequently a higher risk of frac-
ture 2,12,13. 
In vitro and animal studies suggest that besides thyroid hormone, TSH might play a 
role in the skeletal development and maintenance by inhibiting osteoclastogenesis and 
function 2,14 and possibly by exerting effects on osteoblasts as well 2,14. It was also shown 
that deiodinases are likely to regulate thyroid hormone activity in bone 15-17, although 
the exact mechanisms remain unclear. Despite the known regulating role of thyroid 
hormone in the skeleton in experimental setting, little epidemiological data are avail-
able that have translated these effects to human data focusing on childhood growth 
and development. 
The aim of this study was to investigate the association of thyroid function with BMD 
and bone mineral content (BMC) during childhood in a population-based prospective 
cohort. We set out to investigate the potential effects of TSH and FT4 on longitudinally 
measured bone density in children.
METHODS
Study design
This study was embedded in Generation R, a large prospective population-based cohort 
from early fetal life onwards, in Rotterdam, the Netherlands 18. The study was designed 
to identify early environmental and genetic determinants of growth, development and 
health during fetal life, childhood and young adulthood 18. Eligible participants were 
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6690 live-born children born between 2002 and 2006 that visited the research center at 
roughly 6 years of age18. 
Thyroid measurements
TSH and FT4 were measured in cord blood samples that were obtained directly after 
birth (median gestational age at birth 40.1 weeks, 95% range 35.8-42.3 weeks) and in 
serum samples obtained at the age of 6. Plain tubes were centrifuged and serum was 
stored at -80°C. TSH and free thyroxine (FT4) concentrations were determined in cord 
blood samples using chemiluminescence assays (Vitros ECI; Ortho Clinical Diagnostics, 
Rochester, NY). The intra- and interassay variation coefficients were <4.1% for TSH at a 
range of 3.97–22.7 mU/l and <5.4% for FT4 at range of 14.3 – 25.0 pmol/l. At 6 years of 
age, TSH and FT4 were measured using an electrochemiluminescence immunoassay on 
the Cobas e601 immunoanalyzer (Roche Diagnostics). The intra- and interassay coef-
ficients of variation were 1.1-3.0% for TSH at a range 0.04-0.4 mU/L and 1.6-5.0% for FT4 
at a range of 1.6-24.1 pmol/L. 
Bone density measurements
At the age of 6 (95% range 5.6-7.9 years) and at the age of 10 years (median 9.7 years, 
95% range 9.0-10.9 years) BMD was measured using a dual-energy X-ray absorptiometry 
(DXA) scan (Idxa; General Electrics – Lunar, 2008) using procedures described previously 
19. BMD measured by DXA was expressed as BMC (in g) per projected bone area (in cm2). 
As recommended by the International Society for Clinical Densitometry, BMC and BMD 
values of the total body without the head was used, so that bone density of the skeleton 
is best represented 20. Due to size effects, all models were adjusted for height and soft 
tissue mass 21. For the same reason, BMC values were standardized for bone area 21.
Covariates 
Weight and height were measured without shoes and heavy clothing. DXA scans were 
used to assess the lean and fat mass of the body composition; subsequently soft tis-
sue mass was determined by adding lean mass to fat mass. Information on ethnicity 
was obtained through questionnaires and was defined by the country of origin of the 
parents, according to the classification of Statistics Netherlands 18. Information on 
educational level of the mother was used as a proxy for socioeconomic status and was 
obtained through questionnaires. Information about participants’ sex, birth weight and 
gestational age at birth was obtained using medical records and hospital registries. 
Statistical Analysis
The association of TSH and FT4 with BMD and BMC was examined using multiple linear 
regression models. We used restricted cubic splines utilizing three knots to account for 
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possible non-linearity. Multivariable associations were graphically depicted by plots and 
standardized beta estimates with 95% confidence intervals for the regression models 
are presented in Supplemental Table 2. All model covariates were selected based on 
biological plausibility, a 10% change in the effect estimate or residual variability of the 
model. All models were adjusted for age, sex, soft tissue mass, height and educational 
level of the mother. Cord blood models were additionally adjusted for the SD score of 
birthweight. As already in childhood a substantial variation is present in bone density 
depending on the ethnic origin 22, the associations were additionally examined in a sub-
group of European participants. Multiple imputation according to Markov Chain Monte 
Carlo method was used to cope with the missing values of the covariates 23. The percent-
age of missing data was: 16.6% for educational level of the mother at child’s age 6, 9.2% 
for education level of the mother at enrolment, 2.5% for ethnicity, 2.1% for birth weight, 
2.0 % for child’s sex, 1.6% for gestational age at birth and <1% for other covariates. Data 
on thyroid function and bone density measurements were not imputed and were used 
as predictor variables only. Five imputed datasets were created and pooled for analysis. 
There were no statistically significant differences between the imputed and the original 
dataset. All analyses were performed using Statistical Package of Social Sciences version 
21 for Windows (SPSS Inc. Chicago, IL, USA) and R statistical software version 3.3.3 (‘lm.
beta’, ‘rms’and‘foreign’ package).
RESuLTS
At median age of 6 years 6690 participants visited the research center (Figure 1). For 
4306 children information on thyroid function was available (Figure 1). Participants that 
used medication that could interfere with thyroid function (n=7) or that suffered from 
endocrinological disease (n=4), chronic illness (n=10) or cancer (n=2) were excluded 
(Figure 1). After exclusions, the total study population comprised of 4204 participants 
at median age of 6 years and 3404 participants at median age of 10 years, (Figure 1); 
descriptives of the study population are shown in Table 1. Of the total group, 2675 and 
2318 participants at the median age of 6 and 10 years, respectively, were of European 
origin. Descriptives of the European subgroup are presented in Supplemental Table 1. 
Thyroid function and bone density in the total population
In the total population, at median age of 6 years, TSH was inversely associated with both 
BMD and BMC (P=0.003 and P=0.038, respectively; Figure 2) and FT4 was inversely asso-
ciated with BMD and BMC (P=0.047 and P=0.003, respectively; Figure 2). TSH was not as-
sociated with BMD and BMC at median age of 10 years (P=0.15 and P=0.52, respectively; 
Figure 3), whereas FT4 was inversely associated with both BMD and BMC at median age 
CHAPTER 4.3
192
of 10 years (P=0.048 and P=0.018, respectively; Figure 3). These effects attenuated when 
the models were adjusted for bone density at median age of 6 years (P=0.80 and P=0.76, 
respectively; Supplemental Table 2). 
Thyroid function and bone density in the subgroup of European participants
As Generation R is a multi-ethnic cohort and ethnicity-related differences in bone 
density are already present in childhood 22, we performed a sensitivity analysis by in-
vestigating the associations in a subgroup of participants of European descent. TSH was 
not associated with BMD or BMC assessed at median age of 6 years (P=0.11 and P=0.21, 
respectively; Figure 4). FT4 was not associated with BMD, but there was an inverse as-
sociation of FT4 with BMC (P=0.10 and P=0.014, respectively; Figure 4). 
TSH was not associated with BMD or BMC at the median age of 10 years (P=0.79 and 
P=0. 79, respectively; Figure 5). FT4 was inversely associated with both BMD and BMC at 
median age 10 (P=0.031 and P=0.037, respectively; Figure 5). These effects attenuated 
when the models were adjusted for bone density at the age of 6 (P=0.85 and P=0.87, 
respectively; Supplemental Table 2).
Figure 1. Flowchart showing selection procedure of the study population
Europeans at age 6 
(N=2675) 
Europeans at age 10 
(N=2318) 
Live-born children included in 
Generation R  
(N=9749) 
N=23 excluded: 
- Thyroid (interfering) 
medication usage (N=7) 
- Endocrinological disease or 
treatment (N=4) 
- Chronic illness (N=10) 
- Cancer (N=2) 
Children that visited the research center 
at age 6 
(N=6690) 
Children with information on thyroid 
function at age 6 
(N=4306) 
Children with 
information on  bone 
density at age 6 
(N=4204) 
Study population after exclusions 
(N=4283) 
Children with 
information on bone 
density at age 10 
(N=3404) 
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Table 1. Descriptives of the total study population
Characteristic Value
At birth
TSH cord blood, median (95%range), mu/L 9.35 (3.35-33.5)
FT4 cord blood, median (95%range), pmol/L 20.5 (15.4 - 28.8)
Birth weight, median (95%range), g 3450 (2306 - 4475)
Gestational age at birth, median (95%range), weeks 40.1 (35.8 - 42.3)
Educational level of the mother, n(%)
No education or primary education 670 (11.8%)
Secondary education 2374 (41.7%)
Higher education 2647 (46.5%)
At median 6 years
BMD without head, median (95%range), g/cm2 0.55 (0.47 - 0.70)
BMC without head, median (95%range), g 514 (366 - 792)
TSH, median (95%range), mu/L 2.29 (0.87 - 5.18)
FT4, median (95%range), pmol/L 16.8 (13.8 - 20.8)
Age, median (95%range), years 6.0 (5.6 - 7.9)
Weight, median (95%range), kg 22.6 (17.6 - 34.2)
Height, median (95%range), cm 119 (109 - 133)
Educational level of the mother, n(%)
No education or primary education 522 (9.2%)
Secondary education 2205 (38.7%)
Higher education 2964 (52.1%)
At median 10 years
BMD without head, median (95%range), g/cm2 0.68 (0.57 - 0.82)
BMC without head, median (95%range), g 921 (661 - 1320)
Age, median (95%range), years 9.7 (9.0 - 10.9)
Weight, median (95%range), kg 34.8 (25.6 - 52.0)
Height, median (95%range), cm 141 (130 - 155)
General characteristics
Child’s sex, n(%)
Male 2891 (50.8%)
Female 2800 (49.2%)
Ethnicity child, n(%)
Dutch 3204 (56.3%)
Turkish 416 (7.3%)
Surinamese 423 (7.4%)
North-African 351 (6.2%)
Asian 206 (3.6%)
Other western 509 (8.9%)
Other non-western 582 (10.2%)
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Cord blood thyroid function and bone density
Cord blood thyroid function was not associated with bone density measurements at 
any age, apart from an inverse association of FT4 with BMD at the age of 6 in the total 
population (Supplemental Figure 1-4). 
DISCuSSION
In the current study, we show that thyroid function is associated with bone density mea-
surements during childhood. We demonstrate that higher FT4 is associated with lower 
bone density at median age of 6 and 10 years. We did not detect consistent associations 
of TSH with bone density during childhood. 
Population studies in both euthyroid and hyperthyroid adults show that higher 
thyroid hormone concentrations and/or lower TSH concentrations are associated with 
lower BMD 2,12. Children with untreated hyperthyroidism are reported to have a lower 
Figure 2. The association of thyroid function with bone density at 6 years in the total study population
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Plots show the linear regression models of TSH and FT4 with bone mineral density (BMD) and bone min-
eral content (BMC) standardized for bone area at age 6, as predicted mean with 95% confi dence interval. 
Analyses were adjusted for age , sex, soft tissue mass, height, ethnicity and educational level of the mother .
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BMD compared to healthy controls 24,25, but these fi ndings are not generalizable to a 
healthy pediatric population. Little epidemiological data are available on the infl uence 
of thyroid function on the bone development, and to our knowledge, this is the fi rst 
study to investigate the association of thyroid function with bone density in healthy 
children. Optimizing peak bone mass in children and adolescents is considered as an im-
portant strategy to prevent osteoporosis in later life 26. Understanding the physiology of 
bone mass accrual will help to identify potential risk factors and targets for intervention. 
In the current study, we identifi ed an inverse association of FT4 with BMD and BMC in 
early childhood, suggesting that high thyroid hormone levels might lead to lower bone 
density already during childhood. These results are in line with data from experimental 
studies which show that thyroid hormone stimulates osteoblast proliferation, bone 
matrix synthesis and mineralization 2,12,27. Moreover, it has also been shown that thyroid 
hormone regulates bone mass 28 and that it stimulates osteoclast activity and bone 
resorption directly, or indirectly via osteoblasts or other pathways 2,12,27. 
Figure 3. The association of thyroid function with bone density at 10 years in the total study population
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Plots show the linear regression models of TSH and FT4 with bone mineral density (BMD) and bone min-
eral content (BMC) standardized for bone area at age 10, as predicted mean with 95% confi dence interval. 
Analyses were adjusted for age , sex, soft tissue mass, height, ethnicity and educational level of the mother .
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In the European population we detected stronger eff ects of FT4 on BMC than on 
BMD at the age of 6. A potential explanation is the method of assessing bone density, 
because using BMD measurement can overestimate true BMD when measuring large 
bones, whereas on small bones BMD can be underestimated, suggesting that, during 
childhood growth, BMD might be a less reliable measurement for bone density 21. BMC 
adjusted for bone area, height and soft tissue mass, refl ects true bone density better and 
is therefore more reliable and may provide a more precise measurement 29.
Our results suggest that the inverse association of FT4 with bone density at the age of 
10 is driven by the eff ects of FT4 earlier in childhood, in this case at 6 years. Furthermore, 
the ‘Bone Mineral Density in Childhood Study’ showed that bone density tracks in time, 
which means that if adjusted bone density scores are low in childhood, they will remain 
low later in childhood and adolescence as well 30. This suggests that early infl uences 
during childhood may be important for bone density in later age. Hence, early child-
hood thyroid function might infl uence the quality of bone accrual throughout early 
Figure 4. The association of thyroid function with bone density at 6 years in the European subgroup
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Plots show the linear regression models of TSH and FT4 with bone mineral density (BMD) and bone mineral 
content (BMC) standardized for bone area , as predicted mean with 95% confi dence interval. Analyses were 
adjusted for age , sex, soft tissue mass, height and educational level of the mother .
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childhood, and might therefore be important for bone density at a later age as well. 
Further studies are needed to investigate the eff ects of early life thyroid function on 
bone density in adulthood.
Experimental studies suggest that TSH might directly exert eff ects on bone by inhibit-
ing osteoclastogenesis and function 2,14 and possibly by exerting eff ects on osteoblasts 
as well 2,14. However, the results are not consistent and this remains a controversial 
hypothesis 2,28. Some studies in adults suggest that high TSH might protect against bone 
loss 31-33, although it is postulated that FT4 has a greater impact on bone turnover than 
any direct eff ect of TSH 33. In the longitudinal analysis within the total population and in 
the European subgroup overall, we did not detect associations of TSH with bone density 
in childhood. The association of TSH with bone density we detected in the total popula-
tion cross-sectionally might therefore be subject to residual or unmeasured confound-
ing. Apart from the ethnicity related diff erences in bone density 22,34,35, TSH levels are also 
known to diff er between ethnic groups in the Generation R cohort (unpublished data). 
Moreover, genetics are known to have great impact on both bone density 36 and thyroid 
Figure 5. The association of thyroid function with bone density at 10 years in the European subgroup
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Plots show the linear regression models of TSH and FT4 with bone mineral density (BMD) and bone mineral 
content (BMC) standardized for bone area , as predicted mean with 95% confi dence interval. Analyses were 
adjusted for age , sex, soft tissue mass, height and educational level of the mother .
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function 37. Further research is needed to examine the possible ethnic and/or genetic 
differences in the association of TSH with bone density. 
For the current study, we were able to study the association of childhood thyroid func-
tion with longitudinally measured bone density in a population-based setting using de-
tailed information on covariates for a large number of participants. The main limitation 
of this study is that only one thyroid function measurement at median age of 6 years was 
available, which limits generalization of the results to older ages in childhood. Moreover, 
the observational design of this study does not allow for inference of causality and does 
not preclude the existence of residual confounding even though we were able to adjust 
for a large number of covariates.
In conclusion, this study provides new insights into the influence of thyroid function 
on bone density during childhood. We show an inverse association of FT4 with bone 
density and our data suggest that early childhood thyroid function could be a deter-
minant of the quality of bone mineral accrual throughout childhood. We did not detect 
consistent evidence for an effect of TSH on bone density. Future studies are needed to 
investigate whether these associations persists later in childhood and adulthood and to 
investigate whether these effects are genetically determined. 
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Supplemental Figure 1. The association of cord blood thyroid function with bone density at 6 years
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Plots show the linear regression models of cord blood TSH and FT4 with bone mineral density (BMD) and 
bone mineral content (BMC) regressed for bone area at age 6, as predicted mean with 95% confi dence in-
terval. Analyses were adjusted for age, sex, soft tissue, height, SDS birth weight, ethnicity and educational 
level of the mother.
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Supplemental Figure 2. The association of cord blood thyroid function with bone density at 10 years
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Plots show the linear regression models of cord blood TSH and FT4 with bone mineral density (BMD) and 
bone mineral content (BMC) regressed for bone area at age 10, as predicted mean with 95% confi dence in-
terval. Analyses were adjusted for age , sex, soft tissue, height, SDS birth weight, ethnicity and educational 
level of the mother .
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Supplemental Figure 3. The association of cord blood thyroid function with bone density at 6 years in the 
European population
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Plots show the linear regression models of cord blood TSH and FT4 with bone mineral density (BMD) and 
bone mineral content (BMC) standardized for bone area at age 6, as predicted mean with 95% confi dence 
interval. Analyses were adjusted for age , soft tissue mass, height , SDS birth weight, and educational level 
of the mother .
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Supplemental Figure 4. The association of cord blood thyroid function with bone density at 10 years in 
the European population
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Plots show the linear regression models of cord blood TSH and FT4 with bone mineral density (BMD) and 
bone mineral content (BMC) standardized for bone area at age 10, as predicted mean with 95% confi dence 
interval. Analyses were adjusted for age , sex, soft tissue mass, height , SDS birthweight and educational 
level of the mother at birth.
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Supplemental Table 1. Descriptives of the European study population
Characteristic Value
At birth
TSH cord blood, median (95%range), mu/L 9.79 (6.54, 35.1)
FT4 cord blood, median (95%range), pmol/L 20.7 (15.6, 28.9)
Birth weight, median (95%range), g 3500 (2360, 4520)
Gestational age at birth, median (95%range), weeks 40.1 (35.7, 42.3)
Educational level of the mother, n (%)
No education or primary education 152 (4.2%)
Secondary education 1360 (37.5%)
Higher education 2110 (58.3%)
At median 6 years
BMD without head, median (95%range), g/cm2 0.54 (0.47, 0.65)
BMC without head, median (95%range), g 508 (366, 749)
TSH, median (95%range), mu/L 2.38 (0.91, 5.38)
FT4, median (95%range), pmol/L 16.5 (13.7, 20.5)
Age, median (95%range), years 6.0 (5.6, 7.6)
Weight, median (95%range), kg 22.4 (17.7, 31.4)
Height, median (95%range), cm 119 (109, 132)
Educational level of the mother, n(%)
No education or primary education 69 (1.9%)
Secondary education 1214 (33.5%)
Higher education 2340 (64.6%)
At median 10 years
BMD without head, median (95%range), g/cm2 0.68 (0.57, 0.80)
BMC without head , median (95%range), g 915 (665, 1275)
Age, median (95%range), years 9.7 (9.1, 10.7)
Weight, median (95%range), kg 34.4 (25.6, 49)
Height, median (95%range), cm 142 (130, 154)
General characteristics
Child’s sex, n(%)
Male 1823 (50.3%)
Female 1800 (49.7%)
Ethnicity child, n(%)
Dutch 3204 (88.4%)
Other European 419 (11.6%)
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Supplemental Table 2. Estimates for the association of childhood thyroid function with bone density
Model Outcome
Total study population European study population 
Standardized β 95% CI P value Standardized β 95% CI P value
Childhood thyroid function with bone density at age 6
TSH BMD -0.028 -0.046, -0.010 0.003 -0.017 -0.039, 0.004 0.11
TSH BMC -0.027 -0.052, -0.001 0.038 -0.018 -0.048, 0.011 0.21
FT4 BMD -0.011 -0.022, -0.000 0.047 -0.012 -0.026, 0.002 0.10
FT4 BMC -0.023 -0.038, -0.008 0.003 -0.024 -0.043, -0.005 0.014
Childhood thyroid function with bone density at age 10
TSH BMD -0.015 -0.035, 0.005 0.15 -0.003 -0.027, 0.020 0.79
TSH BMC -0.009 -0.036, 0.018 0.52 -0.004 -0.035, 0.027 0.79
FT4 BMD -0.012 -0.024, -0.000 0.048 -0.017 -0.032, -0.002 0.031
FT4 BMC -0.019 -0.035, -0.003 0.018 -0.021 -0.042, -0.001 0.037
Childhood thyroid function with bone density at age 10 adjusted for bone density at 6
TSH BMD -0.003 -0.017, 0.011 0.67 0.000 -0.015, 0.017 0.95
TSH BMC 0.009 -0.018, 0.020 0.93 0.008 -0.022, 0.023 0.94
FT4 BMD -0.001 -0.009, 0.007 0.80 0.001 -0.009, 0.011 0.85
FT4 BMC -0.002 -0.013, 0.010 0.76 0.001 -0.013, 0.016 0.87
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This thesis examines the associations of thyroid function and hCG with various outcomes 
in early life. The association of thyroid function with pregnancy outcomes is investigated 
with a specific interest in potential underlying mechanisms such as the effects on the 
placental function and metabolic effects in terms of homocysteine concentrations. Also, 
the associations of the pregnancy hormone hCG (which is known to stimulate the thy-
roid) with pre-eclampsia and fetal growth were investigated, and we studied if thyroid 
function could be a pathway or an effect modifier of these associations. Furthermore, 
the studies presented in this thesis investigate major determinants of childhood thyroid 
function, as well as the associations of childhood thyroid function with relevant thyroid 
hormone target organs including the cardiovascular system and bone. This chapter pro-
vides a general discussion of the main findings presented in previous chapters, method-
ological considerations, clinical implications and future perspectives for the field.
REFLECTION OF MAIN FINDINGS
Thyroid function in pregnancy
Thus far, a great effort has been put into investigation of the adverse effects of gestational 
thyroid dysfunction and the optimization of thyroid hormone availability in pregnancy 1,2. 
The necessity of such studies is substantiated by the clinical associations of thyroid (dys)
function with pregnancy complications of major public health concern. These include 
premature delivery, pre-eclampsia and low birth weight 3-8 which altogether underlie a 
large portion of maternal and fetal morbidity and mortality worldwide. However, little is 
known on the factors that could mediate the effects of gestational thyroid function on 
these relevant outcomes. Elucidating such mechanisms could provide novel insights into 
clinical follow-up, identification of high-risk groups and could eventually allow for early 
and targeted interventions. One of the first potential mechanisms that we investigated 
is the placental function. Experimental studies have shown that thyroid hormone exerts 
effects on both endometrium and trophoblast function 9-13 and it has been postulated 
that an optimal thyroid hormone concentration is crucial for a successful placentation 
13,14. However, these associations are largely unexplored in epidemiological studies, 
which is particularly important for verification of the results on a population level and 
extraction of potential clinical implications. Chapter 2.1 of this thesis aims to translate 
the experimental data into a population setting and investigates the association of 
gestational thyroid function with placental function, as assessed by placental vascular 
resistance. Moreover, we investigate how relevant this potential association is for the 
effects of thyroid function on pregnancy complications that represent a major public 
health burden.
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In Chapter 2.1, we demonstrate that a higher maternal FT4 concentration in early 
pregnancy is associated with higher placental vascular resistance in mid- and late preg-
nancy and that high thyroid function may influence placental function, which could be 
occurring potentially through impaired placentation. The association of high FT4 with a 
higher vascular resistance in both the fetal and maternal compartment of the placenta 
(umbilical and uterine arteries) suggests that thyroid hormone affects the formation 
of the placenta as a whole, i.e. feto-placental and utero-placental circulation. The as-
sociation of high FT4 (measured in early pregnancy) with a higher placental vascular 
resistance measured repeatedly in the second and third trimester suggests that the 
effects of thyroid hormone on placental development may have a persistent impact 
throughout pregnancy. These associations were similar in a subgroup of euthyroid 
women, suggesting that even ‘high-normal’ thyroid hormone availability may lead to 
a suboptimal placentation. In general, placentation is a complex process and impair-
ment at any stage may result in pregnancy complications 15. We hypothesized that the 
detected associations of thyroid hormone with placental vascular resistance could be 
explained via regulating effects of thyroid hormone on trophoblast function as well as 
on angiogenic factors and cytokines that play a role in the process of placentation 10,16 
because this could result in impaired placental function and manifest as high placental 
vascular resistance later in pregnancy. The findings presented in Chapter 2.1 provide a 
basis for future studies that may want to assess the exact mechanisms and particularly 
investigate the effects of thyroid hormone variation on early placentation. Future studies 
should aim to explore the crucial time point when trophoblast is vulnerable to variation 
in thyroid hormone concentration and quantify to what extent the availability of thyroid 
hormone plays a role in the functionality of placental tissue.
When it comes to metabolic effects of thyroid function, there is abundant evidence 
about the regulating effects of thyroid hormone on metabolism throughout the whole 
body, from early development onwards 17. It is particularly interesting that thyroid func-
tion may have a role in the specific pathways of homocysteine metabolism. Homocyste-
ine is a non-protein amino acid, known for its detrimental effects when present in high 
concentrations, especially for cardiovascular system and cerebrovascular health 18. It has 
been suggested that high homocysteine has a role in female reproductive health, in 
pathophysiology of pregnancy complications and in adverse outcomes in neonates 19-25. 
Experimental studies in animals have shown that thyroid hormone regulates the activity 
of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase, enzymes 
required for re-methylation of homocysteine 26. Furthermore, thyroid hormone may 
stimulate processes that have depleting effects on folate and vitamin B12, while 
these vitamins are important co-factors for the metabolism of homocysteine 27-33. The 
population-based data on the effects of thyroid function on homocysteine are scarce, 
especially during pregnancy, and therefore we cannot be sure if relevant findings from 
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animal studies affect human physiology and pathophysiology that may be relevant 
for the outcomes of pregnancy and in early life. In Chapter 2.2 we aim to translate the 
experimental data to human physiology by investigating the effects of thyroid func-
tion on homocysteine concentrations and relevant metabolic factors in pregnancy 
and in the neonatal period. This chapter adds a new perspective to the knowledge on 
the specific role of thyroid hormone availability in the homocysteine metabolism. In 
part, because this is the first population-based study investigating these associations, 
but also because the focus was on both pregnancy and neonatal period – crucial time 
points that most likely reflect different thyroid hormone related effects with an impact 
on child development and health. We investigated which of the two hypothesized 
mechanisms may underlie the effects of thyroid hormone on homocysteine metabo-
lism and show that in pregnant women, higher FT4 concentrations are associated with 
higher homocysteine whereas, in neonates, higher FT4 and lower TSH are associated 
with higher homocysteine. In the latter case, the associations were mediated by the ef-
fects of thyroid function on folate and vitamin B12 concentrations. These results suggest 
that in case of neonates, the effects of high thyroid hormone on high homocysteine 
concentration may be mediated by depleting effects of thyroid hormone on folate and 
vitamin B12. This was not the case in pregnant women. We also investigated whether 
the underlying mechanism of the detected associations might involve effects on the 
enzymes of the re-methylation cycle and did not detect any difference based on the 
genetic polymorphism of MTHFR, which is one of the enzymes of the re-methylation 
cycle. These findings may serve as a starting point for future studies that are required 
to replicate our results and further investigate the underlying mechanism for the 
detected associations in pregnant women, for which we may have been statistically 
underpowered. Of particular interest would also be to investigate the role of vitamin B6 
on the effects of thyroid function on homocysteine metabolism, given that besides the 
re-methylation pathway, a large proportion of homocysteine is actually metabolized to 
cystathionine via vitamin B6-dependent pathway 34. Such studies could be performed in 
a population-based setting to investigate the potential mediating effects of vitamin B6 
in the association of thyroid hormone with homocysteine. Of interest would also be to 
investigate potential differences in metabolic effects between women that were taking 
multivitamin supplementation versus folic acid supplements only during pregnancy.
One of the aims in an epidemiological study is to investigate and unravel potential 
mediating pathways in the association of an exposure and an outcome 35. Based on the 
associations in Chapters 2.1 and 2.2 and based on previous studies of thyroid function on 
pregnancy outcomes, we investigated the potential mediating role of placental function 
and homocysteine in the associations of thyroid function with pregnancy complications. 
Results of these analyses suggest that up to 10.4% and 12.5% of the previously shown 
associations of thyroid function with pre-eclampsia and birth weight, respectively, 
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could be mediated via changes in placental hemodynamics, whereas up to 13.3% of 
the association of thyroid hormone with birth weight could be mediated via effects on 
homocysteine concentration. These analyses are important in unraveling the physiol-
ogy and potential underlying mechanisms for the associations studied. The mediating 
effects detected in these chapters were not consistent across pregnancy outcomes and 
ultrasound measurements in case of placental function, suggesting that the associa-
tions of thyroid hormone with pregnancy outcomes still remain largely explained either 
by direct effects of thyroid hormone, or via other mediators. Future studies are needed 
to confirm our findings, investigate the extent of mediation via placenta and metabolic 
effects on homocysteine and explore other potential pathways in the effects of thyroid 
function with pregnancy outcomes. Of particular interest would be experimental inves-
tigation of the effects of early thyroid hormone variation on the placental formation. 
Chapter 2 investigates functional and metabolic effects of thyroid function during 
pregnancy. These results suggest that higher thyroid hormone concentrations are 
associated with higher placental vascular resistance and with higher homocysteine 
concentrations and these associations might have a small contributory role in the 
previously studied effects of gestational thyroid function on pregnancy outcomes, 
such as pre-eclampsia and low birth weight. This suggests that early pregnancy thyroid 
hormone concentrations are relevant for various aspects of pregnancy, including early 
effects, such as placentation, but also metabolic effects related to homocysteine con-
centrations, which may be implicated in pregnancy complications.
hCG and pregnancy outcomes
Multiple studies have suggested that hCG metabolism is associated with pregnancy 
outcomes including pre-eclampsia and fetal growth 36-45. The complicating factor in 
drawing a conclusion from these results are considerable between-study differences 
in terms of gestational age of hCG measurement, specific isoform of hCG that was as-
sessed and regarding the outcome assessment such as for example specific phenotype 
of pre-eclampsia. Moreover, because of the exceptional ability of hCG to stimulate the 
thyroid during pregnancy, it is not known whether the associations of hCG with major 
pregnancy complications could in part be explained by the effects of hCG on thyroid 
function and we examined this hypothesis in Chapters 3.1 and 3.2. In addition, due to 
the co-regulatory role of hCG in angiogenesis, we investigated whether the effects on 
vascular endothelial growth factors in pregnancy could partially explain the associa-
tions of interest.
In Chapter 3.1 we show an association of high total hCG concentration in combination 
with high sFlt-1/PlGF ratio and a high risk of pre-eclampsia. The results suggest that up 
to 40% of the association of hCG with pre-eclampsia may be mediated via effects of hCG 
on the ratio of angiogenic factors - sFlt-1 and PlGF. Thus far, it has been accepted that 
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a hyperinflammatory response plays a role in the pathophysiology of pre-eclampsia, 
although the exact pathophysiological mechanism is unclear 46-48. Because it is known 
that sFlt-1/PlGF ratio is higher in the circulation of pre-eclamptic women compared to 
healthy women 49,50, we aimed to examine and quantify the potential effects of hCG on 
the balance between pro- and anti-angiogenic growth factors and its role in the as-
sociation of hCG with pre-eclampsia. These findings add to the current understanding 
of the pathophysiology of pre-eclampsia, which underlies a great portion of maternal 
and fetal morbidity and mortality worldwide 46,51-53. Future studies should replicate our 
results regarding the mediating role of sFlt-1/PlGF in the pathophysiology involved and 
further elucidate underlying mechanisms of the association of hCG with pre-eclampsia 
for example by repeatedly measuring hCG and studying effects on pro- and antian-
giogenic factors concentration and their ratio from very early pregnancy onwards to 
detect the crucial time-point when the unfavorable sequence of events predisposing to 
pre-eclampsia occur.
Furthermore, in Chapter 3.2, we demonstrate that low early-pregnancy hCG is associ-
ated with a lower birth weight and with a risk of being born small for gestational age 
(SGA). These associations seem to arise due to a decrease in fetal growth in the second 
half of pregnancy. Sex-specific differences were detected in the pattern of longitudi-
nally examined association of hCG with fetal growth, mainly in higher concentrations 
of hCG, whereas the associations of low hCG with low birth weight and a decrease in 
fetal growth were independent of fetal sex. The novel findings shown in this chapter 
suggest a specific role of hCG in fetal growth during the transitional period from first 
to second trimester, as the association of low hCG with low birth weight and SGA was 
limited to hCG concentrations measured in 11th and 12th week of gestation. This period 
is important as it reflects the start of maternal blood supply to the intervillous space 
and thereby a shift from hypoxic to an oxygenated fetal environment 54. The underlying 
mechanisms might involve effects of hCG on trophoblast shell and arterial plugs 55. These 
results suggest that SGA in general may be pre-determined potentially by a sequence 
of events related to low hCG concentrations at a specific time-point in early pregnancy, 
which is different from cases of for example low birth weight occurring in pre-eclampsia, 
as we show that high hCG concentrations are associated with pre-eclampsia partially 
via effects on the balance between pro- and antiangiogenic factors. Future studies that 
would replicate our findings may want to investigate additional mechanisms underlying 
detected associations. 
We did not detect a mediating or modifying role of thyroid function in the associations 
of hCG with pre-eclampsia or fetal growth. This suggests that although the physiology 
of hCG and thyroid function in pregnancy is interrelated, these two hormones have a 
separate role in same pregnancy complications. For example, we hypothesized that the 
association of hCG with pre-eclampsia is partly due to the contributing effects of high 
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hCG on the unfavorable balance between pro- and anti-angiogenic factors in pre-ec-
lampsia, or that it is a compensatory response of trophoblast to feto-placental hypoxia, 
whereas the association of thyroid hormone with pre-eclampsia is hypothesized to be 
due to the effects of thyroid hormone on endothelial cell dysfunction 5. However, in this 
thesis, we investigated the associations of hCG concentration with fetal growth and pre-
eclampsia, whereas future studies may want to assess the possibility of the mediating or 
modifying effects of thyroid function in the association of hCG with different pregnancy 
complications.
The results of Chapter 3 show the associations of hCG concentration with the risk of 
pre-eclampsia as well with the risk of fetal growth restriction and being born SGA. These 
results suggest that the two extremes of the hCG range have different mechanisms in 
contributing to pregnancy complications, as we show an association of low hCG with 
decreased fetal growth and risk of SGA in general and an association of high hCG with 
the risk of pre-eclampsia which practically may also lead to SGA. The effects of low hCG 
on fetal growth were limited to a specific gestational period, whereas the effects of high 
hCG on the risk of pre-eclampsia were not time-dependent or this could not be detected 
due to potential lack of power given that effect modification may be difficult to detect in 
dichotomous outcomes 56. Both associations exhibited fetal sex-specific characteristics, 
implying that these differences need to be considered when studying the effects of hCG. 
This thesis adds a novel component to the understanding of the physiology of preg-
nancy specific hormone - hCG, and its role in multifactorial pregnancy complications 
that underlie a great portion of maternal and fetal morbidity and mortality. 
Thyroid function in childhood
The essential tool for clinicians in diagnosing thyroid disorder is a proper reference 
range. A certain variability in the reference range cutoffs might not affect diagnosing 
overt disease but may largely aggravate diagnosing mild forms of thyroid dysfunction. 
The literature overview provided in Chapter 4.1 of this thesis shows a considerable 
variability in the reported pediatric reference ranges for TSH and FT4, especially in the 
first week of life. Even in children aged ≥1 year, the variability was relatively large, as is 
exhibited, for example, by the reported upper limit for TSH (2.36 to 6.57 mU/L). Besides 
the differences across age-categories and studies using different assays, differences 
were also present between studies using a similar assay 57-59. Moreover, the population 
size and selection of the study population may be suboptimal, as some studies lack the 
sufficient size for calculation of reference ranges or do not exclude the individuals with 
diseases that affect thyroid function 2. A principal factor that complicates the interpreta-
tion of childhood reference ranges overall, is the lack of consensus on the calculation of 
reference ranges. For instance, while some studies use the non-parametric approach, 
utilizing 2.5th-97.5th range or the 5th-95th reference range, some studies use a (semi-) 
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parametric approach defining normality based on +/- 1.96 or 2 standard deviations 
from the mean 60. This complicates the utilization of the reference ranges in the clinical 
practice and hampers the general conclusion from the literature summary, which could 
be overcome by standardization of the methodology in the reference range calculation. 
The determinants of thyroid function are important in understanding childhood 
physiology and differences compared to adult population. In the population-based 
cohort of children investigated in Chapter 4.1, a stable association of FT4 with TSH is 
demonstrated, suggesting that the hypothalamic-pituitary-thyroid (HPT) axis in children 
at the age of 6 is likely not subject to pathology. Future studies should longitudinally 
investigate the potential changes in this association later in childhood and adolescence, 
to gain further insight in the crucial time-points when HPT axis becomes vulnerable to 
pathological changes. Of interest would also be to investigate how is this association af-
fected by genetic variation. The major determinants of childhood thyroid function were 
age, sex, ethnicity, anthropometric characteristics and time of venipuncture and the 
between-individual differences in these characteristics were shown to largely influence 
the variation in TSH and FT4 values. Therefore, these determinants should be taken into 
account for interpretation of thyroid function tests.
Although there is substantial evidence on the role of thyroid function in the cardiovas-
cular system development 61-63, little epidemiological data are available on this matter. 
Given that early-life determinants may shape the development of the cardiovascular 
system and affect its function throughout adulthood 64-68, knowledge on these deter-
minants could have predictive value for cardiovascular health. The results shown in 
Chapter 4.2 suggest that higher FT4 is associated with a lower left ventricular mass at 
the age of 6 years. Our results suggest that the effects of FT4 on the left ventricular mass 
may be mediated via effects of FT4 on the lean body mass, which is a strong determi-
nant of left ventricular mass 69,70. Therefore, it is likely that in this young population, we 
could examine the developmental influence of thyroid hormone. Future studies should 
investigate whether the effects on the left ventricular mass persist to a later age and 
whether they might to any extent program clinically relevant entities, such as left ven-
tricular hypertrophy. Longitudinal measurements of the cardiovascular function would 
enable an investigation of the variability in this association over time and long follow-up 
would permit an assessment of the crucial time point when cardiac structure is subject 
to adverse effects of thyroid (dys)function.
Investigation of early determinants of blood pressure is encouraged by the longitudi-
nal studies that have shown that blood pressure tracks from childhood to adulthood 68. In 
line with the previous reports 71,72, the results of Chapter 4.2 show that TSH is associated 
with higher blood pressure in childhood. It has been speculated that the association of 
TSH with blood pressure is a result of the common genetic factors that are associated 
with both thyroid function and blood pressure 73. A novel finding of this thesis is that 
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FT4 is associated with blood pressure potentially via effects on arterial stiffness. The 
mechanism underlying this association is likely to be different from the association of 
TSH with blood pressure, as FT4 (but not TSH) was associated with the measurement of 
arterial stiffness. This suggests that the effects of thyroid hormone on the arterial wall 
potentially via initiation of endothelial dysfunction and effects on arterial stiffness 74-77, 
may create structural changes that could have effects on blood pressure already in child-
hood. This is further substantiated by the evidence of atherosclerotic changes already in 
early childhood 78. Future studies should quantify the potential role of thyroid hormone 
in early arterial changes and elucidate other contributive factors for high blood pressure 
that may be modifiable and could be implemented in preventive strategies.
Longitudinal studies have shown that bone mineral density (BMD) tracks from 
childhood to adulthood, suggesting that low BMD at early age may be a risk factor for 
osteoporosis in adulthood 79. While adverse effects of childhood hyperthyroidism on 
bone accrual are known 80,81, little epidemiological data are available on the influence of 
mild thyroid variations on bone development. The results shown in Chapter 4.3 suggest 
that higher thyroid hormone concentrations are associated with lower BMD throughout 
childhood. Another concept worth of discussion originates from reports from animal 
studies, showing a direct role of TSH in the skeletal metabolism 82, while translation of 
these results into human population setting is controversial 83. In Chapter 4.3 an as-
sociation of TSH at the age of 6 with BMD was detected cross-sectionally, but not at 
the age of 10, and was overall not present in the European subgroup, suggesting that 
this association could be subject to residual/unmeasured confounding effect. Future 
studies should investigate to what extent detected associations of thyroid function with 
BMD persist in later age and whether this may have an impact on the clinically relevant 
entities related to osteoporosis. The differences in the associations between total and 
European population detected in Chapter 4.3 deserve special investigation, particularly 
regarding the potential role of genetic polymorphism.
Chapter 4 of this thesis provides a summary of the available studies on thyroid func-
tion reference ranges for pediatric population and quantifies the differences in the refer-
ence values based on the age, assay, population and calculation methodology. Age, sex, 
ethnicity, anthropometric characteristics and time of venipuncture were identified as 
major determinants of TSH and FT4 in childhood. The novel findings described in Chap-
ter 4 add to the current knowledge on the physiology of childhood and early effects of 
thyroid hormone on major target organs, which may prove useful in early prediction of 
clinically relevant events related to cardiovascular and bone health.
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METHODOLOGICAL CONSIDERATIONS
There are several methodological aspects of this thesis that are worth of discussion. 
First of all, the response rate at baseline for the Generation R cohort was 61% based on 
the number of children at birth and women that participated in the cohort had fewer 
pregnancy complications compared to women that did not participate 84, suggesting a 
selection towards a healthier population. This may lead to lower prevalence rates of for 
example pre-eclampsia and consequently reduce statistical power and generalizability 
of the results to other less healthy populations. However, studies have shown that selec-
tive participation at baseline does not affect the studied associations within population-
based cohorts 85,86, suggesting that it is not likely that the associations detected in this 
thesis are biased due to non-response at baseline. On top of this, hCG measurements 
were available in 89% of women, whereas thyroid function was measured in early 
pregnancy serum samples that were available in 71% of women 87, leaving a possibil-
ity of biased estimates in the studies investigating the associations of hCG and thyroid 
function with different outcomes. This might be overcome in future population-based 
cohorts by earlier inclusion of women in the study, preferably pre-conceptionally, so 
that a larger percentage of early-pregnancy blood measurements is available. Another 
relevant point is loss to follow-up, as at 6 years of age, approximately 70% of children 
that visited the research center had their blood drawn successfully, and the missing 
measurements were mainly due to a non-consent for venipuncture or failure of the 
procedure. A sensitivity analysis performed by comparison of main characteristics be-
tween children with and without available thyroid function measurements in this thesis 
showed no systematic differences in the outcomes of interest, which may represent an 
argument against biased estimates. 
In the studies included in this thesis, differential misclassification is not a likely source 
of bias as the parents and data collectors were not aware of the specific research ques-
tion. In addition to this, data on exposures were measured from the blood samples, and 
data on the outcomes were obtained from hospital registries or via direct measurement 
of placental function, fetal ultrasound or cardiovascular function and body composition. 
Nonetheless, non-differential misclassification might have occurred, for example in case 
of women’s report on folic acid use during pregnancy, as some women have likely used 
combined multivitamin formulas, which potentially could have led to an underestima-
tion of the effect estimates. Future studies could overcome this misclassification by 
specifying in the questionnaire which type of vitamin supplementation did women take 
during pregnancy.
Although the studied associations in this thesis were adjusted for multiple potential 
confounders, residual or unmeasured confounding cannot be excluded due to obser-
vational nature of this study. This might, for example, include the influence of environ-
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mental factors, genetic susceptibility or the interaction of the two. In some cases, one 
variable can be both a confounder and a mediator (Figure 1) and this was explored in this 
thesis. Several potential (partial) mediators were identified, including placental function 
in the association of thyroid hormone with pre-eclampsia and birth weight, and lean 
body mass in the association of thyroid hormone with left ventricular mass. In the first 
case, the mediating effect estimates were small and not consistent across pregnancy 
outcomes and placental ultrasound measurements, whereas, in the latter case, effects 
were more robust. This suggests that the association of thyroid function with pregnancy 
complications is largely explained by either direct effects of thyroid hormone or by other 
unmeasured or unknown mediators. However, it is still possible that in some cases, 
the methodology used for mediation analyses was not sensitive enough to accurately 
examine and detect the potential mediating effects. The possibility that one variable 
could be both a confounder and a mediator was explored for example in case of body 
composition, that could both mediate and confound the association of thyroid function 
with cardiovascular outcomes 69. This is also due to the complicated and potentially 
bidirectional association of thyroid function with BMI 88 whereas not much is known on 
the association of thyroid function with specific body composition components in child-
hood. This was explored in Chapter 4.2 where we identified lean body mass (and not fat 
mass) as a mediator in the association of thyroid hormone with left ventricular mass. 
This stepwise approach shows the importance of combining the biology and statistical 
methodology in disentangling clinically relevant associations.
CLINICAL IMPLICATIONS
This thesis provides several concepts that could improve the clinical perspective and 
healthcare during pregnancy and in early childhood and adds to translation of the 
experimental studies into clinically relevant associations. In line with that, this thesis 
Figure 1. A statistical mediation and confounding model
Mediator 
Exposure  Outcome 
Confounder 
221
General discussion
5
shows that higher thyroid hormone concentrations in early pregnancy are associated 
with higher placental vascular resistance and with higher homocysteine concentrations, 
which have both been associated with adverse pregnancy outcomes. This underlines the 
importance of optimization of thyroid hormone concentration in pregnancy and may 
add to the understanding of the potential adverse effects of levothyroxine (over)treat-
ment during pregnancy. Furthermore, the results of this thesis that show associations 
of hCG concentrations with risks of fetal growth restriction and pre-eclampsia, may be 
incorporated in clinical prediction models. This means that by using hCG concentration 
profile together with other risk factors, the probability of adverse events in pregnancy 
could be analyzed. Finally, the results of this thesis concerning thyroid function in early 
childhood may improve clinical perspective of the pediatric population in several as-
pects; by summarizing all the available reports on thyroid function reference ranges in 
one study, the knowledge that is necessary for clinicians to properly diagnose thyroid 
dysfunction and assess whether a reference interval is generalizable to a specific popu-
lation, becomes easier accessible. The knowledge on the determinants of childhood 
thyroid function described in this thesis may improve identification and/or exclusion of 
the mechanisms underlying an abnormal thyroid function test. In addition, the results 
showing the association of thyroid function with cardiovascular function and bone 
density in childhood may help to identify determinants of clinical events in adulthood. 
This thesis adds novel aspects to the understanding of the physiology of growth and 
development and the functionality of HPT axis in early age. Childhood studies described 
here are important from the perspective of improvement of the knowledge about the 
differences between pediatric and adult population. 
FuTuRE PERSPECTIVES
Different study designs, such as randomized control trial (RCT) or Mendelian randomiza-
tion studies may be used to gain a better insight into causality. For verification of the 
associations of maternal thyroid hormone metabolism with placental function and ho-
mocysteine concentrations, of particular interest would be to perform analysis of RCTs 
that investigate effects of levothyroxine treatment. In some cases, an RCT is not feasible, 
but Mendelian randomization studies may prove useful, such as for example in the case 
of the association of hCG with pregnancy outcomes. Future studies should also inves-
tigate the (patho)physiological mechanisms underlying the associations studied in this 
thesis. Of particular interest would be experimental studies that would investigate our 
results obtained on the association of thyroid function with placental hemodynamics.
More detailed measurements could provide further insight into the strength and 
consistency of the studied associations. For instance, repeated measurements of hCG 
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would enable studying inter-individual differences in the change of hCG concentrations 
during pregnancy and whether that potential variation affects the association with pre-
eclampsia and fetal growth. Longitudinal measurements of childhood thyroid function 
are lacking, and the field could benefit from this type of data particularly for studying 
potential tracking pathways of thyroid function from childhood to adolescence, and to 
gain insight into the consistency of the associations with body composition compo-
nents, cardiovascular function and bone density in later stages of childhood. Long-term 
follow-up observational cohort studies are necessary to study the physiology of varia-
tion in thyroid function over the life course and potential consequences for clinically 
relevant events in adulthood, such as cardiovascular events and osteoporosis. 
CONCLuSION 
The results of this thesis show that hCG and thyroid function are important endocrine 
determinants in early life. The studied associations of hCG concentrations with preg-
nancy outcomes suggest that this hormone may be an important factor and/or marker 
of the pathophysiology of adverse pregnancy outcomes that underlie a great portion of 
maternal and fetal morbidity. The associations of thyroid function with the functional 
and metabolic outcomes of pregnancy and developmental outcomes in childhood 
emphasize its essential role in human physiology from the conception onwards.
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SuMMARY
This thesis investigates developmental and metabolic aspects of hormonal influence in 
early life. The focus was on pregnancy as well as on early childhood. The associations of 
hCG and thyroid function with pregnancy outcomes were examined and we aimed to in-
vestigate potential underlying mediating pathways and delineate the effects of thyroid 
hormone and hCG. We investigated the functionality of hypothalamic-pituitary-thyroid 
axis and determinants of thyroid function in early childhood. The effects of childhood 
thyroid function on major target organs such as the cardiovascular system and bone 
were investigated.
Chapter 1 provides the background on the physiology of pregnancy and childhood 
and the endocrinological aspects relevant for both pregnant women and the offspring. 
The aims of this thesis are described and the setting of the studies is presented.
Chapter 2 focuses on the effects of thyroid function in pregnancy in terms of placen-
tal function and metabolism of homocysteine. In Chapter 2.1, we show that high thyroid 
hormone in early pregnancy is associated with high placental vascular resistance in 
the second and third trimester, in both maternal and fetal placental compartment. Our 
results also suggest that these effects might have a limited mediating role in the effects 
of thyroid function on pre-eclampsia and birth weight. Chapter 2.2 describes the asso-
ciation of thyroid function with homocysteine concentrations in pregnant women and 
in neonates. High thyroid hormone was associated with high homocysteine concentra-
tions and the results suggest that the depleting effects of thyroid hormone on folate and 
vitamin B12 may have a role in this association.
Chapter 3 investigates the associations of hCG concentrations with fetal growth pat-
terns and the risk of pre-eclampsia. Chapter 3.1 shows an association of high total hCG 
with a high risk of pre-eclampsia, which could be partially explained by the effects of 
hCG on the balance between pro- and anti-angiogenic factors, PlGF and sFlt-1. Chapter 
3.2 unravels the pattern of the association of hCG with fetal growth and shows that as-
sociation of low total hCG in the late first trimester with low birth weight arises due to a 
decrease in fetal growth in these pregnancies. In both Chapter 3.1 and 3.2, sex-specific 
differences in the associations of hCG with the outcomes of interest were detected.
Chapter 4 focuses on the aspects of thyroid function in childhood and investigates 
major determinants of childhood TSH and FT4 concentration, as well as the variability in 
existing pediatric reference ranges and the effects of thyroid function on major target 
organs. Chapter 4.1 provides a literature overview of published reference ranges for 
thyroid function in children, showing differences across age categories, assay use and 
population size. Child age, sex, ethnicity and anthropometric characteristics were identi-
fied as major thyroid function determinants and a stable association of FT4 and TSH is 
shown. Chapter 4.2 shows that thyroid function is a determinant of left ventricular mass 
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and this was partially mediated by the effects of FT4 on the lean body mass. TSH and 
FT4 were positively associated with blood pressure, with a potential role of arterial stiff-
ness in the latter case, suggesting different mechanisms via which these hormones are 
associated with blood pressure. In Chapter 4.3, we show a consistent inverse association 
of FT4 with bone density and show that the association of TSH with bone density is not 
consistent .
In Chapter 5, a reflection of main findings of this thesis is provided and methodologi-
cal considerations, clinical implications of the detected associations, as well as future 
perspectives for the field are discussed.
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SAMENVATTING
Dit proefschrift onderzoekt ontwikkelings- en metabole aspecten van hormonale in-
vloeden in het vroege leven. De zwangerschap en de vroege kinderjaren stonden hierin 
centraal. De associatie tussen hCG en schildklierfunctie enerzijds en zwangerschapsuit-
komsten anderzijds werden onderzocht. Daarnaast zochten wij naar mogelijk onderlig-
gende oorzaken die invloed hebben op deze associaties en hebben we de effecten van 
schildklierhormoon en hCG onderzocht. We onderzochten de functionaliteit van de 
hypothalamus-hypofyse-schildklier -as en determinanten van schildklierfunctie tijdens 
de vroege kinderjaren. Tot slot werd er gekeken naar het effect van de schildklierfunctie 
op de kinderleeftijd in relatie tot grote orgaansystemen zoals het cardiovasculaire sys-
teem en de botten.
Hoofdstuk 1 geeft een beschrijving van de fysiologie van de zwangerschap en de 
kinderleeftijd en van de endocrinologische aspecten die relevant zijn voor zowel zwan-
gere vrouwen als hun kinderen. Tevens worden de doelstellingen van dit proefschrift 
beschreven en de setting van de studies uiteengezet.
Hoofdstuk 2 richt zich op de effecten van de schildklierfunctie tijdens de zwanger-
schap in relatie tot de placentafunctie en het metabolisme van homocysteïne. In 
Hoofdstuk 2.1 tonen we aan dat een hoge concentratie schildklierhormoon in de vroege 
zwangerschap geassocieerd is met een hoge vasculaire weerstand van de placenta in 
het tweede en derde trimester. Deze associatie wordt gezien aan zowel het maternale 
als het foetale gedeelte van de placenta. Onze resultaten suggereren ook dat deze effec-
ten mogelijk een mediërende rol spelen in de relatie tussen schildklierfunctie enerzijds 
en pre-eclampsie en geboortegewicht anderzijds. Hoofdstuk 2.2 beschrijft de associatie 
van de schildklierfunctie met homocysteïne concentraties in zwangere vrouwen en 
neonaten. Een hoge concentratie van het schildklierhormoon is geassocieerd met een 
hoge concentratie homocysteïne en de resultaten suggereren tevens dat de relatie van 
schildklierhormoon op folaat en vitamine B12 hier een rol kan spelen. 
Hoofdstuk 3 onderzoekt de associaties van hCG concentraties met foetale groeipatro-
nen en het risico op pre-eclampsie. Hoofdstuk 3.1 geeft een weergave van de associatie 
van een hoge hCG concentratie met een verhoogd risico op pre-eclampsie, welke deels 
verklaard kan worden door het effect van hCG op de balans tussen de pro- en anti-
angiogene factoren PlGF en sFlt-1. Hoofdstuk 3.2 ontrafelt het patroon aangaande de 
associatie van hCG met foetale groei en toont aan dat de associatie van een lage concen-
tratie totaal hCG laat in het eerste trimester met een laag geboortegewicht voortkomt 
uit een verminderde foetale groei in deze zwangerschappen. In zowel Hoofdstuk 3.1 als 
Hoofdstuk 3.2 werden geslachts-specifieke verschillen aangetoond in de associatie van 
hCG met de eerdergenoemde uitkomsten.
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Hoofdstuk 4 richt zich op de aspecten van de schildklierfunctie in de kinderjaren en 
onderzoekt belangrijke determinanten van TSH en FT4 concentraties tijdens de kin-
derleeftijd. Daarnaast wordt ook de variabiliteit onderzocht in bestaande pediatrische 
referentiecurves en de effecten van de schildklierfunctie op grote orgaansystemen. 
Hoofdstuk 4.1 geeft een weergave van de literatuur van gepubliceerde referentiecurves 
van schildklierhormoon in kinderen, waarbij verschillen worden aangetoond tussen 
leeftijdscategorieën, analyse technieken en populatiegrootte. Leeftijd, geslacht, etnici-
teit en antropometrische karakteristieken van het kind bleken belangrijke determinan-
ten te zijn voor de schildklierfunctie. Tevens is er een stabiele associatie van FT4 en TSH 
aangetoond. Hoofdstuk 4.2 laat zien dat de schildklierfunctie een determinant is van 
linker ventrikel massa en dat deze deels werd gemedieerd door de effecten van FT4 op 
spiermassa. TSH en FT4 zijn positief geassocieerd met bloeddruk. In de relatie van FT4 
met bloeddruk is er een potentieel mediërende rol voor arteriële stijfheid gevonden. 
Dit suggereert dat er verschillende mechanismen werkzaam zijn die de associatie van 
TSH en FT4 met bloeddruk verklaren. In Hoofdstuk 4.3 tonen we een consistente inverse 
associatie aan van FT4 met de botdichtheid en van TSH met de botdichtheid, waarbij de 
associatie van TSH niet consistent is tussen Europese subgroepen. 
In Hoofdstuk 5 wordt een interpretatie gegeven van de belangrijkste bevindingen 
van dit proefschrift. Daarnaast worden methodologische overwegingen, klinische 
implicaties van de gevonden associaties en toekomstige perspectieven in dit onder-
zoeksgebied besproken.
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Propositions
1.	 The	 association	 of	 high	 thyroid	 function	 with	 pregnancy	 complications	 is	 partially	 ex-
plained	via	effects	on	placentation.	– This thesis
2.	 High	thyroid	function	is	associated	with	high	homocysteine	concentrations.	The	metabolic	
pathways	 underlying	 this	 association	 are	 different	 between	 adults	 and	neonates.	– This 
thesis
3.	 The	two	extremes	of	the	hCG	range	contribute	to	pregnancy	complications	via	different	
mechanisms.	– This thesis
4.	 Although	 physiology	 of	 thyroid	 hormone	 and	 hCG	 is	 interrelated,	 these	 two	 hormones	
have	different	pathways	in	the	regulation	of	pregnancy	and	fetal	growth.	– This thesis
5.	 Early	childhood	thyroid	function	influences	cardiovascular	health	in	adult	age.	– This thesis
6.	 Translation	 of	 data	 obtained	 from	 in	 vitro	 experiments	 and	 animal	 studies	 into	 human	
population	setting	 is	crucial	 for	unravelling	physiological	pathways	and	 identification	of	
clinically	relevant	associations.
7.	 The	role	of	genetics	in	endocrinology	is	becoming	increasingly	recognized,	and	the	com-
bination	of	genetic	analyses	and	clinical	tools	may	allow	early	diagnosis	and	subsequent	
improvement	of	clinical	outcomes.	
8.	 Paternal	influences	on	offspring’s	health	are	undervalued.	More	investigation	of	the	effects	
of	paternal	genetic	material	and	lifestyle	factors	on	fetal	development	is	needed.
9.	 Comprehension	of	the	patterns	of	childhood	growth	and	development	necessitates	more	
efforts	in	the	investigation	of	the	processes	that	occur	even	before	conception.
10.	The	value	of	observational	studies	lies	in	detection	of	modifiable	pathophysiological	fac-
tors	and	identification	of	high-risk	groups.		
11.	 “It	is	paradoxical,	yet	true,	to	say,	that	the	more	we	know,	the	more	ignorant	we	become	in	
the	absolute	sense,	for	it	is	only	through	enlightenment	that	we	become	conscious	of	our	
limitations.”	– Nikola Tesla
Mirjana Barjaktarović,
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